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SUMMARY
Using in situ hybridisation histochemistry we have demonstrated that :
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1. Enkephalin gene expression is modulated by the dopaminergic system in the rat 
striatum. Intraperitoneal administration of the typical neuroleptic drugs haloperidol 
(Img/kg) and fluphenazine (3mg/kg) significantly increase levels o f proenkephalin ÿ
mRNA in the caudal striatum compared to saline treated controls, although the 
atypical neuroleptic drug clozapine (3 mg/kg) has no effect on the levels of 
pro enkephalin mRNA in the rat. Methiothepin (lOmg/kg), an antipsychotic with 
the ability to antagonise both serotonin and dopamine receptors can also induce 
pro enkephalin mRNA levels in rat striatum. This induction is observed twenty-four
hours after the drugs are given.
j
2. Tachykinin gene expression is modulated by the dopaminergic system in the rat 
striatum. Intraperitoneal administration of the typical neuroleptic drugs haloperidol 
(1 mg/kg) and fluphenazine (3 mg/kg) significantly reduce the levels o f  
preprotachykinin mRNA in the rat striatum, compared to saline treated controls.
iïThis effect is observed twenty-four hours after drug administration. The atypical
Ineuroleptic drug clozapine (3 mg/kg) and the antipsychotic methiothepin 
(lOmg/kg) have no significant effect on the levels of preprotachykinin mRNA in |
the rat striatum.
3. Somatostatin gene expression in the rat striatum is significantly increased by low 
doses of the atypical neuroleptic drug clozapine (3mg/kg) and by the antipsychotic 
drug methiothepin (lOmg/kg), after acute administration. Acute treatment with 
typical neuroleptics have no effect in the rat striatum. Similarly, acute treatment
with clozapine (3 mg/kg) and methiothepin (lOmg/kg) significantly increase the 
levels o f preprosomatostatin mRNA in the rat nucleus accumbens. Chronic 
treatment with clozapine (6mg/kg) also significantly increases preprosomatostatin 
mRNA levels in the rat striatum and in the olfactory tubercle.
4. Neuropeptide Y gene expression in the rat striatum is not changed significantly 
following acute neuroleptic drug treatment.
I
5. Chronic treatment with the neuroleptics fluphenazine (6mg/kg) and clozapine
. . .(6mg/kg) significantly increases the levels of D l dopamine receptor mRNA in the 
rat rostral striatum. Chronic treatment with the above has no effect on the levels of 
5-HT6 receptor mRNA in the rat striatum.
6. Typical neuroleptics including haloperidol (1 mg/kg) and fluphenazine (3mg/kg) 
can significantly induce the immediate early genes c-fos, zif/268, and jun-B in the
:::rat striatum after 30-45 minutes. Haloperidol (1 mg/kg), but not fluphenazine 
(3mg/kg), significantly induces jun-D mRNA in the rat striatum. Haloperidol 
(1 mg/kg) can significantly increase c-fos and jun-B mRNA expression in the rat 
nucleus accumbens, while fluphenazine (3mg/kg) can significantly induce zifi268 
and jun-B mRNA expression in the rat nucleus accumbens. The atypical 
neuroleptic, clozapine (3mg/kg) had no significant effects on the expression of c- 
fos, zif/268, jun-B, and jun-D in either the rat striatum or accumbens regions.
However, the immediate early, gene brain factor-1 (BF-1), was significantly 
induced in the rat caudal striatum twenty-four hours after clozapine (3mg/kg) 
treatment. RHS2 gene expression was not affected by clozapine (3mg/kg) after 
twenty-four hours.
Xlll
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7. Striatal neurones in culture have a similar phenotype to striatal neurones in vivo. 
Cultured striatal neurones express the genes that encode enkephalins, substance P, 
somatostatin, and neuropeptide Y proteins similar to the in vivo situation, but not 
dynorphins. A small percentage of striatal neurones in culture are NADPH-positive 
and acetylcholinesterase-positive similar to the in vivo situation.
8. Dopamine (5gM) and SKF38393 (1/xM), a D1/D5 receptor agonist, can 
significantly induce c-fos and ziff268 mRNA in cultured striatal neurones, 
compared to vehicle treated cultures. Maximal induction occurs after 45 minutes. 
This induction is blocked by SCH23390 (IgM), but not by eticlopride (IgM). The 
SKF3 8393-induced expression of both c-fos and zifi'268 mRNA can be 
significantly reduced by pretreatment with the non-selective kinase inhibitor H7
9. SKF38393 (lnM-5gM) can induce c-fos mRNA and zift268 mRNA in a dose-
XIV
(50gM) and with the selective protein kinase A inhibitor, KT5720 (2gM). The 
phorbol ester, 12-myristate-13 -acetate (lO’^ M) can significantly induce both c-fos
and zifi268 mRNA after 45 minutes. The protein kinase C inhibitor, calphostin C
(Igm), can significantly block the phorbol ester- induced expression of both c-fos
mRNA and zift268 mRNA. Calphostin C (IgM) can also significantly reduce the
SKF38393- induced expression of c-fos mRNA, but is unable to block the
SKF38393- induced expression of zift268 mRNA. Quinpirole (1/iM), a D2-like
receptor agonist, can significantly induce c-fos mRNA in striatal cultures compared
to control. The SKF38393- induced expression of both c-fos and zift268 mRNA 
.can be significantly reduced by coadministration of SKF38393 with quinpirole 
(1/xM).
..;V
4
%
dependent manner in striatal neurone cultures. Pretreatment with antisense
oligonucleotides directed towards the D l dopamine receptor and the D5 dopamine
A
!
receptor at a concentration of IgM can significantly shift the dose response curves 
representing c-fos induction and zifi268 mRNA induction by SKF38393, in a 
downward direction. However, pretreatment with the D l sense oligonucleotide 
(ljuM) has no effect on the dose response curve representing c-fos induction by 
SKF38393 (Inm-SgM). Although the D l sense oligonucleotide caused a 
significant downward shift of the curve representing zift268 induction by 
SKF38393 (InM-SjwM).
10. Serotonin (5-HT) (lnM-5/xM) can significantly induce both zift268 and c-fos 
mRNA in a dose-dependent manner in striatal neurone cultures. Pretreatment with 
ondansetron (200nM), a 5-HT3 receptor antagonist, can block the 5-HT-induced
:expression of zifi268 mRNA , and to a lesser extent c-fos mRNA. Pretreatment
■with the 5-HT1/2 receptor antagonists cyproheptadine (500nM), methiothepin 
(200nM), mesulergine (30-100nM) and spiperone (30-100nM) can block the 5- 
HT- induced expression of both zift268 and c-fos mRNA. The 5-HT2C receptor
XV
agonist m-CPP (lnM-5gM) had no effect bn the expression of zif/268 or c-fos
mRNA. Similarly 8-OH-DPAT (lnM-5/xM), the 5-HTlA receptor agonist, had no
significant effects on either zi0268 or c-fos expression in striatal cultures.
Administration o f the 5-HT2A receptor agonist ± DOI (lnM-5/xM) had no 
.significant effect on the expression of zift268 and c-fos mRNA in cultured striatal 
neurons.
I'
Abbreviations
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NPY Neuropeptide Y
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Chapter 1
::
:
INTRODUCTION
1.1 Anatomical Organisation of the Basal Ganglia
The basic circuitry of the basal ganglia is classically known as being 
composed of multiple intrinsic loops through which most of the key structures 
of the system are reciprocally linked. As early as the 1970*s it was proposed 
that the structures within the basal ganglia fonctioned as integrative centres, 
chanelling information from different origins. The basal ganglia form a 
forebrain system that affects signals from a large part of the neocortex and 
focusses the output of this integrated information to target regions of the 
frontal lobe and brainstem involved in aspects of motor planning and motor 
memory.
The basal ganglia comprise a number of structures including the 
striatum, which is the largest structure in the basal ganglia, the substantia nigra, 
the globus pallidus, the subthalamic nucleus and the entopeduncular nucleus. 
The striatum, which itself comprises caudate nucleus, putamen and ventral 
striatum, receives an excitatory innervation from the substantia nigra pars 
compacta and dorsal raphe nucleus that is primarily dopaminergic and 
serotoninergic respectively (Graybiel and Ragsdale., 1978), and also an 
excitatory glutamatergic innervation from specific cortical areas (Spencer., 
1976; Divac et al.. 1977). In contrast, the striatum projects massively only to 
the globus pallidus, the substantia nigra pars reticulata and to the 
entopeduncular nucleus.
Immunocytochemical studies have revealed an inner complexity to the 
structure of the striatum. Biochemically specialised compartments were first 
detected in sections stained for acetylcholinesterase (AchE) activity (Graybiel 
and Ragsdale., 1978). Small AchE-poor regions referred to as striosomes or 
"patches" were embedded in an AchE-rich tissue of the striatum, which was
later referred to as the extrastriosomal matrix. In time, it was found that there 
were differences in the connections of striosomes and matrix compartments to 
the internal circuit within the basal ganglia, thus making functional differences 
between the striatal compartments likely. The matrix compartment recieves the 
striatal inputs most directly related to sensorimotor processing. By contrast, 
striosomal compartments tends to recieve inputs from neural structures, 
affiliated with the limbic system (Donoghue and Herkenham., 1986). Similarly 
the efferent projections from different striatal compartments show functional 
organisation. This mosaic pattern is presumably important for efficient and 
selective information processing by allowing a specific chemical environment to 
exist.
It has previously been that the rat basal ganglia ha^ a^ similar
structural make-up to the human basal ganglia, and the organisation of 
connections within the rat basal ganglia have been shown to be remarkably 
similar to those in the human basal ganglia. Therefore the rat has been used in 
recent years as an adequate model for experimental research on basal ganglia 
function (Parent et al.. 1991).
1.2 Neurotransmitters and Neuropeptides in the Basal Ganglia
The basal ganglia contain a remarkable diversity of neuroactive 
substances, organised into functional subsystems that have unique 
developmental histories and vulnerabilities in neurodegenerative diseases.
Approximately 95% of striatal neurons in vivo are thought to be 
GABA-ergic projection neurons. Coexistence of GAB A with neuropeptides in
various combinations in the principle circuits and intemeurons of the basal 
ganglia, allows different combinations o f cortical inputs, when projected into 
the basal ganglia, to be channeled not only into different output pathways, but 
also into different chemical environments.
In vivo, GABA-ergic projection neurons have been demonstrated to 
contain either enkephalin peptides or dynorphin and tachykinin peptides (Bolam 
et al.. 1985; Graybiel., 1990; Besson et al.. 1990). The remainder comprise 
possibly three populations o f intemeurons releasing acetylcholine, or GABA 
and neuropeptide Y (NPY), or somatostatin, NPY and nitric oxide (Bolam et 
al., 1984; Phelps et al.. 1985; Smith and Parent., 1986; Graybiel, 1990; VuUlet 
et al.. 1990). Different neuronal populations have been demonstrated to project 
to different areas o f the basal ganglia. It has been shown previously, with the 
use o f retrograde tracing techniques, that the majority of neurons expressing 
enkephalins project to the globus pallidus and few to the substantia nigra. In 
contrast, neurons expressing dynorphin and substance P primarily project to the 
substantia nigra, with only small projections to the globus pallidus (Graybiel, 
1986; Besson et al.. 1990). It has also been reported that there are differences 
in the abundance of mRNAs encoding neuropeptides contained in the same 
population of cells. For example, protachykinin mRNA appears to be 
considerably more abundant than prodynorphin mRNA (Young et al.. 1986), 
although both are located in striatoentopeduncular and striatonigral projection 
neurons. Similarly, somatostatin mRNA appears to be much more abundant 
than neuropeptide Y mRNA (Morris, 1989), although they are coexisting in the 
same cells. Protachykinin mRNA and prodynorphin mRNA show some 
indication of being preferentially located in the "patch" compartment o f the 
striatum (Gerfen and Young, 1988; Morris et al.. 1989).
In vitro, there is only limited evidence to suggest what classes of 
neurons exist in the striatum. However, extracts of primary striatal cultures 
have been shown to contain immunoreactive (ir) somatostatin and substance P
(Kessler, 1986) and proenkephalin mRNA (Schwartz and Simantov, 1988; 
Vilijn et al.. 1988), while analysis at the cellular level has shown the presence o f  
GABA (Messer, 1981; Weiss et al.. 1986; Surmeier et al.. 1988), along with ir- 
leu-enkephalin (Surmeier et al.. 1988) which could arise from the expression o f  
either the prodynorphin gene or the proenkephalin gene and ir-somatostatin 
(Williams et al.. 1991). Of these, only GABA ir-leu-enkephalin and ir- 
somatostatin have been localised to neuronal cells rather than glia (Surmeier et 
al., 1988; Williams et al.. 1991). Therefore, it remains unclear to what extent 
the other neuroactive substances detected in culture extracts are derived from 
non-neuronal cells.
1.3 Characterisation o f Dopamine receptors
1.3.1 Molecular Biologv
The dopaminergic system relies on the interaction of dopamine with 
several receptors. Dopamine can either inhibit or excite neurons (Bloom et al.. 
1965; McLennan and York., 1976). In 1979, Kebabian and Caine characterised 
two classes of dopamine receptor namely the D l and D2 receptors. The 
concept o f two distinct types of dopamine receptors mediating these two 
electrical effects (Cools and Van Rossum., 1976) was strengthened when it was 
found that the inhibition or excitation by dopamine could be selectively blocked 
(Struyker Boudier et al.. 1974; Heiss and Hoyer., 1974). These two receptors 
were found to exert their biological actions by coupling to, and activating
different G-protein complexes. The D l dopamine receptor interacts with Gg 
complexes resulting in the activation o f adenylyl cyclase and an increase in 
intracellular cyclic AMP levels (Kebabian and Greengard., 1971). . The
D2 dopamine receptor interacts with G[ complexes to inhibit cyclic AMPf t  Cll )
production and thus decrease intracellulai^levels (De Camilli 1979).
.Over the past decade the introduction of new molecular biological ■
techniques have enabled the dopaminergic receptors to be cloned. The D2
a
1
receptor was originally cloned using a low stringency screening approach of rat 
complementary DNA (Bunzow et al.. 1988). However the polymerase chain 
reaction approach was used originally to clone the D l receptor from rat 
striatum (Zhou et al.. 1990; Sunahara et al.. 1990) and from mouse 
neuroblastoma cells (Monsma et al.. 1990). The low stringency approach to 
cloning the D l receptor also proved to be successful (Dearry et al.. 1990).
Molecular cloning of G-protein linked receptors advanced rapidly with 
three further members o f the dopamine receptor family being cloned, namely 
the D3, the D4 and the D5 dopamine receptors. The D3 receptor was originally 
identified using a DNA fragment of the D2 receptor as a probe under low 
stringency hybridisation conditions fSokoloff et al.. 1990; Giros., 1990). When 
expressed in eukaryotic cells this receptor was shown to bind D2, but not D l 
ligands. By analysing mRNAs of a human cell line with D2 receptor 
complementary DNA (cDNA) probes, another D2-related mRNA was 
detected. The corresponding cDNA and gene analysis lead to the 
characterisation of the D4 receptor (Van Toi et al.. 1991). The D4 receptor 
when expressed in COS-7 cells, binds D2 antagonists with a pharmacological 
profile distinct from, but reminicent of that of the D2 receptor. The G-protein 
coupled D4 receptor has also been demonstrated to be coupled to adenylate 
cyclase in the mouse retina (Cohen et al.. 1992).
Finally the D l dopamine receptor clone was used as a hybridisation 
probe to identify Dl-related genes. A human D5 and a rat DIB receptor were
subsequently characterised (Zhou et ah. 1990; Sunahara et ah. 1991; Grandy et 
.al., 1991; Tiberi et al.. 1991; Weinshank et al.. 1991). The genes encoding for
1.3.2 Dopamine Receptor Ontogenesis
the lateral ventricle. The labelled cells were shown to have a neuroblastlc and
D5 and DIB receptors are introniess, unlike the genes encoding for the D2, D3 
and D4 receptors, which are known to contain introns. The D5 and DIB
display the same pharmacological profile, similar to that of the D1 receptor and 
are able to stimulate adenylyl cyclase activity.
.The recent development of molecular biology techniques such as in situ
J;::
hybridisation (Le Moine et al.. 1991) and Northern blot analysis (Jaber et al..
1992) have been used to study the localisation and regulation of dopamine 
receptor gene expression in rat and human brain. Using in situ hybridisation , it 
has recently been shown that the mRNA for the two isoforms of the dopamine 
D2 receptor, are detectable from gestational day 14 (G14) in the rat striatal 
primordium. At day 16 , D2 receptor mRNA was present in the lateral part o f 
the striatum and in the germinal ventricular zone lining the lateral ventricle. At 
day 18, D2 receptor mRNA was found in neurons of the caudate-putamen, the 
nucleus accumbens, the olfactory tubercle and the subependymal zone lining
I?i
immature aspect before birth. After birth the topography and aspect of labelled
cells was similar to the one observed in the adult animals (Guennoun and 
Bloch, 1991). A more sensitive method of detection known as reverse 
transcriptase polymerase chain reaction has recently been used to show D2 
mRNA prenatally (Mack et al.. 1991). This method has been used to detect D l,
I
DIB and the D3 mRNA. The D l receptor mRNA was detectable at gestational 
day 11 (G11) in the rat forebrain. The hybridisation signal remained relatively 
faint until G18 when it took on a more intense signal (Cadoret et al.. 1993). By 
gestational day 19, the D l receptor mRNA was detectable by in situ *
hybridisation methodology (Guennoun and Bloch, 1992). The presence of D3 
receptor mRNA was clearly detectable from G14 to G20 (with a maximum at 
G15), even though weak signals were observed as early as G11 (Cadoret et al..
1993). The rat DIB receptor mRNA was detectable from gestational day 12, 
but the signal remained weak until G18-20 (Cadoret et al.. 1993). At present, 
the ontogenesis of the D4 receptor is not fully characterised.
The presence of dopaminergic markers has been reported at very early 
stages of brain development. Indeed, tyrosine hydroxylase and dopamine have 
been detected in the rat striatum at G14 (Foster et al.. 1987) before the full 
maturation of the dopaminergic system. It has also been suggested that the 
development of dopaminergic receptors is dependent on the development of the 
presynaptic nerve terminals containing the transmitters (Deskin et al.. 1981). 
Increasing evidence has shown that the dopamine receptors can be functional at 
very early stages of development. In avian retina embryonic cells in vitro, it has 
been demonstrated that stimulation of early dopamine receptors greatly inhibits 
the motility of the neuronal growth cone via a frinctional Dl-type system 
(Lankford et al.. 1988). The D2 receptor has previously been shown to be 
modulated by guanylnucleotides as early as gestational day 15 (G15), 
suggesting that these receptors were already functionally coupled to a 
regulatory G-protein (Sales et al.. 1989). Furthermore, presynaptic D2 
receptors appear to be functional as soon as dopamine release from striatal 
slices can be detected (De Vries et al.. 1992). Therefore the evidence to date 
suggests that the chemical environment (i.e. neurotransmitters) acts as a 
regulator of neuronal growth during development (Lankford et al.. 1988; 
Mattson, 1988).
1.3.3 Tissue Distribution of Dopamine Receptors
The distribution o f the different dopamine receptor subtypes have 
.revealed some important differences that may underlie functional differences. 
Since tissue distribution of the different dopamine receptors overlap in the 
central nervous system some selectivity may be obtained quantitatively rather 
than qualitatively. It has been shown using blotting analysis that the D3, D4 and 
D5 mRNAs are one to two orders of magnitude lower in abundance than D l 
or D2 mRNAs fSokoloff et al.. 1990; Van Toi et al.. 1991; Tiberi et al.. 1991). 
The anatomical distribution of both D l and D2 subtypes is such that mRNA for 
both subtypes exists in high levels in the caudate-putamen, nucleus accumbens 
and the olfactory tubercle (Meador-Woodruff et a!.. 1991). However, high
levels of D2 mRNA, but not D 1 mRNA are present in the substantia nigra and 
ventral tegmental area, whereas conversely the amygdala contains 
predominantly D l mRNA. The distribution of D5 receptor mRNA was first 
reported to overlap t ^  D l nfRNA (Sunahara et al.. 1991), but recent studies 
have subsequently conflicted with this view. It has since been found that D5 
mRNA is present only in the hippocampus, hypothalamus and the parafasicular 
nucleus of the thalamus (Tiberi et al.. 1991; Meador-Woodruff et al.. 1992).
The newly cloned D2-like receptors, the D3 and the D4 subtypes have
also been shown to have some unique tissue distribution. The distribution of 
D3 receptor gene transcripts in rat brain has been shown to be markedly 
different fi*om that of the D2 receptor gene transcripts. A weak hybridisation 
signal has been observed in restricted parts of the striatum, although D3 
receptor mRNA was found to be highly expressed in the olfactory tubercle- 
island o f Calleja complex, the bed nucleus of stria terminalis and in the nucleus 
accumbens fSokoloff et al.. 1990; Levesque et al.. 1992; Sokoloff et al.. 1992).
î
The expression of the D4 mRNA was shown to be relatively high in the 
monkey frontal cortex, midbrain area, amygdala and medulla, but lower levels 
were detected in the basal ganglia (Van Toi et al.. 1991). In the rat, significant 
levels of expression were found in the hypothalamus, thalamus, olfactory bulb 
and frontal cortex. However, 20-fold higher levels of D4 mRNA were observed 
in the cardiovascular system (O’ Malley et al.. 1991). The D4 dopamine 
receptor transcripts have also been observed in the mouse retina (Cohen et al..
1992).
1.3.4 Cellular Localisation of Dopamine Receptors
The cellular localisation o f dopamine receptors is currently a matter o f 
much controversy. At present there are two schools of thought concerning this 
issue as some research groups support segregation of D l and D2 dopamine 
receptors in the striatum (Gerfen et al.. 1990; Le Moine et al.. 1990; Gerfen, 
1992; Le Moine et al.. 1992), whilst other groups hold to the idea that D l and 
D2 dopamine receptors occur on the same cell (Seeman et al.. 1989; Bertorello 
et al.. 1990: Piomelli et al.. 1991; Surmeier et al.. 1993).
Research supporting segregation of D l and D2 dopamine receptors in 
the striatum is based on studies performed in intact rats, and thus the 
segregation is thought not to be a consequence of denervation of dopaminergic 
nerves. Stimulation o f D l and D2 receptors has been shown to preferentially 
affect the function of striatonigral and striatopallidal neurons, respectively, in 
the intact striatum. Treatment with D2 antagonists rapidly induces expression
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of the immediate early gene c-fos specifically in striatopallidal neurons 
(Dragunow et al.. 1990; Robertson et al.. 1992), Conversely, indirect dopamine 
receptor agonists result in Dl-mediated changes in the mRNA and protein 
levels o f immediate early genes (Cole et al.. 1992; Beretta et al.. 1992; Cenci et 
al., 1992; Steiner et al.. 1993) predominantly in striatonigral neurons. The 
effects of dopamine depletion on striatal neurons are also thought to be 
consistent with differential localisation o f D l and D2 receptors on striatonigral 
and striatopallidal neurons. Enkephalin mRNA and protein, which are 
predominantly localised to striatopallidal neurons ( Gerfen and Young, 1988), 
are elevated by this depletion ( Young et al.. 1986; Gerfen et al.. 1990; Li et al.. 
1990; Gerfen et al.. 1991; Engber et al.. 1992). Conversely in striatonigral 
neurons, mRNA and peptide levels of substance P and dynorphin are decreased 
( Young et al.. 1986; Gerfen et al... 1990; Li et al.. 1990; Gerfen et a l. 1991). 
The levels of D l and D2 receptor mRNA, together with receptor binding, are 
decreased and increased respectively (LaHoste et al.. 1991., Joyce, 1991; Blunt 
et al.. 1992). The lesion-induced alterations of peptide and D l receptor 
mRNAs in striatonigral neurons are reversed by treatment with Dl-selective 
agonists, whereas the alterations in peptide and D2 receptor mRNAs in 
striatopallidal neurons are reversed by D2 receptor agonists (Gerfen et al.. 
1990; Engber et al.. 1992). In situ hybridisation studies have also demonstrated 
that D l and D2 receptors are expressed preferentially in one of two 
populations of striatal efferent neurons, substance P-containing and enkephalin- 
containing neurons respectively, with little or no overlap of expression (Le 
Moine et al.. 1990: Gerfen et al.. 1990; Le Moine et al.. 1991).
Alternatively the hypothesis for colocalisation of dopamine receptors is 
also strongly supported. On the basis of sensitive RNA detection techniques, 
current recordings obtained from single cells in vitro (Surmeier et al.. 1992) 
and immunohistochemical data (Ariano et a l. 1992), Surmeier and colleagues 
have suggested that D l, D2 and D3 receptors are largely colocalised in most
11
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.ilStriatal efferent neurons, especially striatonigral neurons. Using
immunohistochemical techniques, the D2 receptor staining pattern in both
striatonigral and striatopallidal neurons has been observed by several research
groups ( Ariano et al.. 1993; Boundy et al.. 1993). Other
immunocytochemical work relevant to the issue includes localisation of
DARPP-32 which is strongly correlated with D l receptor binding in both
striatonigral and striatopallidal neurons. Recently, other signalling elements in
the D l receptor pathway have been found in both striatonigral and 
.striatopallidal neurons. It has been shown that most medium spiny neurons are 
immunoreactive for a particular G-protein oj-subunit that mediates D l receptor 
activation of adenylate cyclase in the neostriatum (Herve et al.. 1993). Some of 
the in vitro research supporting colocalisation has been argued against, because 
of the possible alterations in cellular environment affecting mRNA levels.
However there has been much research performed in vivo supporting the 
convergence theory, including peptide expression assays (Haverstick et al.,
1989; Morris and Hunt., 1991; Angulo, 1992) and electrophysiological studies 
(Hu et al.. 1990). Ultimately, further research and more sensitive techniques are 
necessary in order to answer the question of dopamine receptor localisation.
..V,a;
1.4 Drug Pharmacologv of Dopamine Receptors
1.4.1 Dl-Like Receptors
The sensitivities of the cloned D l and D5 receptors to antagonist drugs 
are very similar and are also generally the same as those D 1 receptors in native 
tissue (Seeman and Van Toi, 199#). It has been previously shown, with the use 
of binding studies in COS-7 cells, that the compound SCH23390 is a very 
potent antagonist, producing Ki values of 0.35nM and 0.30nM at D l and D5
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receptors respectively. Fluphenazine was shown to have some antagonistic 
properties at the D l and D5 receptors, although much less than SCH23390 
(Sunahara et al.. 1991).
For dopamine receptor agonists, however, it has proved difficult to 
obtain accurate comparisons of the agonist sensitivities of the cloned receptors 
with those in native tissues. This is because dopamine receptors in native 
tissues can readily adopt either a high-aflinity state or low-affinity state for an 
agonist, while cultured cells vary in their ability to reveal the high affinity state. 
COS-7 cells, for example, do not have sufficient or appropriate G-protein 
subunits to allow the high affinity state of a receptor to exist. Agonist drugs 
such as SKF38393, R-fenoldopam, and (-) apomorphine have a very high 
affinity for the Dl-like receptors. However, an important consistent difference 
between the D l and the D5 receptors is that dopamine itself is about ten times 
more potent at the D5 receptor (Sunahara et al.. 1991; Seeman and Van Toi,
1994).
and Van Toi, 1993). Moreover, 7-hydroxy-DPAT is approximately tenfold 
more potent at D3 receptors than at D2 receptors (Seeman and Van Toi,
1993). Quinpirole also has a relatively high affinity for all D 2 -like receptors 
(Van Toi et al.. 1991; Seeman and Van Toi, 1994).
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1.4.2 D2-Like Receptors
Accurate values for many of the agonist potencies at D2, D3, and D4 
receptors are not currently available. Nevertheless, some important selectivities 
are clearly emerging. For example, bromocriptine is about two orders of 
magnitude more potent at D2 and D3 receptors than at D4 receptors (Seeman
In the case of antagonists acting at D2-Hke receptors, haloperidol and 
fluphenazine have relatively high affinity for all D2-like receptors. Clozapine 
has been shown to be one to ten orders of magnitude more potent at D4 
receptors than at D2 or D3 receptors (Van Toi et al.. 1991; Seeman and Van 
Toi, 1994). With the use o f comparative binding studies, the density of D4 
receptors in the human striatum has been shown to be approximately 1 0 % of  
the total population of the D2-like receptors (Seeman et a l. 1993). 
Methiothepin has also been shown to block dopaminergic receptors (Enjalbert 
et al.. 1978; Lloyd and Bartholini, 1974). A small displacement of 
methiothepin was observed following treatment with high concentrations of
haloperidol, a dopaminergic receptor antagonist, suggesting that part of bound 
^H-methiothepin is also associated with dopaminergic receptors (Nelson et al.. 
1979).
1.5 Basal Ganglia Dvsfunction- The Clinical Implications
1.5.1 Parkinson's Disease
I1
Parkinson’s disease was first characterised by James Parkinson in 1817 
as a late onset disease manifested as tremor, ridgitity, postural abnormalities 
and bradykinesia. By 1960, Ehringer and Homykiewicz reported that these 
abnormalities were accompanied by a neurochemical change taking the form of 
a loss o f dopamine in the corpus striatum. In the early eighties Parkinson's 
disease was referred to as a neurodegenerative disease characterised by the loss 
of dopaminergic neurons from the pigmented substantia nigra (Fomo, 1982), i
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A considerable amount of research has been focussed on basal ganglia 
function. Animal studies, together with human postmortem analysis have 
provided a much greater understanding o f the pathophysiological basis for 
Parkinson's disease. The basic observation of decreased striatal dopamine in 
patients with Parkinson's disease was mimicked in the laboratory with 
chemicals such as reserpine, the neurotoxins 6 -hydroxydopamine, which causes 
a permanent lesion of dopaminergic projections to the striatum (Ungerstedt , 
1971) resulting in severe neurological impairment in rats reminiscent of several 
symptoms of Parkinson's disease (Homykiewicz and Kish, 1987), and 1- 
methyl-4-phenyl“l,2,3,6“tetrahydropyridine (MPTP) administered in primates 
which produces classic Parkinsonian-like symptoms thought to be due to the 
build up of a toxic metabolite (Langston, 1985). Further work revealed that 
dopamine depletion in rat brain via lesions increased dopamine turnover in the 
remaining terminals as a result of neuroplastic changes in the striatum 
(Zigmond et a l. 1984). Moreover, recent evidence indicates that this 
neurochemical response is associated with the maintenance of the extracellular 
dopamine concentration at near normal levels despite the loss of dopamine 
terminals (Robinson and Wishaw, 1988; Zhang et al.. 1988). Disruption of 
dopaminergic transmission with the use of dopamine antagonist drugs such as 
spiroperidol in rats previously lesioned, has been shown to result in significantly 
impaired behaviour patterns, but no effects were observed on intact rats given 
the same dose (Heffner et al.. 1977). An increase in the spontaneous firing rates 
of striatal cells have also been associated with dopamine depletion, suggesting 
that the dopamine neurons exert an inhibitory influence on striatal activity (Orr 
et al.. 1986).
A standard treatment for Parkinson's disease sufferers involves 
administration of levodopa, which is taken up by nerve terminals where it is 
decarboxylated to dopamine. The dopamine then activates receptors in the 
region of the depleted striatum and substantia nigra (Kandel and Schwartz,
1985; Gilman et al.. 1985). Several studies have also demonstrated that 
dopaminergic D2 receptor agonists such as apomorphine can produce 
locomotion and stereotyped behaviour in lesioned animals when administered 
at dose levels which were shown to be ineffective in normal rats (Hollister et 
ai., 1974; Kelly et al.. 1975 ). This lead to the suggestion that dopamine 
receptors became “supersensitive” after lesioning (Hollister et al.. 1975). The 
indirect dopamine receptor agonist amphetamine is also known to enhance 
locomotor activity at low doses, whilst producing repetitive stereotyped 
behaviour at high doses. These two aspects of animal behaviour have been 
attributed to separate neural systems, such that dopamine in the caudate is 
essential for stereotyped behaviour and dopamine in the nucleus accumbens 
septi is linked to an enhanced locomotor activity following amphetamine
administration, after a 6 -hydroxydopamine lesion (Kelly et al., 1975).
Amphetamine has been shown to cause the release o f dopamine from the 
caudate-putamen (Ungerstedt, 1971; Voigtlander and Moore, 1973).
Dopamine-containing neurons of the substantia nigra pars compacta are 
known to release dopamine from both the terminals in the striatum and from 
the dendrites in the substantia nigra pars reticulata (Cheramy et al.. 1981). 
When dopamine neurons degenerate as in Parkinson's disease, or are destroyed 
by neurotoxins, the D2 dopamine receptors in the substantia nigra pars 
compacta disappear because the D2 receptors are almost entirely confined to 
dopamine neurons (Quik et al.. 1979; Murrin et al.. 1979). However, D l 
receptor density in the substantia nigra pars reticulata, which is as high as the 
D l receptor density in the striatum (Boysen et al.. 1986), is unaffected by such 
dopamine neurotoxin lesions because the D l receptors are presynaptic and are 
located on the terminals of descending striatonigral fibres (Savasta et al..
1986). Supersensitivity of dopamine D l receptors has been demonstrated in the 
absence of dopamine stimulation (Savasta et al.. 1986). Electrophysiological 
studies have also suggested that D l dopamine receptor stimulation decreases
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cell firing rates in the substantia nigra pars reticulata, presumably by increasing 
release of the inhibitory transmitter GABA from the terminals of the 
striatonigral fibres (Weick and Walters, 1987). This has also been demonstrated 
in nigral slice studies in vitro (Aceves et al.. 1991). It has since been suggested 
that a D1-D2 synergy exists, in which dopamine plays a central role as both a 
regulator and effector (Robertson, 1992).
A reduction in peptide levels in Parkinsonian basal ganglia has also been 
reported (Agid and Javoy-Agid, 1985). A decrease in methionine-enkephalin 
(met-Enk) and leuclne-enkephalin has been observed in the putamen and in 
both segments of the globus pallidus (Taquet et al.. 1983, 1985) indicating that 
these neuronal systems are altered in the disease. The level o f the neuropeptide 
substance P has also been shown to decrease in the lateral globus pallidus in 
Parkinson's disease patients (Mauborgne et al.. 1983).
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The interaction between dopamine and other neurotransmitters in the 
.basal ganglia, in particular the dopamine-glutamate interaction, has been
implicated in neurotoxicity at the nigrostriatal dopamine terminals. Stimulation
of excitatory amino acid receptors of the N-methyl-D-aspartate (NMDA)
subtype has been shown to enhance dopamine release (Snell and Johnson,
1986; Clow and Jhamandas, 1989) and synthesis (Arias-Montano et al.. 1992)
.within the striatum. In the dopamine-depleted striatum, an elevation of NMDA 
receptor binding was shown and was found to be greatest in the dorsal caudate 
and putamen, regions that were found to have extensive loss of dopamine 
transporter sites (Weihmuller et al.. 1992). Similar findings of a relationship 
between reduced striatal dopamine content and increased binding to NMDA 
receptors have been reported in the 6 -hydroxydopamine treated rat model of 
Parkinson's disease (Samuel et al.. 1990).
It has therefore been proposed that a decreased dopamine activity in the 
striatum of Parkinson’s disease patients will, through direct and indirect basal 
ganglia pathways, release the substantia nigra pars reticulata and
Æ
6entopeduncular neurons from their inhibitory controls, due to a lack of 
dopaminergic excitation from the substantia nigra pars compacta. 
Consequently thalamic targets of the substantia nigra pars reticulata and 
entopeduncular nucleus will be inhibited, leading to a diminished 
thalamocortical activation. This reduced cortical activation is thought to result 
in a decreased activity of striatocortical neurons and thus reduced striatal 
glutamate release. Thus the overall effect o f dopamine loss in the striatum is 
inhibition of cortically initiated movement, to cause akinesia, hypokinesia, and 
bradykiesia. As a consequence, upregulation of NMDA receptors within 
striatal target neurons may occur as a compensatory mechanism (Weihmuller et 
al., 1992). In coordination with this result, chronic NMDA receptor 
antagonism can lead to increased receptor sensitivity (Norman et al.. 1990).
1.5.2 Schizophrenia
Ivia
■1
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The discovery of neuroleptics in 1952 (Delay et al.. 1952) initiated
research seeking a possible biological basis for schizophrenia. Various
'
hypotheses have been proposed and are currently under investigation.
The dopamine hypothesis of schizophrenia proposes that dopamine 
pathways are overactive in the disease state (Van Rossum, 1967; Matthysse, 
1973). Much of the evidence for this hypothesis is based on the fact that 
neuroleptic drugs block dopaminergic D2 receptors (Seeman et al.. 1975; 
Creese et al.. 1976). This action of neuroleptics is thought to account for 
neuroleptic-induced Parkinsonism and hyperprolactinaemia. Additional 
evidence for a dopaminergic basis for schizophrenia comes from the 
exacerbating effects of dopamine-mimetic drugs (Seeman, 1987; Lieberman,
1987) and the elevation of dopamine D2 receptors in the post-mortem brains 
taken from schizophrenic patients (Cross et al.. 1981; Joyce et al.. 1988;
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Reynolds et al.. 1988; Seeman and Niznik, 1990). The density o f D l dopamine 
receptors remains normal in schizophrenia (Seeman et al.. 1987; Seeman and 
Niznik, 1990).
A different approach to understanding the pathophysiology of
cortex in schizophrenic patients (Nishikawa et al.. 1983; Deakin et al.. 1989) 
may provide neurochemical evidence for a dysfunction of this transmitter 
system. Hence it has been suggested that drugs effective in alleviating the 
symptoms of schizophrenia that do not respond to classical antipsychotics may 
do so by interaction with glutamate systems. Recent evidence has emerged 
showing human cortical pyramidal neurons to be enriched with 5-HTlA 
receptors (Bowen et al.. 1992). This provides a potential receptor mechanism
schizophrenia is provided by use of phencyclidine, which can be used to induce 
a syndrome of both negative and positive schizophreniform symptoms. The 
behavioural effects o f phencyclidine are due at least in part, to its ability to 
block glutamate function via the NMDA receptor (Javitt and Zukin, 1991). 
Reported alterations in glutamatergic synaptic markers, particularly of frontal I
for the modulation of cortical glutamatergic neurons, raising the possibility that 
an interaction with 5-HTlA receptors may contribute to the restoration of 
normal glutamatergic fiinction after neuroleptic drug administration.
1 .6  Second Messenger Pathwavs induced bv Dopamine Receptor Stimulation
Cori and co-workers made the initial discovery that protein 
phophorylation was essential for all forms of signal transduction (Cori and 
Cori., 1945). In the mid 1950's Sutherland and his associates contributed to this 
finding by discovering that cyclic AMP was the "second messenger" involved in 
the transmission of effects of noradrenaline in the liver, and later demonstrated
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that cyclic AMP caused the transfer of phosphate groups between key proteins 
(Robison and Sutherland., 1971).
The ability of dopamine receptors to induce different second messenger 
pathways has thus far been studied in D l and D2 receptors (Vallar et al.. 
1990). The D l and D2 dopamine receptors induce two types of signal 
transduction pathway, one obligatory and several cell specific. In D l or D2 
receptors the obligatory pathway is detected in every cellular environment and 
represents stimulation or inhibition of adenylyl cyclase, respectively. However, 
dopamine can also induce additional and sometimes different signal 
transduction pathways depending on the cell type.
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Figure 1 : Signalling pathways of the D l and D2 dopamine receptors in the 
mouse fibroblast Ltk-and the rat somatomammotroph GH4C1 cells. DA 
represents dopamine, CTX and PTX means cholera toxin- and pertussis toxin- 
sensitive, respectively. G = G protein; PLC = phospholipase C; AC = adenylyl 
cyclase; PIP2 = phosphoinositol bisphosphate; IP3 = inositol triphosphate. The 
direction of arrows indicates whether the second messenger increases or 
decreases.
m a n n e r 111 ehdl j IA The D l receptor has also been associated with an
increased hydrolysis of phopholipids and calcium mobilization in xenopus 
oocytes (Mahan et al.. 1990). The D2  receptor, while inhibiting adenylyl 
cyclase activity, does not affect phosphoinositide hydrolysis in GH4C1 cells and
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In every cell studied, stimulation of the D l dopamine receptor increases cyclic 
AMP production. In addition, in GH4C1 cells, the D l receptor potentiates 
activation of L-type voltage-dependent calcium channels in a cyclic dependent
I
causes a decrease in intracellular free calcium mediated by a hyperpolarizing
( i )
effect, mostly due to activation o f potassium channels. However, in Ltk-cells, 
activation of the D2 receptor leads to an increase in intracellular free calcium
partly due to release of calcium ions from intracellular stores following the 
rapid stimulation of phosphoinositide hydrolysis and , in part, to influx from 
extracellular medium ( Gatti et al.. 1991 ). In addition, in Chinese hamster ovary 
(CHO) cells, D2 receptors have been shown to mediate the potentiation of 
arachidonic acid release by a mechanism that involves protein kinase C, and is 
independent of adenylyl cyclase inhibition (Kanterman et al.. 1990).
Activation of kinase enzymes prior to protein phosphorylation and the 
resultant physiological effect has proved to be an important target for the 
understanding of receptor mediated events. It has become clear that a great 
many different protein kinases exist (Hunter, 1987). These kinases can be 
broadly divided into two large groups, the protein seryl or threonyl kinases and 
the protein tyrosyl kinases, based on their specificities towards the different 
amino acids in the protein (Krebs, 1985). A given kinase may phosphorylate a 
number of different proteins, however it usually recognises a short sequence of 
amino acids referred to as a 'consensus sequence'. This was first demonstrated 
by work on the cyclic AMP-dependent protein kinase (PKA) (Kemp et al.. 
1975; Humble et al.. 1975; Kemp et al.. 1976). Using synthetic peptides the 
consensus substrate sequence for PKA was defined (
Kemp et al.. 1977). It was concluded that PKA preferentially phosphorylated a
2 1
serine located at the second position after a pair of arginines as in the following 
sequence X-Arg-Arg-X-Ser-X (X= neutral amino acid).
1.7 Cyclic AMP-dependent Protein Kinase (TKAl
Cyclic AMP-dependent protein kinase (PKA) is an enzymatically 
inactive tetramer composed of two regulatory (R) and two catalytic (C) 
subunits. PKA undergoes dissociation when the enzyme is activated by cyclic 
AMP (Brostrom et al.. 1971 ; Gill and Garren, 197^; Kumon et al.. 1971: Tao 
et al.. 1970). The following equation for the activation reaction was composed 
after the quaternary structure of the enzyme had been determined (Beavo et al.. 
1975; Rosen et al.. 1975) and the extent of cyclic AMP binding clarified 
(Corbin et a l. 1978).
R2 C2  + 4cAMP = R2  (cAMP) 4  + 2C 
The regulatory subunits exist in dimeric form which is retained after 
dissociation, whereas the catalytic subunits exist as monomers. ^ Each R subunit 
binds two molecules o f cyclic AMP.
In the brain PKA is broadly distributed in specific areas (Cadd and M^ 
Knight., 1989). It plays an important role in neuronal regulation over different 
time frames. Protein kinase A acutely modulates the activity or function of 
neuron -specific enzymes (Zigmond et al.. 1989) and/or channel proteins (Li et 
al., 1992; Sculptoreanu et al.. 1993) by catalysing the phosphorylation of these 
proteins. In such instances, evoked PKA activity produces rapid changes in 
neuronal function via direct phosphorylation of existing protein molecules. 
Alternatively, translocation of the active catalytic subunit of PKA into the 
nucleus and subsequent phosphorylation of nuclear proteins, including 
transcriptional activators, gives rise to slower long term changes in neuronal
2 2
function. In such instances PKA regulates de novo synthesis o f mRNA leading 
to new protein synthesis.
In many cyclic AMP-responsive genes an octomer sequence motif 
known as the cyclic AMP (cAMP) response element (CRE) resides in the 5' 
upstream region and mediates cAMP responsiveness (Roesler et al.. 1989; 
Goodman et al.. 1990). PKA regulates the transcriptional activity of the CRE 
by catalysing the phosphorylation o f transcription factors. One such 
transcription factor is the CRE-binding protein CREB (Hoeffler et al.. 1988; 
Gonzalez et al.. 1989). After phosphorylation by PKA CREB can activate 
transcription of CRE-containing genes (Gonzalez and Montminy., 1989; Lee et 
ai., 1990).
1.8 Protein Kinase C (PKCl
In the nervous system, activation of protein kinase C (PKC) has been 
related to enhancement of neurotransmitter release (Malenka et al.. 1986; 
Malenka et al.. 1987), control of growth differentiation (Burgess et al.. 1986; 
Spinelli and Ishii, 1983) and modification of neuronal plasticity (Routenberg,
1985).
PKC consists of a family of closely related proteins highly concentrated 
in the central nervous system. This protein kinase is present in a wide variety of 
tissues. Recent reports indicate that PKC's are heterogenously distributed in the 
brain and that neurons contain the highest levels of PKC (Huang, 1987; Brandt 
et a l. 1987). Molecular cloning has established the existence of several PKC 
isoforms, illustrating the diversity of this enzyme family. PKC's can be divided 
into two major groups, group A and group B, based on their sequence 
similarity at several coding regions. Group A PKC-catalysed phosphorylation
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on their structural similarities. Among these families is the fos family whose 
members are closely related to c-fos (e.g. fos-B, Zerial et al.. 1989) or the jun 
family, whose members are closely related to c-jun (e.g. jun-B, Ryder et al..
has been shown to be dependent on calcium and phosphatidylserine for its
activation (Takai et a l. 1979; Kaibuchi et al.. 1981).
Protein kinase C can be activated by a naturally occurring product |
diacylglycerol (DAG), an intermediate in the biosynthesis and degradation of 
glycerolipids. DAG is thought to increase the affinity of the enzyme for calcium 
and phospholipid (Takai et al.. 1979; Kishimoto et al.. 1980). Tumour- 
promoting phorbol esters have also been shown to stimulate activity of PKC's in 
vitro (Blumberg, 1980; Chiang et al.. 1981). It is currently the idea that DAG 
may be derived from the hydrolysis of a small pool of membrane 
phosphatidylinositol 4, 5-bisphosphate (PIP2 ) by phosphatidylinositol-specific 
phospholipase C, resulting in a rise in inositol triphosphate (IP3 ) and
consequently intracellular calcium and diacylglycerol (Berridge, 1987). This 
signalling pathway has been linked to the actions of many neurotransmitters.
Another potential source of DAG is derived through hydrolysis of
phosphatidylcholine (Chan et al.. 1989).
1.9 Immediate Earlv Genes
Immediate early genes (lEGs) were initially characterised in non- 
neuronal cells while studying growth factor responsive-genes. This research lead
to the discovery of a unique class of genes, whose transcription can be activated 
within minute^ The c-fos and c-myc protooncogenes were among the first lEGs 
to be identified (Kelly et al.. 1983; Greenberg and Ziff, 1984). Many lEGs have 
since been identified in the brain and can be divided into distinct families based
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1988) and jun-D (Ryder et al.. 1988) or the homeobox POU-domain containing
proteins (e.g. RHS2, Le Moine and Scott Young, 1992) or the homeobox fork 
head gene, BF-1 (Mathis et al.. 1992). However, some lEGs are structurally ' i-L- ..
unique, as for example zifr268, a zinc finger containing protein (Millbrandt,
'1987). lEGs have a number of characteristics that makes them different from late 
response genes. Their expression tends to be low in quiescent cells, but is rapidly
induced at the transcriptional level within minutes of extracellular stimulation. 
This transcriptional induction is transient and independent of new protein 
synthesis. Although, the subsequent shut-off of transcription requires new 
protein synthesis.
The lEG is currently thought to function as a transcription regulatory 
factor, that may act as a molecular switch coordinating changes in gene 
expression (Sheng and Greenberg, 1990). Direct evidence for a regulatory
function came from the findings that many lEGs were found to encode 
transcription factors. This has been best established for c-fos and c-jun, both of  
which were initially identified as protooncogenes (Van Beveren et al.. 1983; 
Maki et al.. 1987). Recently it has been demonstrated that the products of these 
lEGs can interact with each other to form a heterodimeric transcription factor 
complex (Halzonetis et al.. 1988; Kouzarides and Ziff, 1988; Nakabeppu et al., 
1988; Rauscher et al.. 1988). This interaction was later shown to occur through 
a conserved dimérisation domain referred to as a 'leucine zipper' that is present 
in both fos and jun proteins (Landschultz et al.. 1988; Kouzarides and Ziff, 
1988; Bos et al.. 1989; Gentz et al.. 1989; O'Shea et al.. 1989). The leucine 
zipper domain was shown to have an or- helical structure (Landschultz et al..
1988). Adjacent to the leucine zipper, a highly basic stretch of amino acids 
were identified and shown to be required for the interaction of the fos/jun 
heterodimer with DNA (Kouzarides and Ziff, 1988; Gentz et al.. 1989; 
Neuberg et al.. 1989; Turner and Tjian, 1989). The heterodimer was 
demonstrated to bind with high affinity to the DNA consensus sequence -
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TGACTCA- (reviewed by Curran and Franza, 1988). The sequence -
TGACTCA- was initially identified as a phorbol ester-inducible promoter
element and the binding site for a transcription factor activity termed AP-1
(Angel et al.. 1987; Lee et al.. 1987). Fos and jun have since been shown to be
major components of the AP-1 site (Bohmann et al.. 1987; Rauscher et al..
1988). Different combinations of fos/jun and jun/jun dimers have been
demonstrated to bind to the AP-1  site in vitro (Nakabeppu et al.. 1988; Cohen 
.et al.. 1989). There is also some evidence of functional specificity for some 
lEGs. It has been shown in vitro that c-fos/c-jun complexes activate 
transcription of genes containing AP-1 sites, while c-fos/jun-B complexes
.f
appear, under some circumstances, to repress transcription (Chiu et al.. 1989;
Schutte et al.. 1989).
The mRNA encoding the immediate early genes Jun-D and c-jun is 
present constitutively in striatal neurons, and the corresponding proteins are 
likely to be available to form complexes with c-fos once it is synthesised. The 
mRNA encoding jun-B is not normally detectable in striatal neurons. Zif/268,
the zinc finger containing immediate early gene protein, was shown to bind to a
cloMqm encodeddifferent DNA consensus sequence, -GCGGGGGGCG-. The DNA binding^
by the homeobox genes, RHS2 and BF-1 is relatively large in comparison to other 
.gene families studied. The POU-domain for RHS2 spans 145 amino acids (Le 
Moine and Scott Young, 1992) and for BF-1, the DNA binding sequence spans 
56 amino acids (Tao and Lai, 1992).
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1.10 Mechanisms of Induction of Immediate Earlv Genes
lEGs have been shown to be induced by a wide variety o f physiological 
stimuli, including electrical excitation, neurotransmitters and growth factors 
(Greenberg et al.. 1985, 1986; Morgan and Curran, 1986; Bartel et al.. 1989). 
Studies have shown that many of the stimuli used to induce lEGs have a 
common feature in that they lead to or substitute for, calcium influx through 
voltage sensitive calcium channels (Greenberg et al., 1986; Morgan and Curran,
1986).
The molecular basis of lEG regulation by trans-synaptic stimulation has been
studied primarily in PC 12 cells, Transcriptional activation o f c-fos as a result of 
. . .calcium influx involves a specific site on the gene termed a calcium response ■ :
element (CaRE) (Sheng et al.. 19881. This site was later shown to be 
indistinguishable from the cAMP response element (CRE) and that cAMP and 
calcium signals converge on this element in vivo (Sheng et al.. 1990). It has 
been demonstrated that both calcium and cAMP stimulation of PC 12 cells result 
in the rapid phosphorylation of transcription factor CREB, the, nuclear protein 
that binds specifically to the calcium/CRE (Gonzales and Montminy, 1989;
Sheng et al.. 1990). In response to cAMP, CREB is phosphorylated at a specific 
residue (Ser-133) known to be recognised by cyclic AMP dependent protein 
kinase (PKA) and to be important for activation of CREB as a transcription 
factor in vitro and in vivo (Yamamoto et al.. 1988; Gonzales and Montminy,
1989). This phosphorylation is thought to activate CREB via an allosteric 
mechanism (Yamamoto et al.. 1990), although it is still incompletely understood.
CREB is phosphorylated at the identical Ser-133 position in response to calcium
stimulation (Sheng et al., 1990). However evidence suggests that this
phosphorylation is mediated by a calcium regulated protein kinase (Sheng et al..
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1.11 Neuroleptics
Neuroleptics of various chemical classes have been used for more than 
35 years for the treatment of psychiatric disorders (Leysen and Niemegeers, 
1985). Neuroleptic drugs have been divided into two major classes, namely 
'typical' neuroleptics, such as haloperidol and fluphenazine, and 'atypical' 
neuroleptics such as clozapine and fluperlapine. It is now well accepted that 
blockade of dopamine D2 receptors plays a major role in their antipsychotic
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1990). The phosphorylated CREB then is thought to interact with the basic 
transcriptional machinery to stimulate gene transcription.
Genes containing calcium/CRE's include not only lEGs like c-fos and zifr268 
(Christy et al.. 1988; Changelian et al.. 1989), but also a group o f neuropeptide 
genes including somatostatin (Montminy et al.. 1986; Montminy and Bilezikjian,
1987), and proenkephalin ( Comb et al.. 1986).
While calcium and cAMP signalling pathways are likely to mediate gene 
activation by many different neurotransmitters in the central nervous system, 
another intracellular signalling mechanism has been shown to be involved in the 
regulation of neuronal lEG expression. The activation of the lEG, c-fos, by the 
protein kinase C pathway has been demonstrated to be mediated by a distinct 
upstream regulatory element known as the serum response element (Gilman et 
al., 1986; Prywes and Roeder, 1986; Treisman, 1986; Greenberg et al.. 1987; 
Sheng et al.. 1988; Gilman, 1988). The serum response element is a specific 
binding site for a nuclear protein termed the serum response factor (Gilman et 
al., 1986; Prywes and Roeder, 1986; Treisman, 1986; Greenberg et al.. 1987). 
This interaction plays a crucial role in c-fos activation by a diverse set o f stimuli, 
including phorbol esters (Sheng et a l. 1988).
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action (Leysen and Niemegeers, 1985; Meltzer et al.. 1989; Richelson, 1984; 
Seeman, 1980). However treatment with higher dosages o f  typical' neuroleptics 
has been shown to provoke adverse reactions such as extrapyramidal side effects 
following acute treatment and tardive dyskinesia after prolonged chronic
treatment. Mesolimbic and mesocortical dopamine D2 receptors were suggested 
to play a role in the antipsychotic effects of the drugs whereas extensive "j
occupancy of striatal D2 receptors was thought to be responsible for 
extrapyramidal side effects (Crow et a!.. 1977; Stevens, 1973; Wilk et al.. 1975).
The atypical neuroleptic, clozapine, has been shown to produce much less acute 
extrapyramidal side effects than typical neuroleptic drugs (Matz et al.. 1974). 
There have been no reliable reports that clozapine produces or exacerbates 
tardive dyskinesia, although it can block the symptoms of tardive dyskinesia 
(Meltzer and Luchins, 1984). In two relatively recent clinical trials, clozapine 
was shown to be a more effective antipsychotic drug than the typical neuroleptic 
chlorpromazine (Claghom et al.. 1987; Kane et al.. 1988). Meltzer (1989) 
suggested that the clinical advantages of the use o f clozapine may be due to a 
biological effect o f the drug on neurotransmitter systems. They later 
demonstrated that atypical antipsychotic drugs could be distinguished from
typical antipsychotic drugs on the basis of lower D2 and higher 5-HT2 pKi 
values.
More recently it has been suggested that potent serotoninergic 5-HT2 receptor 
antagonism could alleviate negative symptoms in schizophrenia. Moreover, 5- 
HT2 antagonists were shown to reduce neuroleptic-induced catalepsy in rats 
(Balsara et al.. 1979; Hicks, 1990), to increase neuroleptic-induced dopamine 
turnover (Sailer et al.. 1990), to cause a slight, indirect activation of midbrain 
dopaminergic neurons (Ugedo et al.. 1989), restoring phasic rather than tonic
activity (Svensson et al., 1989), and to reduce neuroleptic-induced
extrapyramidal side effects (Reyntjens et al.. 1986;
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1.12 Long term effects on late response genes in the basal ganglia
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Bersani et al.. 1990). Therefore it has been suggested that a critical balance
between 5-HT2 and dopamine D2 receptor antagonism is essential for the
beneficial effects of antipsychotic drugs (Meltzer et al.. 1989).
Clozapine, the prototype for atypical neuroleptics, shows higher affinity for
5-HT2 than for D2 receptors. However, it also shows a potent histamine HI
.receptor antagonism, which results in severe sedation. In addition, clozapine 
binds to 5-HTlC receptors, to a l-  adrenergic and to muscarinic receptors with 
5-10 times higher affinity than to D2 receptors. Therefore these additional 
properties may play a role in both the therapeutic and resultant side effects of 
clozapine treatment (Grohmann et al.. 1989). The relatively higher affinity of 
clozapine for D4 receptors than for D2 receptors was proposed as a possible 
underlying mechanism for the particular clinical properties of this compound 
(Van Toi et al.. 1991). Interest has consequently focussed on the ability o f  
neuroleptic drugs to cause long-lasting alterations in basal ganglia function, by 
changing the pattern of gene expression in striatal neurons.
«
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In 1978, Hong and colleagues demonstrated that either chronic blockade of 
dopamine receptors by neuroleptic drugs or lesioning the nigrostriatal pathway 
could increase levels of enkephalin peptides in the striatum. Consistent with this, 
in situ hybridisation studies later revealed changes in mRNA levels of 
proenkephalin after chronic treatment with dopamine receptor antagonists.
Chronic treatment with haloperidol, the relatively non-selective dopaminergic 
receptor antagonist, dramatically increased the levels of proenkephalin mRNA in 
the rat striatum (Sabol et al.. 1983; Tang et 'al.. 1983; Angulo et al.. 1986; Sivam 
et al., 1986; Romano et al.. 1987; Morris et al.. 1988). In situ hybridisation
»s
studies have also shown that unilateral nigral lesions induce a dramatic ipsilateral
increase in striatal proenkephalin mRNA levels (Angulo et al.. 1986; Young et
al-, 1986; Morris et al.. 1989; Cadet et al.. 1991), suggesting that the
nigrostriatal pathway exerts a tonic inhibition on the activity of the striatal
enkephalin-containing cells. The cells o f the ventral tegmental area were
demonstrated to exert a similar inhibition on the activity o f the enkephalin cells
o f the nucleus accumbens (Morris et al.. 1989). More recently, the elevation in
striatal proenkephalin mRNA levels following a nigrostriatal lesion, has been
positively correlated with an increase in rotation rate after subcutaneous
administration of amphetamine (Cadet et al.. 1991).
Conversely, studies have shown that the repeated administration of
dopamine receptor antagonist drugs can decrease the concentration of substance
P in the substantia nigra (Hong et al.. 1978; Hanson et al.. 1981; Le Douarin et
al., 1983; Oblin et al.. 1984; Sudzak and Gianutsos, 1984). Further evidence has
. .demonstrated that the levels of protachykinin mRNA, the precursor protein for
substance P, are decreased in the rat striatum after chronic treatment with the
antipsychotic drug, haloperidol (Bannon et al.. 1986). From in situ hybridisation
studies, the levels o f striatal protachykinin mRNA has been shown to be
»decreased following a nigral lesion, suggesting a tonic dopaminergic facilitation 
of the activity of the tachykinin cells (Young et al.. 1986). Recent evidence 
suggests that the release of substance P is decreased in the ipsilateral substantia ■
nigra after dopaminergic denervation of the striatum (Lindefors et al.. 1989).
In animal models of Parkinson's disease, met-Enk levels are increased in the
striatum (Engber et al.. 1991; Dacko and Schneider, 1993), while substance P
has been shown to be either unaltered (Sivam et al.. 1987) or decreased
(Lindefors et al.. 1989). Ceballos and colleagues have more recently suggested
that the population of neurons co-locallsing met-enkephalin and substance P can 
.adapt according to the extent of degeneration in the substantia nigra in 
Parkinson's disease patients. Patients with greater than 80% loss o f dopamine in
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the caudate show an increase in both met-enkephalin and substance P levels. 
However, in patients with approximately 50% loss of dopamine content in the 
caudate, levels of both peptides were markedly reduced by 80%.
A decrease in somatostatin mRNA has been observed in the striatum of rats
decreases preprosomatostatin mRNA levels not only in the caudoputamen, but
bhiSalso in the nucleus accumbens and in the frontal cortex. Therefore^suggest.a a 
widespread influence of dopamine on somatostatin neurons in target areas of the
1984; Radke et al.. 1988). It was suggested that this effect may be related to the
treated with haloperidol, suggesting that dopamine may be involved in the
• r
regulation of somatostatin mRNA levels (Salin et al.. IS ). Haloperidol
■I
mesencephalon. This is compatible with previous findings showing a decrease in 
immunoreactive somatostatin measured by radioimmunoassay in the striatum and
in the nucleus accumbens after chronic haloperidol treatment (Beal and Martin,
.
blockade of a stimulatory action of dopamine on somatostatinergic neurons is
mediated through dopamine D2 receptors, since haloperidol was shown to 
preferentially block D2 receptors (Sailer and Salama, 1986). However, it has 
since been shown that the region within the striatum, in which haloperidol 
significantly affects the levels of preprosomatostatin mRNA crresponds to an ■'i;
area of relatively low D2 dopaminergic binding sites (Dubois and Scatton, 1985;
gBoysen et al.. 1986). This implies that other mechanisms may be involved in the 
efïect o f haloperidol on preprosomatostatin mRNA levels in this brain region.
Evidence to support this further came from the observation that lesions of the 
nigrostriatal dopaminergic neurons, which markedly reduce dopamine levels in 
the striatum do not affect the number of neurons expressing somatostatin-like 
immunoreactivity in the striatum ipsilateral to the lesion (Salin et al.. 1990).
The mRNA levels of the neuropeptide prodynorphin were not greatly 
affected by chronic neuroleptic drug treatment (Morris et a l. 1988). A similar 
lack of effect on expression of prodynorphin mRNA was observed following 
nigral lesions (Young et al.. 1986; Morris et al.. 1989).
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Sailer and colleagues (1989) found that chronic treatment with the atypical 
neuroleptic clozapine increased the intensity o f preprosomatostatin mRNA in 
neurons, but not the number of neurons expressing the gene, in the nucleus 
accumbens. No effect was observed with clozapine in the striatum. The 
hypothesis that dopamine exerts opposite effects on the levels of 
preprosomatostatin mRNA in the striatum through an action on D1 and D2 
dopamine receptors was thought to be compatible with this lack of effect in the 
striatum. However, it has been suggested that the blockade of other
I
neurotransmitter receptors such as muscarinic, 5-HT2, and noradrenergic
receptors by clozapine (Kelley and Miller, 1975; Peroutka and Snyder, 1980)
may be responsible for the different effects of clozapine and haloperidol on 
.somatostatinergic neurons in the striatum (Sailer et al.. 1990). This evidence 
substantiates the present suggestion for a differential effect o f some antipsychotic 
drugs in the nigrostriatal and mesolimbic system (Chiado, 1988). The idea of a 
different mechanism of action of atypical and typical antipsychotic drugs has
gained further support from the finding that suggests that clozapine, but not 
haloperidol, increases the levels of glutamic acid decarboxylase mRNA, the 
enzyme involved in the synthesis of GAB A, in neurons of the globus pallidus
I
(external pallidum), implying a differential effect of these antipsychotic drugs on 
one o f the major output systems of the basal ganglia (Mercugliano et al.. 1989).
Dopaminergic receptor antagonists of D1 and D2 receptors have also been 
demonstrated to affect in opposite directions, the levels o f immunoreactive 
neuropeptide Y, a peptide colocalised with somatostatin in striatal neurons 
(Sandell et al.. 1986; Smith and Parent, 1986). Chronic treatment with 
SCH23390, which preferentially blocks D 1 dopamine receptors, increases the 
number o f neurons expressing neuropeptide Y-like immunoreactivity in the 
striatum. The dopaminergic D2 receptor antagonists, haloperidol and sulpiride 
were shown to have an opposite effect (Kerkerian et al.. 1988). Similarly at the 
cellular level it was shown that neuropeptide Y mRNA could be clearly increased
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in the rat striatum following chronic administration of the D1/D5 receptor
antagonist SCH23390 for three days (Morris, 1989).
1.13 Effect of Antipsychotic Drug Treatment on Immediate Early Gene 
Expression
The antipsychotic drugs are effective in the treatment of severe psychiatric 
disorders. Although many exert serious side effects and have limitations in 
efficacy which in turn has spurred a search for better compounds and a greater 
understanding of the pharmacology of antipsychotic drugs. The full therapeutic 
effect of antipsychotic drugs generally takes several weeks to emerge. Therefore 
it has been postulated that their interaction with neurotransmitter receptors are 
merely the initial step in their actions, and that the therapeutic effects result from 
adaptive processes that may occur in response to repetitive or chronic receptor 
occupancy by the drugs. A likely candidate mechanism for such drug induced 
neural plasticity is receptor -mediated regulation of neuronal gene expression. It 
is currently the idea that the induction of cellular lEGs may be'a critical signal 
transduction step in neural plasticity induced by neuroleptic drugs, with the 
protein products o f lEGs functioning to activate or repress genes that encode 
proteins involved in the differentiated functions of target neurons.
Recent evidence has shown that the dopaminergic system in brain is capable
o f responding in an adaptive manner to neuroleptic drug exposure, by inducing a
number o f dopamine D2 receptors (Seeman, 1980). This neurotransmitter system
has also been shown to participate in the induction of certain lEGs. The
dopamine precursor L-DOPA has previously been demonstrated to activate the 
.lEG c-fos in the rat striatum ipsilateral to a 6 -hydroxydopamine lesion of the 
substantia nigra via stimulation of dopamine D1 receptors (Robertson et al..
34 :ii
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1989). In agreement with this, systemic administration of D1 receptor agonists,
in particular SKF38393, have been shown to induce c-fos and 2dfr268 mRNA in
striatal neurones of rat brain after lesioning (Robertson et al.. 1990; Cole et al.,
1992). In contrast, haloperidol, a relatively non-selective dopamine receptor
antagonist together with selective dopamine D2 receptor antagonists such as YM 
.09151, eticlopride and (+) butaclamol have been shown to induce c-fos protein 
in rat striatal neurons (Miller, 1990; Deutch et al.. 1992; Slrinathsinghji et al.. 
1994) and in the nucleus accumbens (Dragunow et al.. 1990; Deutch et a l. 
1992), but not in other brain regions. Similarly, Nguyen and colleagues (1992) 
have shown that both c-fos and zift268 can be induced in the caudate-putamen at
■y
the mRNA level by systemic administration of haloperidol or amphetamine.
However the atypical neuroleptic, clozapine, was unable to induce c-fos mRNA
in the caudate-putamen, but was able to induce the expression of c-fos in the
.nucleus accumbens. A similar induction of ^ s  immunoreactivity has been
demonstrated in the shell but not the core region of the nucleus accumbens in the
rat after acute systemic clozapine treatment (Deutch et al.. 1992). Whilst the
selective D1 dopamine receptor antagonist, SCH23390 was demonstrated to
have no effect on the levels of fos protein (Dragunow et al.. 1990). A similar
lack of effect on the expression of c-fos mRNA in rat striatum has been observed
following systemic administration of the selective D2 receptor agonist LY
171555, but this compound was able to reverse completely the haloperidol 
.induced expression of c-fos mRNA (Miller, 1990). It was later shown that a 6- 
hydroxydopamine lesion of the substantia nigra alone could lead to a long lasting 
expression of fos related antigens in striatal neurons ipsilateral to the side of the 
lesion (Dragunow et al.. 1991). At present there is circumstantial evidence 
linking the haloperidol induction of c-fos to the subsequent increase in 
proenkephalin mRNA (Sonnenberg et al.. 1989; Donovan et al.. 1992), but this 
has been questioned by recent results suggesting that it is not the E)s protein that 
interacts with the proenkephalin enhancer, but it is a cAMP-responsive element ,>>1
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binding protein that appears to play a major interactive role ( Konradi et al.. 
1993 ).
A number of psychomimetic drugs including D-amphetamine and cocaine, 
with markedly different pharmacologic and clinical properties, have also been 
reported to activate striatal c-fos expression and a clear drug-specific pattern of 
gene activation has been shown in neurons o f the sensory-motor and limbic 
striatum (Robertson et al.. 1989; Graybiel et aï.. 1990; Nguyen et al.. 1992). The 
mechanism of induction of c-fos is thought to involve the stimulation of D1 
dopamine receptors (Robertson et al.. 1989; Graybiel et al.. 1990). Therefore, 
both PKA and calcium or PKC signalling may underlie the induction of c-fos, as 
D1 receptors are positively coupled to adenylate cyclase (Stoof and Kebabian., 
1981) and to inositol phospholipid (Mahan et al.. 1990) signalling pathways. It 
has previously been shown in vitro that the lEG c-fos can be induced through 
interaction of nuclear proteins with c AMP-responsive regulatory elements 
(CREs) present in the gene (Greenberg et al.. 1985) and some PKC effects have 
been reported as well (Goodman, 1990).
It is known that c-fos can form dimers with members o f the jun family o f  
lEGs in order to effect target gene transcription. The mRNA,s encoding two 
members of this family, c-jun and jun-D, are present constitutively in striatal 
neurons and the corresponding proteins are likely to be available to form
complexes with c-fos when it is synthesised. The mRNA encoding another LEG 
belonging to this family, jun-B, is not normally detectable in striatal neurons.
However there is some evidence for the induction of jun-B after acute 
administration of cocaine (Hope et al.. 1992), amphetamine and apomorphine 
(Cole et al.. 1992). These drugs are known to have agonist properties at a 
number of receptors, including dopamine receptors.
As yet there is still no firm evidence linking the induction o f any immediate 
early gene with any effect on a late-reponse gene. However, there has been 
some speculation on a potential link between the induction of fos and jun
.
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sproteins and enkephalin mRNA expression (Sonnenberg et al.. 1989) Although, 
contrary to this suggestion, more recent research implies that it is not the fos 
protein that interacts with the enkephalin enhancer (Konradi et al.. 1993).
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1.14 Characterisation of Serotonin Receptor Subtypes
Serotonin (5-hydroxytryptamine, 5-HT ) is a biogenic amine
neurotransmitter that is known to be involved in the homeostatic regulation of
the fundamental physiological functions such as sleep, temperature regulation,
learning and memory and pain. Disruptions in the serotoninergic system may be a
critical factor in many pathological disorders affecting society today, including
.anxiety, depression, schizophrenia, eating disorders and obsessive compulsive 
disorder (Lopez-Ibor, 1988). A centralisation of the serotoninergic system in the 
raphe area of the central nervous system, together with its diverse projections to 
all brain areas confirms the potential of serotonin to be a homeostatic regulator.
The transduction of serotoninergic signals across the neuronal membrane is 
mediated by a diversity of receptor subtypes that in mammals appear to fall into 
seven distinct classes, designated 5-HTl to 5-HT7, on the basis of their affinities 
for serotonin or sequence similarities. With the exception of the 5-HT3 receptor 
which is a ligand gated ion channel, all of the other members of the serotonin 
receptor family belong to the large class of receptors that are* linked to their 
effector function via guanine-nucleotide binding proteins with the putative seven 
transmembrane domain structure characteristic of many receptors (Hoyer and 
Schoeffier, 1991). Within receptor classes, a number of serotonin receptor 
subtypes have been identified. The fiinctional significance, if any, in terms of the 
physiological role of many o f these newly cloned receptors is as yet to be 
identified and therefore is of great importance in understanding the functions of 
serotonin in the brain.
The 5-HT 1 “like subcategory has been further subdivided into four different 
subtypes (Hartig et al.. 1992), which have recently been cloned, namely the 5- 
HTIA (Kobilka 1987; Fargin et_al., 1988), the 5-HTlB (Voigt et al..
1991; Branchek et al.. 1991), the 5-HT ID (Hamblin and Metcalf, 1991) in rat,
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the 5-HT ID in the canine (Zgombick et al.. 1991), the 5-HTlDb (Demchyshyn
et a l. 1992) in human and the 5-HT IE (Hartig et al.. 1992) in the rat. All
members of the 5-HTl subgroup are characterised by their high affinities for
serotonin (Ki < lOOnM) and their ability to inhibit cellular cAMP production (
De Vivo and Mayaani, 1990 ). Distinction between the receptors in this group
has been made on the basis o f the affinities for a series of drugs showing some
subtype selectivity e.g. 8 -hydroxy DP AT is a selective agonist for the 5-HTl A
receptor (Gozlan et_al-, 1983) and rawolscine a selective agonist for the 5-HT ID
receptor fFrazer et al.. 1990). 5-HTl A receptors have been widely studied and
agonist compounds acting at this receptor site have been shown to possess
anxiolytic (Traber and Glasser, 1987; Gleeson et al.. 1989; Brocco et al.. 1990),
antidepressive (Cervo et d., 1988; Glasser, 1988; Glennon, 1990),
antihypertensive (Hartog and Wouters, 1988; Mandai et al.. 1989; Stubbs et al..
1991) and possibly antipsychotic (Ahlenius, 1989) and neuroprotective 
.(Bielenberg and Burkhardt, 1990; Bode-Greuel et al.. 1990) properties. Indeed 
.the 5-HTl A partial agonists buspirone, ipsapirone and gepirone have been 
shown to exert anxiolytic and antidepressive effects in humans (Glennon, 1990; 
Robinson et al.. 1989; Traber and Glasser, 1987). The 5-HT IB receptor was 
distinguished from the 5-HT lA  subtype with the use of the drug spiperone, as 
5-HTl A sites have high affinity for spiperone, while conversely the 5-HTlB site 
has a low affinity for spiperone (Pedigo et al.. 1981). A similar distribution of 5- 
HTIA receptors has been observed in many different animal species 
(Marcinkiewicz et al.. 1984; Waeber et al.. 1989). The highest density of 5- 
HTIA sites was observed in the limbic system including the hippocampus, 
septum, amygdala and cortical limbic areas. This high concentration in the limbic 
system is thought to be consistent with their involvement in mood and anxiety. 
The recently cloned 5-HTlB receptor subtype has been shown to have high 
affinity binding of ^H-5-HT with a different pharmacological profile to the 5- 
HTIA subtype. In situ hybridisation has revealed that the 5-HT IB mRNA is
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located within cells of the dorsal and median raphe nuclei suggesting an 
autoreceptor function, in the CAl region o f the hippocampus, in the striatum, 
cortex and in the cerebellum. The human encoding the 5-HT IB receptor 
has been shown to be most abundant in the striatum (Jin et al.. 1992). Both the 
5-HT IB and the 5-HT ID receptor subtypes are defined on both pharmacological 
and biochemical grounds by their ability to inhibit adenylate cyclase activity 
(Schoeffier et al.. 1990). The 5-HTIB receptor has been suggested to be the 
evolutionary antecedent of the 5-HT ID receptor which is present in bovine and 
human brain in high concentrations in the substantia nigra and basal ganglia 
(Heuring and Peroutka, 1987). The 5-HT IE receptor mRNA has been located 
on the terminal fields of some serotoninergic neurons. Characterisation of this 
receptor subtype is still necessary.
Another subclass of 5-HT receptors is the 5-HT2 subtype. At present there 
are three structurally similar subtypes referred to as 5-HT2A, 5-HT2B (formerly 
the 5-HT2F), and 5-HT2C (formerly the 5-HTlC) (Pritchett et al.. 1988) whose 
activation results in phospholipase C-mediated phosphatidylinositoi lipid 
hydrolysis (Conn and Sanders-Bush, 1986; Conn et al.. 1986) which liberates the 
second messengers diacylglycerol and inositol triphosphate. Diacylglycerol 
activates the enzyme protein kinase C, whereas inositol triphosphate increases 
the intracellular free calcium concentration (Taken, 1989; Irvine, 1989). Both 
increases in intracellular calcium and activation of protein kinase C have been 
observed in response to activation of 5-HT2A (Pritchett et ai.. 1988; Berg et al.,
1994) and 5-HT2C receptors (Lutz et al.. 1993; Boddeke et a l. 1993). In 
addition to coupling to phospholipase C- mediated phosphatidylinositoi lipid 
hydrolysis, 5-HT2A and 5-HT2C receptors have been shown to mediate 
phospholipase A2-mediated arachidonic acid release (Felder et al.. 1990). Long 
term exposure to agonists (Dillon-Carter and Chuang, 1989; Sanders-Bush and 
Breeding, 1990; Ivins and Molinoff, 1991) or antagonists (Blackshear et al.. 
1983; Sanders-Bush and Breeding, 1988 ) have also been demonstrated to down
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regulate these receptors. The newly cloned 5-HT2B (formerly 5-HT2F) receptor 
(Foguet et al.. 1992; Kursar et al., 1992; Loric et a l. 1992) has recently been 
characterised. The 5-HT2B receptor subtype was shown to stimulate production 
o f inositol 1,4,5-trisphosphate in transformed cells and has a unique
!pharmacological profile consistent with the evidence that this receptor subtype 
mediates contractions in the rat stomach fundus (Wainscott et a l. 1993).
The distribution of 5-HT2 receptor subtypes shows some overlap, although 
there are some differences. Both the 5-HT2A and 5-HT2C subtype mRNA have 
been shown to be present at intermediate levels in the caudate-putamen, 
accumbens nucleus and substantia nigra pars compacta. However, their 
distribution in the caudate-putamen is quite different. The 5-HT2C receptor 
mRNA is in addition present in the basal nucleus of meynert, stria terminalis, 
entopeduncular nucleus and subthalamic nucleus and was found to be most 
predominant in the amygdala. While the 5-HT2A transcripts were restricted to 
only a few nuclei in these areas (Pompeiano et al.. 1993). It has very recently 
been shown that there are important fundamental differences in the signal
transduction systems for 5-HT2A and 5-HT2C subtypes. In transfected CHO 
cells activation of 5-HT2C, but not 5-HT2A receptors reduces receptor 
mediated inhibition of adenylate cyclase activity. Furthermore, this effect of the 
5-HT2C subtype is independent of activation of PKC and an increase in 
intracellular calcium concentration (Berg et al.. 1994). Attempts to visualise 
transcripts for the third member of the 5-HT2 receptor family, the 5-HT2B (5- 
HT2F) with probes and PGR analysis has so far failed in rat brain (Foguet et al..
1992).
The 5-HT3 receptor is a ligand-gated ion channel which when activated 
causes a fast depolarising response. Kilpatrick and colleagues (1987) were the 
first to identify 5-HT3-binding sites in the brain. More recently, Maricq and 
colleagues have isolated a cDNA clone encoding a 5-HT3 receptor from NCB- 
20 cells (Maricq et al.. 1991). The mRNA encoding this receptor is identified in
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brain, spinal cord and in the heart. The receptor protein is located mainly in the 
dorsal hindbrain, nuclei of the cranial nerves, and the area postrema (Palacios et 
al., 1990).
A 5-HT4 receptor subtype is also known to exist, however it is the least well 
characterised of all the 5-HT receptors. The 5-HT4 receptor has been detected in 
the CNS by measuring 5-HT stimulation of cyclic AMP formation either in intact 
neurons in culture (Dumuis et al.. 1988, 1989) or in isolated neuronal 
membranes (Bockaert et al.. 1989, 1990), or in the gastrointestinal tract by 
monitoring 5-HT-mediated changes in contractile responses of the guinea pig 
ileum (Clarke et al.. 1989; Craig and Clarke, 1990). This receptor has also been 
characterised in radioligand binding studies (Clarke et al,, 19891 but has not yet | „ 
been cloned.
A fifth member of the 5-HT receptor family has been isolated from mouse 
brain (Plassat et al.. 1992). This 5-HT receptor is referred to as the 5-HT5A, as 
a 5-HT5B subtype has recently been sequenced (Matthes et al.. 1993). 5-HT5 
receptors are known to have very high affinity for ergot compounds such as 
lysergic acid diethylamide and methysergide, but have relatively low affinity for 
5-HT. The 5-HT5A subtype was found to be expressed predominantly in the
cerebellum, cerebral cortex, hippocampus and olfactory bulb. While the 5-HT5B
receptor mRNA was expressed predominantly in the medial habenula and in the 
CAl field of the hippocampus and raphe nuclei.
A recent report has described the cloning of another structurally and 
pharmacologically distinct 5-HT receptor from rat brain, namely the 5-HT6 
receptor. This receptor subtype has been shown to exhibit high affinity for a 
number of antipsychotic and tricyclic antidepressant drugs, including clozapine, 
amoxapine and amytriptyline (Monsma et al.. 1993). In cells transfected with this 
receptor, serotonin elicits a potent stimulation of adenylyl cyclase activity which 
is blocked by antipsychotic and antidepressant drugs (Sebben et al.. 1994). This 
receptor subtype has been localised in motor limbic and cortical regions of the
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1.15 Drug Pharmacology of Serotonin receptors
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brain, with the highest levels present in the striatum, a potentially important site 
of action of antipsychotic drugs with regard to both extrapyramidal sysmptoms 
and perhaps cognitive functioning. (Monsma et al.. 1993). A similar 5-HT 
receptor subtype has recently been isolated in mouse neuroblastoma cells 
(Unsworth and Molinoff, 1993).
Most recently a 5-HT7 receptor subtype has been proposed IShen et al..
1993). The serotoninergic 5-HT7 receptor has since been cloned and shown to 
be positively coupled to adenylate cyclase when transfected into a Chinese 
hamster ovary cell line (Tsou et al.. 1994). Similar to the 5-HT6  receptor, this 
receptor subtype has high affinity for antipsychotic drugs such as clozapine. The 
5-HT7 receptor has not yet been fully characterised, however, both the 5-HT6 
and 5-HT7 receptor subtypes are known to pharmacologically resemble the 5- 
HT2 receptor (Monsma et al.. 1993; Shen et al.. 1993).
...1
■É:
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Early on in the studies on neuroleptic drugs, evidence was obtained 
demonstrating that the serotoninergic system could influence the action of
antipsychotic drugs (Kostowski et al.. 1972) and some neuroleptic drugs could 
increase 5-HT turnover, perhaps by blockade of 5-HT receptors (Leysen et al.. 
1978). With the discovery of specific agonists and antagonists for serotonin 
receptor subtypes, a potential role of particular clinical importance was 
evident, since the binding affinités of many atypical antipsychotics such as 
clozapine, melperone and amperozide (Meltzer et al.. 1989; Christensson et al..
1990) are particularly high for certain serotonin receptor subtypes.
In vitro, the pKi values of typical neuroleptic drugs for 5-HT2-binding 
sites tends to vary over a wide range, with a number being quite potent, such as
methiothepin and spiperone (pKi = 9.4) (Meltzer et al.. 1989). Both 
fluphenazine (pKi = 8 .6 ) and haloperidol (pKi = 7.7) have some affinity for the 
5-HT2A receptor subtype (Meltzer et al.. 1989; Audinot et al.. 1993). 
Haloperidol has a much lower affinity for the 5-HT2C serotonin receptor 
subtype (Audinot et al.. 1993). Previous studies have also demonstrated that 
haloperidol has only a weak affinity for the 5-HTl A, 5-HTlB, 5-HT ID and 5- 
HT3 receptors (Meltzer et al.. 1989). Therefore it has been suggested that 
haloperidol would not be expected to achieve effective blockade at clinically 
relevant doses at 5-HTlD, 5-HT2C, or 5-HT3- binding sites in humans with 
the possible exception of weak 5-HT2A receptor blockade, because the clinical 
dose is based on its potent D2 receptor antagonism (pKi = 9.0) (Meltzer and 
Nash, 1991).
Many atypical antipsychotic drugs have been found to have a relatively
high affinity for 5-HT2-binding sites in vitro as compared to the typical drugs 
.relative to their respective affinities for D2 dopamine receptors (Meltzer et al..
1989). Clozapine has been shown to have high affinity for both the 5-HT2A
(pKi = 8.3, Meltzer et al.. 1989; pKi = 8.3, Roth et al., 1991; pKi = 7.6,
Audinot et al.. 1993) and the 5-HT2C receptor (pKi = 8.14, Roth et al., 1991;
‘pKi = 8 .1 , Audinot et al.. 1993). As yet, it is not clear whether atypical drugs, 
.like clozapine, are superior in treating schizophrenia compared with typical
antipsychotic drugs, and whether they also do not produce tardive dyskinesia.
It is likely that at clinically effective doses of clozapine, which correlate with its
affinity for the D2 receptor (Seeman, 1981), clozapine produces effective
occupancy of the 5-HT2A and 5-HT2C receptors because it has a significantly 
.higher affinity for these receptors than for the D2 receptor. Clozapine has also 
been reported to have submicromolar affinity for 5-HTl A receptors in human 
brain tissue (IVIason and Reynolds, 1992) and a moderate affinity for the 5-HT3 
receptor (Watling et al.. 1990).
%
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There is a possibility that, because o f pharmacokinetic and 
pharmacodynamic reasons, in vitro affinities may not predict in vivo
occupancies of specific drugs. Active metabolites^ rapidkdissociatfdn fi-om a 
Fhefa b e
receptor site oMocal differences in drug metabolism due to differences in brain
:rcytochrome P450 enzymes may cause significant differences between in vivo 
occupancy and in vitro affinities (Meltzer and Nash, 1991). Meltzer et al.
(1989) have previously demonstarted that some drugs such as chlopromazine, 
are significantly more effective in blocking D2 receptors in vivo than would be 'f
predicted from their in vitro affinities.
The highly selective D 1-like receptor antagonist, SCH23390, has also 
been reported to interact with the central 5-HT system (Bischoff et_al., 1988).
Similar to selective 5-HT2 receptor blockers, SCH23390 was shown to inhibit
3 Ï[ H]-spiperone binding in the rat frontal cortex, in vivo. In vitro, SCH23390 ; |
3was shown to inhibit [ H]-ketanserin binding to 5-HT2 sites. Biochemical
*:■parameters linked to dopamine and 5-HT were not changed, except in the
■i’:.Striatum where SCH23390 increased homovanilic acid levels. SCH23390 was 
shown to have only a weak affinity for 5-HT IB and 5-HTl A receptors.
In general terms, the following research work was performed in order to 
understand further the role of the immediate early gene in striatal functioning, 
which at present is unclear. We have attempted to investigate how m^or 
transmitter systems, in particular the dopaminergic and serotoninergic systems, 
have the ability to activate certain immediate early genes known to be present 
in the striatum. With the use of a number of selective drugs, novel molecular 
biological approaches and an in vitro ‘model’ of the striatum, a wide spectrum 
of possible receptor mechanisms will be investigated. The ultimate aim of
1which will be to isolate a receptor mechanism and second messenger pathway 
prior to the induction of an immediate early gene under investigation.
Since a number of disease states including Parkinson’s disease and 
schizophrenia have been identified, and in turn linked to a dysfunction of the 
basal ganglia, we were particularly interested in the neuropeptide systems in the 
striatum which are known to be vulnerable in many neurological diseases. 
Neuroleptic drugs are the conventional treatment for schizophrenia, therefore 
to understand how neuroleptics effect transmitter / neuropeptide systems in the 
striatum may provide an important insight into certain diseases. Recently it has 
been proposed that the activation of immediate early genes may be connected 
to a change in the expression of a late response gene (for example, a gene 
encoding a neuroepeptide). Therefore, to aid in the understanding of this 
potential relationship, we have also investigated how neuroleptics effect a 
number of immediate early genes. Hopefully this research will provide useful 
information on the complex functioning of the basal ganglia.
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Chapter 2
METHODS
I'.ï
a
predicted protein (Montminy et al. 1984 ) ; preprotachykinin (36~mer),
2 . 1  Oligonucleotide Probes
Oligonucleotide probes of unique sequence were synthesised on an
Applied Biosystems DNA synthesiser. The probe sequences were as follows: c-
.fos (45-mer), complementary to nucleotides spanning amino acids 1-15 (Curran
et al. 1987) ; Jun-B (60-mer), complementary to nucleotides spanning the last
20 amino acids of the predicted protein (Ryder et al. 1988) ; Jun-D (60-mer),
.complementary to the last 20 amino acids of the predicted protein (Ryder et al.
1989) ; zifr268 (45-mer), complementary to nucleotides spanning amino acids
2-16 (Millbrandt, 1987) ; preproenkephalin (45-mer),complementary to bases
388-432 of the predicted gene sequence (Howells et ah 1984; Yoshikawa et al.
1984) ; prodynorphin (45-mer), complementary to bases 862-906 of the
predicted gene sequence (Civelli et al, 1985; Morris et al, 1986) ;
proneuropeptide Y (45-mer), complementary to bases 1624-1668 of the
predicted gene sequence fLarhammar et al. 1987) ; preprosomatostatin (45-
.mer) , complementary to the sequence encoding for amino acids 78-92 of the
I
complementary to bases 172-207 of the predicted gene sequence (Krause et al.
1987) ; BF-1 (45-mer), complementary to bases 445-489 (Tao and Lai, 1992) ; 
RHS2 (45-mer), complementary to bases 35-79 (Le Moine et al. 1992 ) ; D 1 
dopamine receptor (45-mer), complementary to bases 142-186 (Monsma et ah
1990) ; D2 dopamine receptor (45-mer), complementary to bases 640-684 ( 
Bunzow et al , 1988), and the 5-HT6  receptor (45-mer), complementary to 
bases 702-746 (Monsma et al. 1992); Tubulin T26 (45-mer) complementary to 
part o f the 3’ non-coding region: 
GGGAAACAGCATAGAAGCATCGATGCCTGC AGCTAGTGCT GGAGC 
(Miller et al.. 1987); D1 dopamine receptor antisense complementary to bases 
1-15 (Sunahara et al.. 1990) ; D5 dopamine receptor antisense complementary
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to bases 1-15 (Sunahara et al.. 1991) and a D1 sense. A sense "message" probe 
for preprosomatostatin and Microtubule-associated protein (MAP2) were also 
synthesised.
2,2 In situ Hvbridisationàn cryostat sections
In situ hybridisation was performed according to the method describedKtedeo (and
previously ( Morris et al. 1986, Wisden .e t a l  -j Frozen coronal
A
brain sections (2 0 gm) were cut using a cryostat (Reichart-Jung) at the level of
the rostral and medial striatum (taken 1.6mm anterior and 0.4mm posterior to
bregma). The sections were mounted onto sterile fridge-cooled slides (BDH)
.previously baked in aluminium foil at 180°C and coated in a 0.01% solution of
poIy-L-lysine hydrobromide made up in Diethylpyrocarbonate (DEPC)-treated
water. The sections were then dried at room temperature. Following this, the 
.sections were fixed in an ice cold 4% (weight/volume) solution of 
.depolymerized paraformaldehyde freshly prepared in Ix phosphate-buffered 
saline (IxPBS) [ 10 x PBS is 1.3M sodium chloride, 70mM di-sodium 
hydrogen orthophosphate, 30mM sodium di-hydrogen orthophosphate made up 
in sterile water.] for 5 minutes. The sections were then transferred into IxPBS
for 1-2 minutes and then dehydrated in graded ethanol solutions (i.e. 70%, 
95%, and 100%) for several minutes.
0.6pmol oligonucleotide probes (45-mers) were 3' -end labelled with 
lOpmol of the isotope 5-[a- ^^S]dATP (NEN, specific activity 1300 Ci/mmol), 
i.e. using a 33:1 molar ratio of isotope to oligonucleotide and with terminal 
deoxynucleotidyl transferase (TdT, Pharmacia). The specific activity of the 
probes was in the region of 1 .0  x 1 0  ^dpm/gg.
For a 12.5/xl reaction volume, in a sterile eppendorff tube mix together: 
4.0gl DEPC-water
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2.5/til 5 X reaction buffer. Reaction buffer (5x) contains IM potassium 
cacodylate, 125mM Tris/HCl, 1.25mg ml-1 bovine serum albumin, pH 6 .6 , at 
250C.
2.0jx\ of oligonucleotide at concentration of 0.3pmol for a 45-mer, 
O.Spmol is equivalent to 5 ng )
2.8^1 [a- 35s]dATP (1300 Ci/mmol)
1.2^1 TdT. tJhe Mi xcur'e w'o.^
The reagents were mixed very carefully by pipette. Then incubated for 1-3 
hours in a water bath at 30-35°C. The reaction was^inhibited by adding 40^1
DEPC-treated water. A Sephadex G-25 spin column was then prepared using a
1ml syringe plugged at the tip with glass wool. The syringe was filled with
Sephadex G-25 solution (i.e. a 1:1 solution of sephadex G-25 powder and Tris/
EDTA buffer[ lOmM Tris, ImM EDTA] and spun for 1 minute to obtain a
.column. Then 50^1 of the reaction mixture was added to the Sephadex G-25
spin column and spun at 2000 rpm for 1 minute in a MSE MINOR centrifuge,
to remove unincorporated nucleotides. After collecting the eluate in a sterile
eppendorff tube, 2  gl of the eluate was analysed by liquid scintillation
counting. The counts would be expected to be in the range 300 000 to 800 000'
d.p.m. 2jul“ .^ Then 2 jul of a IM solution of dithiothreitol (DDT) made up in 
sterile water was added to the tube. This is known to preserve the probe from 
oxidation. The probe was stored at -20°C until use.
Sections were removed from 1 0 0 % ethanol and allowed to air dry.
■
Following this, the sections were hybridised with the selected probe at 42°C
overnight. In a sterile eppendorff tube, the radiolabelled probe was diluted 
. . .1:100/1:200 in a hybridisation buffer containing 50% deionised formamide,
0 .0 2 % poly adenylic acid, 1 0 % 4x standard saline citrate (4x SSC) [ Ix SSC=
0.15M sodium chloride, 0.015 M sodium citrate, pH= 7.0 ], 5% 0.5M sodium 
phosphate, pH 7.0, 1% O.IM sodium pyrophosphate and 10% dextran sulphate 
made up in sterile water. After adding 2 gl of DTT to the mixture and vortexing
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thoroughly, 120pd o f probe/hybridisation buffer was applied to each slide. The 
slides were gently covered with a parafilm coverslip. Any air bubbles present 
were removed with blunt ended forceps. A small piece o f tissue paper was 
saturated with 4 x SSC and placed alongside the slides in a sealed petri dish to 
maintian humidity. The slides were then incubated overnight at 42°C.
After overnight incubation slides were transferred into coplin jars 
containing 250ml o f prewarmed 1 x SSC at 55^C. The parafilm was gently 
peeled off and discarded. The slides were washed twice in 1 x SSC at 55°C for 
approximately 30 minutes per wash with constant agitation. Following this, the 
slides were transferred into 0.1 x SSC at room temperature for 15 minutes, and 
then briefly dehydrated through 70% ethanol, 95% ethanol and 100% ethanol, 
before being allowed to air dry.
The sections were then exposed to autoradiographic film ( Kodak 
XAR-5) at room temperature. Dry slides were attached to paper with scotch 
tape and exposed to autoradiographic film for 3 days to 2 weeks depending on 
the probes used and the efficiency of their tailing. Under safe light conditions 
films were developed for 1 minute in D19 (Kodak), rinsed in water for 30 
seconds, fixed in Unifix fixative (Kodak) for 4 minutes and finally rinsed in 
water for 2 0  minutes. Once the films had been developed , the slides were 
dipped in Ilford K5 liquid photographic emulsion. Slides were dipped under 
safe light in a filtered 1:1 solution of emulsion : distilled water containing 0.5% 
glycerol prewarmed to 45°C. Slides were allowed to dry before being 
transferred to light-tight slide boxes containing fresh silica gel. The boxes were 
stored in the fridge at 4®C until time of development. As a general rule slides 
were stored for 5 X the exposure time on film.
Exposed boxes were allowed to come to room temperature. Under safe 
light conditions the slides were then transferred into glass racks prior to 
immersion in 250ml D19 developer (Kodak) at 19*^ C for 2 minutes. After 
developing, slides were immersed in water for 30 seconds and then transferred
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into 250ml of a freshly prepared solution of 30% sodium thiosulphate for 4 
minutes. The slides were then transferred into water for at least 30 minutes in 
order to wash off excess fixative. Sections were then counterstained in either a
0.2% solution o f neutral red for 2-5 minutes or a 0.25% solution of cresyl 
violet for 5 minutes and dehydrated in serial solutions of ethanol for several 
minutes. Finally sections were transferred into histoclear for several minutes. 
Excess histoclear was allowed to drain o f f , following which the slides were 
mounted with glass coverslips (Chance) and DPX mounting medium.
2.3 In situ hybridisation of cell cultures
The method used for in situ hybridisation of cell cultures was essentially 
identical to that described for in situ hybridisation of cryostat sections. 
However we found it necessary to dilute 'hot' probes to 1:400 with 
hybridisation buffer to reduce the risk of background labelling to a minimum.
Autoradiographic films and slides were developed as previously 
described. Cultures were counterstained with a 0.2% solution of neutral red for 
1 minute or with a 0.25% solution of cresyl violet for 1-5 minutes before 
dehydration and coverslipping.
2.4 Controls for in situ hybridisation
For in situ hybridisation using synthetic oligonucleotides, two types of  
control experiment were employed.
1. Competition hybridisations - where sections/cultures were hybridised with a 
25 -fold excess of the unlabelled oligonucleotide probe.
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2 . Sections/cultures were hybridised with a 'sense' oligonucleotide probe having 
the same length, base composition and specific activity as a region on the 
messenger RNA (mRNA).
2.5 RNA Extraction
The brains from six wistar rats (250-300g) were removed and tissue 
fi-om several brain regions including the cerebellum, hippocampus, striatum, 
cortex and olfactory bulb was carefully dissected out and rapidly frozen on dry 
ice. The brain tissue was weighed individually and stored at -80°C in sterile 
plastic tubes until extraction.
Total RNA was extracted using the guanidinium/ hot phenol method 
previously described by Chomzynski and Sacchi in 1987. Under sterile 
conditions, tissue o f predetermined weight was put into a 50ml plastic tube 
containing 5ml/g guanidinium isothiocyanate solution ( guanidinium 
isothiocyanate solution = lOOg guanidinium thiocyanate powder, 5% IM Tris, 
pH 7.6, and 2% 0.5M EDTA made up to 94.84mls in DEPC-treated water. 
Heat solution to 60°C, sterile filter, and add 21.2mls 2 0 % sarcosyl and 2,lmls 
jS- mercaptoethanol such that the total volume = 2 1 2 mls) and a few drops of 
antifoam. Using a polytron homogeniser at setting 7, tissue was homogenised 
for a few minutes. An equal volume (5ml/g) of phenol preheated to 60°C, was 
then added and the tissue allowed to stand in a water bath at bO^C. Following 
this, 2.5ml/g preheated salt solution, solution III, was added at 60°C (solution 
III = lOOmM sodium acetate, pH 5.2, lOmM Tris/ hydrochloric acid, pH 7.4, 
and ImM EDTA). Then 5ml/g chloroform, maintained at room temperature, 
was added to the tissue and the tube shaken vigorously for 5-10 minutes whilst 
in the water bath at 60°C. The tissue was then cooled on ice and centrifuged at
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4000rpm for 10 minutes at room temperature. The aqueous phase was 
removed to another tube and re-extracted with phenol/chloroform (volume 
ratio = 3:1). Following this, the aqueous layer was removed to another tube 
and re-extracted four times with phenol/chloroform (volume ratio = 1 :1 ) and 
finally extracted with chloroform alone (volume ratio = 1:1). Then 2.5 volumes 
of ethanol was added to precipitate the RNA. At this stage strands of RNA 
were visibly forming in the ethanol. After overnight storage at -20°C an RNA 
pellet was formed. The tube was spun for 10 minutes at 4000rpm at room 
temperature, and then the pellet resuspended in 50gl DEPC-treated water and 
diluted 1:100. The optical density at 260/280 was measured, and 10/il aliquots 
stored at -80°C until use.
2.6 Northern Blot Analvsis
The method for northern blotting was performed according to the 
method previously described by Wisden et al.. in 1988. Firstly a formaldehyde 
gel was prepared in a total volume of ISOmls by heating together 1.64g agarose 
powder with 96.4mls DEPC-treated water in a conical flask previously baked 
to 180°C. Once melted, the gel was allowed to cool slightly. Following which, 
23.6mls formaldehyde was added together with 3Omis DEPC-treated 5 X 
Running buffer (5 X Running buffer = 200mM morpholinopropanesulphonic 
acid (MOPS), pH 7.0, 50mM sodium acetate, pH 7.0, and 5mM EDTA, the 
solution appears yellow after autoclaving ) in a fume hood. Meanwhile the 
sides of an ethanol cleaned perspex gel holder were taped securely with scotch 
tape. The comb was attached to one end approximately 2.0mm from the base. 
The gel holder was then positioned in a horizontal gel electrophoresis 
apparatus (BIO-RAD ) previously sterilised with ethanol. Warm gel was slowly
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poured into the holder to ensure no bubble formation and allowed to set. Once 
the gel had set, the tape and the comb were removed. A 1 x MOPS solution 
was added to the apparatus and the gel was then pre-run at 65 volts for 1 hour. 
During this time brain tissue RNA samples were prepared by adding together: 
lOfd aliquots of p(A) + RNA 
4,6jxl 5 X Running buffer 
3.5/il formaldehyde 
lOgl formamide.
The sample was vortexed and left for 15 minutes at 55°C in order to denature 
the RNA. The sample was then chilled on ice. 4ptl loading buffer (loading buffer 
-  50% glycerol in water, ImM EDTA, 0.4% bromophenol blue, and 0.4% 
xylene cyanole made up in DEPC-treated water ) was added and then the
A:'
samples were allowed to run for 4 hours at 120 volts or until the bromophenol
dye had migrated three-fourths down the gel. A standard DNA sample was run 
alongside the tissue samples as a marker. Then the gel was removed from the 
gel holder and placed onto clingfilm. After cutting the standard DNA sample 
away from the gel, it was immersed in a ethidium bromide solution (l/ag/ml) for 
15 minutes and visualised under ultra violet light. The gel was then 
photographed on an ultraviolet transilluminator, before being blotted to record 
marker positions. The gel to be blotted was then transferred directly onto nylon 
membrane. After soaking approximately ten pieces of Whatman 3MM filter 
paper approximately 23 x 50cm, in 10 X SSC, the filter paper was placed onto 
a tray. Carefully the gel was then placed upside down (i.e. sample well 
openings down ) on top of the filter papers. Following this, a piece of hybond 
filter paper ( nylon membrane) was cut to fit the gel and placed on top and 
smoothed out carefully. Then, 2 x 3MM wet filters (Whatman) were packed on 
top followed by a box of tissues. Finally a weight was placed over the gel to 
ensure good transfer. The gel was then left overnight to allow the transfer 
process to take place. By capillary action, the 1 0  X SSC would be expected to
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soak up the tissues and in the process, the single strand RNA in the gel would
be transferred to the underside of the nylon membrane. The RNA was then
1
- !
crosslinked by ultraviolet irradiation onto the nylon membrane. The blot could 
then be stored in the freezer at -SO^C until use.
Northern blots were hybridised with oligonucleotide probes previously 
3'- end labelled with the enzyme TdT and the isotope©^^P-dATP ( 6  000 
Ci/mmol, Dupont) at 42^C overnight. The probes were labelled to a specific 
activity of LOxlO^^ dpm/gg. The method of probe labelling was identical to 
the method previously described under in situ hybridisation with labelled 
probes, however the quantity of components within the reaction mixture were 
adjusted according to the radioisotope, such that the reaction mixture 
contained:
2.5/xl 5 X buffer 
l,25gl oligonucleotide 
1.55/il DEPC-treated water 
6.0/nI 32p. dATP 
1,2m1 TdT.
When using the isotope <iC^ 2p_(jATP, a high energy /S- particle emitter, all
procedures should be shielded by perspex to avoid radiation contamination. 
Blots were prehybridised with 10ml hybridisation buffer for 1 hour at 40°C. 
Following this, the blot was hybridised with a 3'- end labelled probe overnight 
at 42°C in a heat-sealed plastic bag. The following day, the blot was washed in 
1 X SSC at 55^C for 1 hour, then in 1 X SSC for 15 minutes at room 
temperature, and finally briefly rinsed in 0 ,1  X SSC at room temperature. The 
blot was then covered with cling film and smoothed. Finally the northern blot 
was exposed to Kodak XAR-5 autoradiographic film at -80^C with an 
intensifying screen for approximately 2-5 days. Development of the film was as 
previously described. The blot was then washed in 0.5 X Denhardt's solution, 
25mM Tris-HCl, pH 7.5, and 0 .1% sodium dodecyl sulphate for 60 minutes at
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90-95°C, followed by a wash in distilled water at 65 for 15 minutes. The 
nylon membrane was then reusable for hybridisation with another ^^P-labelled 
probe.
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2.7 Primary Neuronal Culture
Striatal neurons were cultured using a modification o f the methods of 
Thayer et al (1986), Surmeier et al (1988) and Vilijn et al (1988). Timed 
pregnant Wistar rats (200-3 OOg) were killed with an overdose of anaesthetic 
injected intraperitonealy (Sagatal) on gestational day 17 (E l7). Embiyos were 
removed from the uterus, decapitated and placed in ice cold calcium-free 
Earle's Modified Eagles Medium (EMEM). Following removal of the brains 
from the crania, the dorsal striata of each embryo was dissected out in cold 
EMEM using the optic chiasm as the posterior marker ( Misgeld and Dietzell,
1988). From each dissecting session the tissue was pooled from ten embryos ( ^
on average). The tissue was then minced and washed three times in cold
■I
EMEM. Cells were dissociated in 10ml of a 0.67% trypsin solution made up in 
sterile saline, at 37°C for 45 minutes. The trypsin was inactivated with 1.5mls 
heat-inactivated foetal calf serum (FCS). Following trypsinisation the cells were 
washed three times in cold EMEM and spun at 5 OOg in a DAMON/IEC i
centrifuge for 2 minutes per wash. The cells were then resuspended in 
Dulbecco's Modified Eagles medium (DMEM) supplemented with 20% FCS ( 
volume/volume), and penicillin-streptomycin solution ( 1 0 0  units penicillin, 
lOOjug/ml streptomycin). The tissue was triturated in supplemented DMEM 
using a pasteur pipette and cells were seeded at a density of approximately 0.15 
X 10^ cells/cm^ as monolayer cultures onto either sterile glass coverslips in 24- 
well plastic culture plates (Nunc) or onto 8 -well multichamber glass slides
(Nunc) previously coated with poly-D-lysine (4^g/ml) for 24 hours, rinsed in 
EMEM and then coated with laminin (6 ^g/ml) for 6  hours. The cultures were 
grown in a humidified incubator supplied with 95% oxygen and 5% carbon 
dioxide. After 24 hours the medium was changed to DMEM supplemented 
with 10% horse serum, and on day 5 the medium was replaced with 
DMEM/10% horse serum containing 20/xM cytosine arabinoside in order to 
control proliferation of glial and other non-neuronal cells. On day 9 the 
cytosine arabinoside was omitted. The culture medium was changed every 4 
days thereafter in the 24-well culture plates used for immunocytochemistry. 
However for the cells seeded onto multichamber slides to be used for ding 
stimulation, the medium was changed to DMEM supplemented with tJltroser 
G' (Gibco, BRL), and penicillin-streptomycin solution. This was necessary to 
obtain serum-free conditions. Cells were generally used 1 2 - 2 0  days after 
seeding. Prior to use, cells were fixed in a 4% buffered paraformaldehyde 
solution.
2 , 8  Immunohistochemistrv
Prior to immunohistochemistiy, cultures were fixed in an ice cold 4% 
solution of buffered formalin in O.IM phosphate-buffered saline (PBS). The cell 
culture wells were rinsed three times in O.IM PBS for 1 0  minutes and then 
incubated in O.IM PBS containing 20% normal goat serum (NGS), at room 
temperature for 60 minutes. The cultures were then incubated overnight with 
specific antibodies against neurone specific enolase (NSE), met-enkephalin 
(met-ENK), and glial fibrillary acidic protein (GFAP) , at dilutions of 1; 20 
000, 1: 60 0 0 0 , and 1: 40 000 respectively, in 50mM PBS with 1% NGS, 1.5% 
sodium chloride, and 0.5% Triton X-100 added. After rinsing in PBS three
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times for 5 minutes per rinse, the cultures were incubated with biotinylated 
secondary antibody (Vector) for 60 minutes, rinsed in O.IM PBS twice for 10 
minutes, and then incubated with ABC-conjugated horse radish peroxidase 
(ABC Elite kit. Vector) for 60 minutes in accordance with manufacturers 
instructions. The peroxidase was visualised with 0.1% diaminobenzidine made 
up in O.IM phosphate buffer, pH 7.2, containing 0.02% hydrogen peroxide and 
0.05% nickel chloride. 50^1 of filtered DAB chromogen was added to each 
well. A blue/grey reaction product was visible 2-15 minutes after the addition 
o f DAB chromogen.
2.9 NADPH-Diaohorase Staining
NADPH-diaphorase histochemistry was performed according to the
method of Valtschanoflf et al (1992). Tissue culture slides or slide- mounted
sections (50jum) of rat brain were fixed by immersion in 4% paraformaldehyde
solution in O.IM phosphate buffer, pH 7.2. Slides were preincubated in O.IM»
phosphate buffer containing 0.25% Triton X-lOO for 5-10 minutes and then 
transferred to a freshly prepared buffer-Triton solution containing 0.5 mg/ml 
NADPH and 0.2mg/ml nitro blue tétrazolium in a light-tight container. The 
slides were incubated in this solution at 37°C for 1-2 hours. After incubation 
the slides were rinsed in phosphate buffer, dehydrated in serial solutions of
alcohol and finally coverslipped with DPX mounting medium.
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2.10 Acetylcholinesterase Staining
Adult rat striatal sections and cultured striatal neurones were collected 
on slides as previously described. The slides were then washed four times in 
distilled water for 3 minutes per wash and incubated in a modified 'Koelle' 
medium containing 500^g/ml copper sulphate, 750jng/ml glycine, 1.15mg/ml 
acetylthiocholine iodide, and 0.05mg/ml ethopropazine, in sodium acetate 
buffer, pH 5.0. The slides were incubated in modified 'Koelle' medium for 
approximately three hours at 37*^ C. After incubation the slides were washed 
four times, 3 minutes per wash, in distilled water and then immersed in an 
ammonium sulphide solution made up in 0.5M acetic acid, for 60 seconds.
Following this, the slides were washed four times in distilled water for 3 |
minutes each wash. The stain was then enhanced with a 0.25% silver nitrate 
solution for 30 seconds followed by four rinses of 3 minutes each in distilled 
water. Finally slides were dehydrated in 70%, 95%, and 1 0 0 % ethanol 
respectively for 4 minutes each and coverslipped in DPX mounting medium.
..-
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2.11 Drues and Compounds Used
Tris[hydroxymethyl] aminomethane, dimethyl sulphoxide, N,N-dimethyl 
formamide, ethylenediaminetetraacetic acid, (3-[N-Morpholino]propanesuifonic 
acid) MOPS, cyproheptadine hydrochloride, cresyl violet acetate, poly-L-lysine 
hydrobromide, poly-D-lysine hydrobromide, 3-hydroxytyramine (dopamine), 5- 
hydroxytryptamine, fluphenazine dihydrochloride, haloperidol, nickel chloride 
hexahydrate, nitro blue tétrazolium, hydrogen peroxide, cytosine j3-D- 
arabinoside, DL- Dithiothreitol, diethylpyrocarbonate, acetylthiocholine iodide, 
ethopropazine, phorbol- 12-myristate-13-acetate, polyadenylic acid potassium 
salt, nicotinamide adenine dinucleotide phosphate tetrasodium salt, glycerol, 
/?- mercaptoethanol, diaminobenzidine, triton X-100, phorbol-12 myristate-13- 
acetate ( Sigma ). Methiothepin mesylate, mesulergine hydrochloride, (±) -l-(  
2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI), S(-)- 
eticlopride hydrochloride, (±) SKF-38393, R(+) - SCH-23390 hydrochloride, 
spiperone hydrochloride, (±) -8 -hydroxy-2 - (di-n-propylamino)-tetralin 
hydrobromide, l-(3-chlorophenyl)piperazine 2 -hydrochloride, (-)-quinpirole 
hydrochloride ( RBI ). Sodium chloride, sodium dihydrogen orthophosphate, 
disodium hydrogen orthphosphate, sodium thiosulphate, sodium citrate, DPX 
mountant, sodium acetate, sodium hydroxide, copper sulphate (BDH ). Silica 
gel 4-7 mesh ( Fisons ). Antifoam A, polyethylene glycol, guanidinium 
thiocyanate, sodium N-lauroylsarcosinate, formamide, formaldehyde ( Fluka ). 
Ammonium sulphide solution, glycine, paraformaldehyde ( Aldrich Chemical 
Co. Ltd.). Ultra pure DNA Grade Agaroses, sodium dodecyl sulphate, xylene
cyanole, bromophenol blue, ethidium bromide tablets ( BIO-RAD ). Clozapine
■ ;
( Sandoz ). Ondansetron (Glaxo). Sephadex G-25 medium, dextran sulphate 
sodium salt, terminal deoxynucleotidyl transferase ( Pharmacia ). Terminal 
deoxynucleotidyl transferase buffer ( Boehringer-Mannheim ). [a- ^^SjdATP,
cX 32p„dATP ( MEN, Dupont ). PGEM marker (Promega) Acetic acid, 
hydrochloric acid, chloroform ( Prolab ). Histoclear ( National Diagnostics ). 
Ethyl alcohol ( Hayman Ltd. ). Silver nitrate ( Johnson Matthey Materials 
Technology U.K. ). Dulbecco's Modified Eagle's medium, Earle's Modified 
Eagle's medium, Dulbecco's Modified Eagle's medium nutrient mixture - F1 2 ,
heat-inactivated foetal calf serum, Hank's Balanced salts solution without 
calcium and magnesium, Ultroser G, trypsin solution (2.5%), trypsin-EDTA 
solution (0.25%), mouse laminin, penicillin-streptomycin solution, horse serum, 
normal goat serum ( Gibco, BRL ). Neurone specific enolase, met-enkephalin, 
glial fibrillary acidic protein ( Affiniti ). 8 -well multichamber slides (Nunc).
All drug compounds used for in vivo experiments were dissolved in 
0.9% physiological saline, with the exceptions of haloperidol which was 
dissolved in 0 .2 % acetic acid , fluphenazine dihydrochloride, and clozapine 
which were dissolved in 0.5% dimethylsulphoxide.
All drug compounds used for in vitro experiments were dissolved in 
DEPC-treated water, with the exceptions o f haloperidol which was dissolved in 
0 .2 % acetic acid, fluphenazine dihydrochloride and clozapine which were 
dissolved in 0.5% dimethylsulphoxide, KT5720, calphostin C, and phorbol-12- 
myristate-13 acetate which were dissolved in dimethylsulphoxide. The stock 
drug solutions were then diluted in Hank’s Balanced Salts Solution, to obtain 
the final concentration.
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2.12 *In vivo* Expérimenta! Design
2.12.1 Acute Drug Treatment
Four groups of male Wistar rats (180-250g) were treated acutely with 
vehicle (isotonic saline, n=5), haloperidol (Img/kg, n=3), fluphenazine 
(3mg/kg, n=3; 6 mg/kg, n-3), clozapine (3mg/kg, n=5). Drugs were delivered 
by intraperitoneal injection in volumes of 1 ml/kg of body weight at staggered 5 
minute time intervals. After 30 minutes the animals were killed by stunning and 
decapitation, the brains rapidly removed and placed onto dry ice. The brains 
were then processed for the detection o f mRNA encoding the transcription 
factors c-fos, ziff268, jun-B and jun-D using in situ hybridisation 
histochemistry.
Five groups of male wistar rats (180-25Og) were treated for a 24 hour 
time period with vehicle (physiological saline, n= 5), haloperidol (Img/kg, n= 
3), fluphenazine (3mg/kg, n= 3), clozapine (3mg/kg, n= 6 ), and methiothepin 
(lOmg/kg, n= 3). Drugs were injected intraperitonealy (Iml/kg of body weight) 
at staggered time intervals. After 24 hours, the animals were killed by stunning 
and decapitation and their brains processed for the detection of mRNA 
encoding a specific region of the preproenkephalin, preproneuropeptide Y, 
preprosomatostatin, preprotachykinin, RHS2 and BF-1 using in situ
hybridisation histochemistry.
2.12.2 Chronic Drug Treatment
Three groups of male Wistar rats (250-28Og) were chronically treated 
for 5 days with vehicle (osmotic mini pump containing vehicle, n= 4), clozapine 
(3 mg/kg, n - 4), and fluphenazine (3 mg/kg, n= 4). The drugs were administered
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via osmotic mini pumps (Alzet). Freshly prepared drug solutions were carefully 
injected into the osmotic mini pumps according to the manufacturers 
instructions. The animals were anaesthetised with equethesin (4ml/kg) and the 
osmotic mini pumps inserted subcutaneously into the hind limb region. Drug 
release was moderated by the pump to Ijul/ hour. Animals were weighed on the 
second, third and fifth day after insertion o f the osmotic mini pumps and 
checked regularly for any symptomatic effects o f the drugs. After five days the 
animals were killed by stunning and decapitation, and their brains rapidly 
processed for the detection of mRNAs encoding preprosomatostatin, and also 
the dopaminergic D1 receptor and the serotoninergic 5-HT6 receptor.
2.12.3 Time Course Experiments
Male Wstar rats (180-250g) were treated with vehicle (n= 2  per time 
point) or either fluphenazine (6 mg/kg) or clozapine (3 mg/kg) for the following 
time periods: 15 minutes (n= 3), 30 minutes (n~ 3), 45 minutes (n= 3), 90 
minutes (n= 3) and 3 hours (n- 3), Both drugs were delivered by 
intraperitoneal injection in volumes of 1 ml/kg. After the specified times, the 
animals were killed by stunning and decapitation, and their brains rapidly frozen 
on dry ice. The brains were then processed for the detection o f mRNA 
encoding the transcription factors c-fos, jun-B, and zifi268, and the late 
response genes proenkephalin and preprosomatostatin.
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2.13 Tn vitro* Experimental Design
All striatal neurone cultures were treated with drugs for 45 minutes at 
37^C. The drugs were delivered directly to the bathing medium in 20fxl 
volumes, making the assumption that the total volume bathing the cells was 
0.4ml. After 45 minutes the cells were fixed in a 4% buffered 
paraformaldehyde solution, rinsed in 1 X PBS, dehydrated in ethanol and 
processed for in situ hybridisation as previously described.
2.13.1 Time Course Experiment In Vitro
Striatal neurone cultures were treated with haloperidol (final bath 
concentration IjxM) administered to each well of an 8 -well multichamber slide 
for the following time intervals: 90 minutes (n= 3), 60 minutes (n= 3), 45 
minutes (n= 3), 30 minutes (n~ 3), 20 minutes (n= 3), 10 minutes (n= 3), 5 
minutes (n= 3), and at time zero (n= 3). The slides were then fixed and 
processed for the detection of mRNA encoding the transcription factors 
ziJ&'268, jun-B and c-fos.
2.13.2 Treatment with Agonist Compounds
Striatal neurone cultures were treated with vehicle (Hank's Balanced 
Salts Solution), the dopaminergic agonists SKF 38393 (final bath concentration 
lnM-5/xM), dopamine (final bath concentration lnM-5/xM), and quinpirole 
(final bath concentration l^M), the serotoninergic agonists 8 -hydroxy-DPAT 
(final bath concentration lnM-5/iM), mCPP (final bath concentration InM- 
5juM), ±-DOI (final bath concentration lnM-5^M) and the protein kinase C
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stimulating dmg phorbol-1 2 - myristate-13-acetate (final bath concentration 1 0 " 
^M) at 37°C. After 45 minutes the cells were fixed and processed for the 
detection of c-fos and zifi268 mRNA using in situ hybridisation.
2.13.3 Treatment with Antagonist Compounds
Striatal neurone cultures were pretreated for 30 minutes with the
dopaminergic antagonist compounds SCH 23390 (final bath concentration
1/xM), eticlopride (final bath concentration 1/xM), the serotoninergic antagonist
.compounds cyproheptadine (final bath concentration 500nM), ondansetron 
(final bath concentration 200nM), methiothepin (final bath concentration 
200nM), mesulergine ( final bath concentration 30, lOOnM), clozapine (final 
bath concentration lOOnM), and spiperone (final bath concentration 30,100nM) 
prior to the addition of SKF 38393 (final bath concentration lnM-5/iM) or 5- 
hydroxytryptamine (final bath concentration lnM-5)uM) respectively. Similarly 
cultures were pretreated for 30 minutes with the protein kinase A inhibitor, 
KT5720 (final bath concentration 2(jM )  and the protein kinase C inhibitor, 
calphostin C (final bath concentration ljuM) prior to the addition of SKF 38393 
(final bath concentration 1/xM). Cultures treated with calphostin C were left 
under conventional room lighting for the first five minutes of the incubation 
period in order to activate tliis compound (Bruns et al., 1991). After 45 
minutes the cells were fixed and processed for the detection of c-fos and 
zif/268 mRNA using in situ hybridisation.
:y-
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2.14 Dopamine Receptor Antisense Experiment
Striatal neurone cultures were treated for 2  days at 37®C with 15-mer 
antisense oligonucleotides complementary to the D1 dopamine receptor and to 
the D5 dopamine receptor. The antisense oligonucleotides were delivered in a 
volume of 0.5/xl, such that the final bath concentration was l i^M. As an 
appropriate control for specificity of effects of these oligonucleotides, cultures 
were also treated with a D1 sense oligonucleotide, identified as having the 
same sequence as a region of the D1 receptor mRNA, administered at a 
concentration of ljuM. After 2 days, the cultures were acutely treated with SKF 
38393 (lnM-5jaM) for 45 minutes, at 37°C . Slides were fixed and then 
processed for the detection of both c-fos and zifi268 mRNA using in situ 
hybridisation.
2.15 Image Analysis and Statistics Used
To quantitate any drug induced changes in the levels o f mRNA for the 
transcription factors c-fos, zifi268, jun-B, jun-D, RHS2, BF-1, for the 
neuropeptides preproenkephalin, preprotachykinin, preprosomatostatin, 
proneuropeptide Y, and for the 5-HT6, and dopamine D1 receptors, initially 
densitometry of film images was done using the MCID SCIR image analysis 
system. Bilateral measurements of mean relative optical density (R.O.D.) were 
taken from brain sections on autoradiographic film, in the regions of the 
striatum and nucleus accumbens from two sections per animal. For cell culture 
analysis, four measurements of mean R.O.D. were taken from each well of an 
8 -well multichamber slide exposed to film. For a higher cellular resolution 
quantification the density of silver grains were measured after dipping slides in 
liquid photographic emulsion using a Macintosh image analysis system (“image
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vl.52” software [NIH]). For a single culture well, a total of fifteen 
measurements of mean number of pixels occupied by silver grains per unit area, 
were taken fi-om three fields of view.
Following this, analysis of variance ANOVA, ( one-way unstacked or 
two-way stacked) was performed on the data for each drug treatment 
(Minitab). The Dunnett’s post-hoc test was then used to assess statistical 
significance of any drug induced changes between individual groups in all 
experiments unless stated otherwise. However, for the in vivo experimental 
work on immediate early genes it was necessary to use the more stringent 
statistical test, the Mann-Whitney U test. Two-way ANOVA, general linear 
model (Minitab), was used to analyse in vitro drug dose response curves in the 
presence and absence of antagonist compounds.
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Chapter 3
Regulation of Late Response Gene 
Expression in vivo
INTRODUCTION
3.0 Neuroleptic Modulation of Late Response Genes In Vivo
It has been known for some time that neuroleptics act by blocking 
dopamine receptors and are clinically effective in the treatment of a number of 
diseases which are thought to originate from a dopaminergic dysfunction in the 
central nervous system. Disease states such as schizophrenia and Parkinson’s 
disease are known to be manifestations arising from a dysfunction of the 
dopaminergic system within the brain. Blockade of dopamine receptors in the 
striatum by neuroleptic drugs such as haloperidol have since been shown to 
cause an elevation in the levels of preproenkephalin mRNA and its 
corresponding protein product (Hong et al.. 1978; Sabol et al.. 1983; Tang et 
ai., 1983; Angulo et a l. 1986; Sivam et al.. 1986; Romano et al.. 1987; Morris 
et al.. 1988). Conversely, neuroleptic drug treatment has been shown to reduce 
the levels of the brain neuropeptide substance P in the striatum (Bannon et al.. 
1986 ).
However, most of this research has been performed under conditions of 
chronic drug administration, probably due to the fact that neuroleptic drug 
treatment is clinically effective only after prolonged administration. At present 
there is virtually no information on the acute effects of neuroleptic drugs on 
late response genes in the region of the striatum. With the rapid progression of 
research into immediate early genes and the recent findings that some typical 
neuroleptic drugs can elevate the levels of certain immediate early genes 
including c-fos, jun-B and zifr286 in the striatum (Nguyen et al.. 1992), the 
acute effects of neuroleptics may provide a greater understanding of the 
sequence of events following dopamine receptor blockade.
The atypical neuroleptics such as clozapine, which are known to 
produce less extrapyramidal side effects (Ayd, 1961; Claghom et al.. 1983),
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and are therefore an improved treatment for certain disease states, have been
Vshown to exert different effects on certain late response genes in comparison to 
typical neuroleptics drugs. For example the typical neuroleptic, haloperidol, is 
known to decrease the levels of preprosomatostatin mRNA in the striatum and 
accumbens (Salin et al.. 1989), Whereas the atypical neuroleptic, clozapine, has 
been shown to increase the levels of somatostatin mRNA in the nucleus 
accumbens (Sailer et al.. 1989). This differential regulation o f gene expression 
by atypical compared to typical neuroleptics, may contribute to the different 
clinical profile of drugs such as clozapine. It is known that clozapine is an 
anomoloy, in that it has a much higher affinity for the dopamine D 4 receptor 
than the typical neuroleptic drugs (Van Toi et al.. 1991). Therefore it is of 
great interest to understand further the complete profile of clozapine in terms 
of its effect on late response genes and the possible receptor mechanisms 
involved in the actions of this class of drugs.
i
RESULTS
Short-term Regulation of Proenkephalin Gene Expression in vivo
3.1 Early time course of Fluphenazine on Proenkephalin mRNA expression
3.2 Effect of acute Antipsychotic drug treatment on Proenkephalin mRNA 
levels in the caudal striatum 24 hours later
Chronic treatment with neuroleptics is well known to cause an increase 
in the
levels of the enkephalin gene in the region of the striatum (Sabol et al.. 1983; 
Tang et a l, 1983; Angulo et al.. 1986; Sivam et al.. 1986; Romano et al., 1987; 
Morris et al.. 1988). Therefore we were interested in the acute effects of 
neuroleptic drug treatments on the expression of the enkephalin gene after 24 
hours.
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1Following intraperitoneal administration of fluphenazine (6 mg/kg) to 
male wistar rats (n- 3), the levels of proenkephalin mRNA were not 
significantly changed 15, 30, 45, 90, and 180 minutes after drug 
administration, compared to saline treated control animals (n= 2  per treatment 
group) iryected at the corresponding time points. It can be seen that the mRNA 
levels for the enkephalin gene in the rostral striatum [Figure3.1.1] were not 
significantly affected by fluphenazine (6 mg/kg) at time periods up to three 
hours. A similar lack of effect was observed in the caudal striatum after 
treatment with fluphenazine (6 mg/kg) compared to saline treated control 
animals [Figure 3.1.2].
Figure 3.1.1 : Effect of fluphenazine on preproenkephalin mRNA levels in the 
rat rostral striatum, Fluphenazine (6 mg/kg, n= 3, closed triangles) or vehicle 
(0.9% saline, n= 2, open triangles) were injected i.p. and the animals killed after 
the specified time intervals i.e.- 15, 30, 45, 90, and 180 minutes, and their 
brains processed for in situ hybridisation. Results, obtained from film 
autoradiographs, are expressed as mean relative optical density ± s.e.m.
Figure 3.1.2 : Effect of fluphenazine (6 mg/kg) on preproenkephalin mRNA 
levels in rat caudal striatum. Fluphenazine (6 mg/kg; n= 3, closed triangles) or 
vehicle (0.9%; n= 2, open triangles) were injected i.p., the animals killed after 
the specified time intervals i.e- 15, 30, 45, 90 and 180 minutes, and their brains 
processed for in situ hybridisation. Results, obtained from film autoradiographs, 
are expressed as mean relative optical density ± s.e.m.
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Figure 3.2.1 : Effect of acute neuroleptic drug treatment on the expression of 
proenkephalin mRNA in the rat caudal striatum. Animals were injected i.p. with 
vehicle (0.9% saline), haloperidol (Img/kg), fluphenazine (3mg/kg), clozapine 
(3 mg/kg), or with methiothepin (lOmg/kg). After 24 hours the animals were 
killed and their brains processed for in situ hybridisation. Results, obtained 
from autoradiographic film, are expressed as mean relative optical density + 
s.e.m.; the number of animals per group is shown in parentheses. Statistical 
significance was determined by one way ANOVA followed by post-hoc 
Dunnett’s test, p < 0.05* relative to saline group.
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In saline treated animals a moderate hybridisation signal for 
preproenkephalin was observed in the caudal striatum. Typical neuroleptic drug 
treatments, together with methiothepin were demonstrated to significantly 
increase the levels o f proenkephalin mRNA in the caudal striatum [ F (4, 15) = 
14.40, p -  0.001]. Following intraperitoneal administration o f the typical 
neuroleptic haloperidol (Img/kg, n - 3) a significant induction in the levels o f 
preproenkephalin mRNA were seen ( p< 0.05 ) [Figure 3.2.1], A similar 
increase was observed following treatment with fluphenazine (3 mg/kg, n= 3), 
and this induction was shown to be significantly different from saline treated 
control rats (n- 5), such that p< 0.05 [Figure 3.2.1]. The atypical neuroleptic 
clozapine (n= 6 ) had no effect on the expression of the enkephalin gene. 
However, following administration of the non-selective 5-HT1/2 receptor 
antagonist, methiothepin (lOmg/kg, n= 3), also having a relatively high affinity 
for the dopamine D2 receptor, the levels of preproenkephalin were significantly 
induced such that p< 0.05 [Figure 3.2.1].
Short-term regulation of preprotachvkinin gene expression in the rat 
striatum
3.3 Effect of acute drug treatment on the expression of preprotachkvinin 
mRNA levels in the rat striatum 24 hours later
It has previously been reported that chronic treatment with typical 
neuroleptics can decrease the levels of preprotachykinin mRNA in the rat 
striatum (Bannon et al.. 1986). In this study we have investigated the acute 
effects of typical and atypical neuroleptic drugs on preprotachykinin gene 
expression.
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Following intraperitoneal injections of saline (n= 5), or haloperidol 
(Img/kg; n= 3), or fluphenazine (3mg/kg; n= 3), or clozapine (3mg/kg; n= 6 ), 
or methiothepin (lOmg/kg; n= 3), the levels of preprotachykinin mRNA were 
measured in the rat striatum 24 hours after drug administration.
Analysis of variance revealed that the typical neuroleptics had an effect 
on the level of preprotachykinin mRNA in both the rostral [ F (4, 15) = 6.92, 
p< 0.001 ] and caudal [ F (4, 15) = 3.82, p< 0.05 ] striatum. Haloperidol 
(Img/kg, n= 3) caused a reduction in the levels of preprotachykinin mRNA in 
the rostral striatum, compared to saline treated control animals. This decrease 
was shown to be significantly different from the levels expressed in saline 
treated controls ( p< 0.05 ) [Figure 3.3.1]. Fluphenazine (3mg/kg, n= 3) had a 
tendency to decrease preprotachykinin mRNA levels in the rostral striatum, 
although this decrease was not found to be significant. The atypical neuroleptic 
clozapine (3 mg/kg, n= 6 ) or methiothepin (lOmg/kg, n= 3) had no effect on 
preprotachykinin mRNA levels after 24 hours in the rostral striatum. [Figure
3.3.1]
A similar significant reduction in the levels of preprotachykinin mRNA 
compared to saline treated controls, was observed in the caudal striatum 24 
hours after treatment with haloperidol (Img/kg, n= 3) ( p< 0.05 ) [Figure
3.3.2]. Fluphenazine (3mg/kg, n= 3), also caused a significant decrease in 
preprotachykinin mRNA levels in the caudal striatum, such that p< 0.05 
[Figure 3.3.2]. However, clozapine (3mg/kg, n= 6 ) and methiothepin 
(lOmg/kg, n= 3) had no effects on the levels of preprotachykinin mRNA 
expressed in the rat caudal striatum. [Figure 3.3.2].
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Figure 3.3.1 : Effect of acute neuroleptic-drug treatment on the expression of 
preprotachykinin mRNA in the rat rostral striatum. Animals were injected i.p. 
with vehicle (0.9% saline), or haloperidol (Img/kg), or fluphenazine (3mg/kg), 
or clozapine (3mg/kg) or with methiothepin (lOmg/kg). After 24 hours the 
animals were killed and their brains processed for in situ hybridisation. Results, 
obtained from autoradiographic film, are expressed as mean relative optical 
density + s.e.m.; the number of animals per group is shown in parentheses. 
Statistical significance was determined by one-way ANOVA, followed by post- 
hoc Dunnett’s test, p < 0.05* relative to saline group.
Figure 3.3.2 : Effect of acute neuroleptic drug treatment on the expression of 
preprotachykinin mRNA in the rat caudal striatum. Animals were injected i.p. 
with vehicle (0.9% saline), or haloperidol (Img/kg), or fluphenazine (3mg/kg), 
or clozapine (3 mg/kg) or with methiothepin (lOmg/kg). After 24 hours the 
animals were killed and their brains processed for in situ hybridisation. Results, 
obtained from autoradiographic film, are expressed as mean relative optical 
density + s.e.m.; the number of animals per group is shown in parentheses. 
Statistical significance was determined by one-way ANOVA, followed by post- 
hoc Dunnett’s test, p < 0.05* relative to saline group.
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Short-term regulation of preprosomatostatin gene expression in the rat 
striatum
3.4 Effect of acute drug treatment on the levels of preprosomatostatin mRNA 
in the caudal striatum and in the nucleus accumbens 24 hours later
Previous studies have suggested that high doses of clozapine can cause 
an induction of preprosomatostatin mRNA in the rat nucleus accumbens (Salin 
et al. 1989). Therefore in this study we have investigated the effect of acute (24 
hour ) treatment with low doses of clozapine, together with two typical 
neuroleptics haloperidol and fluphenazine, on the expression of 
preprosomatostatin mRNA.
The levels of preprosomatostatin mRNA in the caudal striatum were 
not changed by the administration o f haloperidol (Img/kg, n= 3) or 
fluphenazine (3mg/kg, n= 3) compared to saline treated control animals (n= 5). 
However, following treatment with clozapine (3 mg/kg, n= 6 ) or methiothepin 
(lOmg/kg, n= 3), an increase in the level of preprosomatostatin mRNA was 
observed in the region of the caudal striatum. This induction was shown to be 
significantly different from saline treated control animals [ F (4, 15) = 9.46, p=
0.01 , p< 0.05] [Figures 3.4.1]. The effect of clozapine (3mg/kg, n= 6 ) on the 
expression of preprosomatostatin in the caudal striatum was significantly 
different fi*om control animals, such that p< 0.05 [Figure 3.4.1]. This acute 
effect o f clozapine can also be seen in figure 3.4.2, as an increase in the number 
of silver grains over cell bodies in the striatum expressing the somatostatin 
gene. Treatment with methiothepin (lOmg/kg, n= 3), caused a greater increase 
in the levels of preprosomatostatin mRNA in the rat caudal striatum than did
I
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clozapine, and this increase was significantly different from control animals ( p<
0 .01) [Figure 3.4.1].
A similar pattern of induction was observed in the rat nucleus 
accumbens. Analysis of variance revealed that the drugs under investigation 
caused an induction in somatostatin gene expression after 24 hours [F (2, 9) = 
7.97, p= 0.006, p< 0.01]. Clozapine (3mg/kg, n= 6 ) caused an increase in the 
expression of preprosomatostatin mRNA in the core region of the accumbens. 
This increase was significantly different from the levels expressed in saline 
treated rats (p< 0.01). [Table 1]. Similarly administration of methiothepin 
(lOmg/kg, n= 3) resulted in an induction of preprosomatostatin mRNA in the 
core region 24 hours after administration (p< 0.01) [Table 1].
Drug Treatment Nucleus Accumbens
Saline 11.10 ±0.82
Clozapine 22.63 ± 2.60 **
Methiothepin 18.15 ±1.50 **
density x 10  ^ ± s.e.m. Significance was determined by one-way ANOVA, 
followed by post-hoc Dunetts t-test. p< 0.01 **
I
Table 1; The expression of preprosomatostatin mRNA in the rat nucleus 
accumbens following a 24 hour treatment with vehicle (physiological saline), 
clozapine (3mg/kg, n= 6 ), or with methiothepin (lOmg/kg, n= 3). Results, 
obtained from film autoradiographs, are expressed as mean relative optical
!i
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Figure 3.4.1 : Effect of acute neuroleptic drug treatment on the expression of 
preprosomatostatin mRNA in the rat caudal striatum. Animals were injected
i.p. with vehicle (0.9% saline), haloperidol (Img/kg), fluphenazine (3mg/kg), 
clozapine (3mg/kg), or with methiothepin (lOmg/kg). After 24 hours the 
animals were killed and their brains processed for in situ hybridisation. Results, 
obtained from autoradiographic film, are expressed as mean relative optical 
density ± s.e.m.; the number of animals per group is shown in parentheses. 
Statistical significance was determined by one-way ANOVA, followed by post- 
hoc Dunnett’s test, p < 0.05* p < 0.01** relative to saline group.
Figure 3.4.2 : Effect of acute treatment with clozapine on the expression of 
preprosomatostatin mRNA in the rat striatum. Photomicrographs show the 
distribution of silver grains over cell bodies in the caudal striatum. On the left, 
the animal was injected i.p with vehicle (0.9% saline) (A) and on the right, with 
clozapine (3 mg/kg) (B) Animals were killed after 24 hours, following which 
their brains were processed for in situ hybridisation. Scale bar represents 25/^m.
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Figure 3.5.1 : Time course effect o f clozapine on somatostatin mRNA levels in 
the rat rostral striatum. Clozapine (3mg/kg; n= 3, closed triangles) or vehicle 
(0.9% saline; n= 2, open triangles) were injected i.p., the animals killed after 
the specified time intervals i.e.- 15, 30, 45, 90, and 180 minutes, and their 
brains processed for in situ hybridisation. Results, obtained fi*om film 
autoradiographs, are expressed as mean relateve optical density ± s.e.m.
Figure 3.5.2 : Time course effect of clozapine on somatostatin mRNA levels in 
the rat caudal striatum. Clozapine (3mg/kg; n= 3, closed triangles) or vehicle 
(0.9% saline; n= 2, open triangles) were injected i.p., the animals were killed 
after the specified time intervals i.e.- 15, 30, 45, 90, and 180 minutes, and their 
brains processed for in situ hybridisation. Results, obtained from film 
autoradiographs, are expressed as mean relative optical density ±  s.e.m.
0 .06  -
15 30 45
Tim e (m in e)
90 180
15 30 45
Time (m ina)
90 180
3.5 The early time course of the clozapine effect on the expression of 
preprosomatostatin mRNA in the rat striatum
The levels o f preprosomatostatin mRNA following treatment with 
saline (n= 2) or clozapine (3mg/kg; n= 3) were not significantly different after 
the following time points; 15, 30, 45, 90, 180 minutes, in either the rostral 
striatum [Figure 3.5.1] or caudal striatum [Figure 3.5.2] in the rat.
Long-term regulation of somatostatin gene expression in the rat striatum 
and nucleus accumbens
3.6 Effect of low doses of clozapine given chronically, on the expression of 
preprosomatostatin mRNA in the rat striatum and olfactory tubercle
Animals were treated with either saline (n= 4) or clozapine (6 mg/kg 
/day, n= 4), administered via an osmotic mini pump for 5 consecutive days, 
following which the levels of preprosomatostatin mRNA were measured by in 
situ hybridisation. Moderate levels of preprosomatostatin mRNA were 
expressed in saline treated animals, in a small population of cells known to 
express the somatostatin gene in both the rostral and caudal striatum. 
Following chronic treatment with clozapine (6 mg/kg, n= 4), an increase in the 
level of preprosomatostatin mRNA was observed in both the rostral and caudal 
striatum. The induction of preprosomatostatin mRNA in the rostral region was 
shown to be significantly different from the levels expressed in saline treated 
rats [ F (1, 6 ) = 7.92, p=0.022, p< 0.05] [Figure 3.6,1]. A similar, and highly
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Figure 3.6.1 : Effect of chronic treatment with clozapine on the expression of 
preprosomatostatin mRNA in the rat rostral striatum. Clozapine (6 mg/kg) or 
vehicle (0.9% saline) was administered via an osmotic mini pump for 5 days. 
Following this, the animals were killed and their brains processed for in situ 
hybridisation. Results, obtained from autoradiographic film, are expressed as 
mean relative optical density + s.e.m. The number of animals per group are 
shown in parentheses. Significance was determined by one-way ANOVA, 
followed by post-hoc Dunnett’s test, p < 0.05* relative to saline group.
Figure 3.6.2 : Effect of chronic treatment with clozapine on the expression of 
preprosomatostatin mRNA in the rat caudal striatum. Clozapine (6 mg/kg) or 
vehicle (0.9% saline) was administered via an osmotic mini pump for 5 days. 
Following this, the animals were killed and their brains processed for in situ 
hybridisation. Results, obtained from autoradiographic film, are expressed as 
mean relative optical density + s.e.m. The number of animals per group are 
shown in parentheses. Significance was determined by one-way ANOVA, 
followed by post-hoc Dunnett’s test, p < 0 .0 1 ** relative to saline group.
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Figure 3.6.3 : ESect o f chronic treatment with clozapine on the expression of 
preprosomatostatin mRNA in the caudal striatum of the rat. Photomicrographs 
show the distribution of silver grains over striatal cell bodies that express the 
somatostatin gene. On the left, is an animal chronically treated with saline (A), 
and on the right , an animal chronically treated with clozapine (6 mg/kg), via 
osmotic mini pump for 5 days (B). p<0.01**. Scale bar represents 25/xm.
Figure 3.6.4 ; Effect of chronic treatment with clozapine on the expression of 
preprosomatostatin mRNA in the rat olfactory tubercle. Clozapine (6 mg/kg) or 
vehicle (0.9% saline) were administered via osmotic mini pumps for 5 days. 
Following this, the animals were killed and their brains processed for in situ 
hybridisation. Results, obtained from autoradiographic film, are expressed as 
mean relative optical density + s.e.m. The number of animals per group are 
shown in parentheses. Significance was determined by one-way ANOVA, 
followed by post-hoc Dunnett's test, p < 0.05* relative to saline group.
' ■ m
%
0 .25 -,
Z, 0.20
0 .15
> 0 .1 0
g 0 .05
CLOZ
0.00
SAL= sa lin e
CLOZ= C lozap ine(6m g/kg)
significant increase in the levels of preprosomatostatin mRNA compared to the 
saline treated controls, was also observed in the caudal regions of the rat 
striatum [ F( 1 ,6 ) = 20.24, p= 0.005, p< 0 .0 1 ] [Figures 3.6.2, 3.6.3], following 
low doses of clozapine.
In the olfactory tubercle, a similar induction of the somatostatin gene 
was observed after chronic treatment with clozapine (6 mg/kg, n= 4), and this 
induction was shown to be significantly different from saline treated control 
animals [F (1,6) = 19.28, p= 0.019, p< 0.05] [Figure 3.6.4].
Short-term regulation of proneuroneptide Y gene expression in the rat 
striatum
3.7 Effect of acute drug treatment on the expression of proneuropeptide Y  
mRNA levels in the rat striatum 24 hours later.
Following intraperitoneai injection of saline (n= 3), or clozapine 
(3mg/kg, n= 3), or methiothepin (lOmg/kg, n= 3), proneuropeptide Y was 
measured in the regions of the rostral and caudal striatum 24 hours after drug 
administration. No significant change in the level of proneuropeptide Y mRNA 
was seen in either the rostral [Figure 3.7.1] or in the caudal [Figure 3.7.2] 
regions of the rat striatum, compared to saline treated control animals.
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Figure 3.7.1 : Effect o f acute drug treatment on the expression of 
proneuropeptide Y mRNA in the rat rostral striatum. Clozapine (3mg/kg, n= 3)
, methiothepin (lOmg/kg, n= 3) or vehicle (0.9% saline, n= 3) were injected i.p. 
After 24 hours, the animals were killed and their brains processed for in situ 
hybridisation. Results, obtained from film autoradiographs, are expressed as 
mean relative optical density + s.e.m.
Figure 3.7.2 : Effect of acute drug treatment on the expression of 
proneuropeptide Y mRNA in the rat caudal striatum. Clozapine (3mg/kg, n= 
3), methiothepin (10mg/kg,n= 3) or vehicle (0.9% saline, n= 3) were injected
i.p. After 24 hours the animals were killed and their brains processed for in situ 
hybridisation. Results, obtained from film autoradiographs, are expressed as 
mean relative optical density + s.e.m.
na«Q
'3oIwAO
O>■
0,07
0 .0 6
0 .0 5
0 . 0 4
0 .0 3
St
® 0.02
0  Sto 0.01
0 .0 0
SAL= sa l in e
CLOZ= C lo zap in e (3 m g /k g )  
METHIO = M eth io th ep in  
( lO m g /k g )
SAL
(3)
CLOZ
(3)
METHIO
(3)
0 .1 2  -t
0 .1 0  -
«XaoA 0 .0 8  -
tiu.wA 0 .0 6  -O
o
d 0 . 0 4  -
o
ado 0 .0 2  -»
0.00
SAL= sa l ine
CLOZ= C lo zap in e (3 m g /k g )  
METHIO- M eth io th ep in  
( lO m g /k g )
SAL
(3)
CLOZ
(3)
METHIO
(3)
Long-term effects of neuroleptics on receptors
3.8 Effect of chronic neuroleptic drug administration on the expression of the 
dopamine D1 receptor mRNA in the rat striatum
The expression of the D1 dopamine receptor in the rat striatum is 
known to be homogenously distributed throughout the striatum.
Animals were treated chronically with saline (n= 4), clozapine (6 mg/kg, 
n= 4) or with fluphenazine (6 mg/kg, n= 4) for 5 days, following which the 
levels of D1 receptor mRNA were measured as previously described.
It was found that both clozapine (6 mg/kg, n= 4) and fluphenazine 
(6 mg/kg, n= 4) when given chronically could increase the expression of D1 
mRNA in the rostral striatum of the rat, F (2, 9) = 5.84, p= 0.01, p< 0.01 
[Figure 3.8.1]. The increase in D1 mRNA after clozapine treatment was 
significantly different from control animals, such that p< 0.05. Similarly chronic 
treatment with fluphenazine (6 mg/kg, n= 4) caused an increase in D1 mRNA in 
the rostral striatum. This increase was greater than the induction due to 
clozapine, such that p< 0.01 [Figure 3.8.1].
In caudal regions , both clozapine (6 mg/kg, n= 4) and fluphenazine 
(6 mg/kg, n= 4) had a tendency to increase the levels of D1 mRNA expressed in 
the striatum. Although statistical analysis revealed no significant differences 
when compared to the control animals [Figure 3.8.2].
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Figure 3.8.1 : Effect of chronic neuroleptic drug treatment on the expression of 
dopamine D 1 receptor mRNA in the rat rostral striatum. Clozapine (6 mg/kg), 
or fluphenazine (6 mg/kg), or vehicle (0.9% saline) were administered via 
osmotic mini pumps for 5 days. Following this, the animals were killed and 
their brains processed for in situ hybridisation. Results, obtained firom 
autoradiographic film, are expressed as mean relative optical density + s.e.m. 
The number o f animals per group are shown in parentheses. Significance was 
determined by one-way ANOVA, followed post-hoc Dunnett’s test. *p < 0.05, 
**p < 0 . 0 1  relative to saline group.
Figure 3.8.2 : Effect of chronic neuroleptic drug treatment on the expression of 
dopamine D 1 receptor mRNA in the rat caudal striatum. Clozapine (6 mg/kg), 
or fluphenazine (6 mg/kg), or vehicle (0.9% saline) were administered via 
osmotic mini pumps for 5 days. Following this, the animals were killed and 
their brains processed for in situ hybridisation. Results, obtained from 
autoradiographic film, are expressed as mean relative optical density + s.e.m. 
The number of animals per group are shown in parentheses. Significance was 
determined by one-way ANOVA, followed by post-hoc Dunnett’s test.
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3.9 Effect of chronic neuroleptic drug administration on the levels of 5-HT6 
receptor mRNA in the rat striatum
The recently cloned 5-HT6 receptor is known to be expressed in the rat 
striatum and have a high affinity for certain anitpsychotic drugs. Therefore we a
have investigated if chronic administration of the neuroleptic drugs clozapine 
(6 mg/kg, n= 4) or fluphenazine (6 mg/kg, n= 4) have any effect on the levels of 
5-HT6 receptor mRNA compared to saline treated control animals.
However, it was found that low doses of clozapine (6 mg/kg) or 
fluphenazine (6 mg/kg) had no effect on the levels of 5~HT6 mRNA in either 
the rostral [Figure 3.9.1] or the caudal regions in the rat striatum [Figure
3.9.2], such that the levels of 5-HT6 mRNA were not significantly different 
from vehicle treated animals.
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Figure 3.9.1 : Effect of chronic neuroleptic drug treatment on the expression of 
serotoninergic 5-HT6 receptor mRNA in the rat rostral striatum. Clozapine 
(6 mg/kg), or fluphenazine (6 mg/kg), or vehicle (0.9% saline) were 
administered via osmotic mini pumps for 5 days. Following this, the animals 
were killed and their brains processed for in situ hybridisation. Results, 
obtained from autoradiographic film, are expressed as mean relative optical 
density + s.e.m. The number of animals per group are shown in parentheses.
Figure 3.9.2 : Effect of chronic neuroleptic drug treatment on the expression of 
serotoninergic 5-HT6 receptor mRNA in the rat caudal striatum. Clozapine 
(6 mg/kg), or fluphenazine (6 mg/kg), or vehicle (0.9% saline) were 
administered via osmotic mini pumps for 5 days. Following this, the animals 
were killed and their brains processed for in situ hybridisation. Results, 
obtained from autoradiographic film, are expressed as mean relative optical 
density + s.e.m. The number of animals per group are shown in parentheses.
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3.10 Northern blot hybridisation analysis of rat RNA
probe, the northern blot of total poly (A) + RNA was hybridised with a
8 1
After total poly (A) + RNA (8 /xg/ sample) from each brain region was 
denatured, electrophoresed on a 1% agarose/ formaldehyde gel and transferred 
to a nylon membrane, the blot was hybridised with a labelled tubulin T26 
probe, as described under methods. The tubulin isoform T26 is a cytoskeletal 
protein present in all brain tissue and therefore was used as an appropriate 
control for M h  content in brain tissue samples. The blot was exposed to
film for forty-eight hours at -80°C. As shown in the autoradiograms o f figure
3.20, the rat T26 probe hybridised with a single major band of total poly (A) +
RNA [Figure 3.10.1, panel a] of length 1800 nucleotides from all brain regions
tested (i.e.- striatum, hippocampus, cortex, olfactory bulb and cerebellum), but
not from rat liver. As can be seen from the autoradiogram, the intensity of
labelling was very similar in all regions after incubation with a tubulin T26
mRNA probe. In accordance with previous findings, the size of band is 
.consistent with that described for rat tubulin T26 in the brain (Miller et al., 
1987). Any other bands appearing on the blot were considered to represent 
degraded material.
To assess the sensitivity and specificity of the rat preproenkephalin
■f
labelled rat preproenkephalin mRNA probe (45-mer, previously described).
After a thirty-six hour exposure to film at -80°C, a single band of length
approximately 1500 nucleotides was observed in the region of the striatum, but
not in the liver, a tissue essentially devoid of proenkephalin peptides [Figure
.3.10.1, panel b]. This size is consistent with that previously determined for 
bovine and rat striatal preproenkephalin mRNA (Dandekar and Sabol, 1982; 
Tang et al.. 1983). The pattern of expression of preproenkephalin mRNA on
. . .
Figure 3.10,1 : Northern blot analysis of (A) tubulin T26 mRNA and (B) 
preproenkephalin mRNA from various regions of the rat brain. Total poly(A)+ 
RNA (8 /xg/sample) taken from five brain regions [ striatum (ST), hippocampus 
(H), cortex (CTX), olfactory bulb (OB), and cerebellum (CB) and also from 
the liver (L)] was denatured and electrophoresed on a 1% agarose, 
formaldehyde gel, transferred to a nylon membrane and hybridised with either 
(A) a ^^P-labelled tubulin T26 probe (previously described) or with (B) a ^^P- 
labelled preproenkephalin probe (previously described) as described under 
methods.
^  1-8 Kb
K CB H ST CTX OB
T /  - #
t 5Kb
the northern blot appeared relatively free from non-specific hybridisation, and 
showed greatest abundance in the rat striatum, with virtually no signal in other 
brain regions. However, with a longer time of exposure, it may be expected 
that a signal representing preproenkephalin mRNA may appear in the region of  
the cortex and cerebellum, but with a much lower intensity (Yoshikawa et al..
1984).
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DISCUSSION
Short-term Regulation of Proenkephalin Gene Expression in vivo
These studies were undertaken to initially determine whether enkephalin 
gene expression is induced by certain antipsychotic drugs after their acute 
administration. It is well known information that antipsychotic drugs can induce 
proenkephalin mRNA levels when given chronically (Sabol et al.. 1983; Tang 
et al.. 1983; Angulo et al.. 1986; Sivam et al.. 1986; Romano et al.. 1987; 
Morris et a l. 1988). We have looked at short-term regulation of a number of 
late response genes, in an attempt to gain further understanding into the 
functional significance of the class of genes referred to as immediate early 
genes. By gaining information on the possible receptor mechanism involved in 
the induction of both late response genes and immediate early genes we have 
been able to contribute indirect information that may aid in understanding the 
relationship between late response genes and immediate early gene induction, a 
theory that currently remains controversial and not well understood.
3.11 Early time course of Fluphenazine on Proenkephalin mRNA expression
The drug fluphenazine was used in this study because of its profile as a 
typical neuroleptic. Clinical use of typical neuroleptic drugs is frequently 
associated with the appearance of undesirable side effects including 
extrapyramidal movement disorders, which further divide into a parkinsonian­
like syndrome and tardive dyskinesia, dependent on the length of drug exposure 
(Baldessarini, 1985; Tarsy and Baldessarini, 1986; Meltzer, 1991). These 
unwanted extrapyramidal behavioural side effects are thought to be a
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consequence of extensive blockade o f dopaminergic D2-like receptors in the 
nigrostriatal (A9) dopamine system (Baldessarini, 1979; Klawans et al.. 1980). 
Fluphenazine is reported to have a marginal selectivity for the D2-Iike 
dopamine receptors (Sailer et al.. 1987), over the D4 dopamine receptor (Van 
Toi et al.. 1991) with a moderate potency at dopamine D 1-like receptors 
(Christensen et al.. 1984), which was an important reason for selecting this 
drug for the following studies.
The results obtained in tins study show that acute injection of the 
typical neuroleptic drug fluphenazine has no effect on the levels of 
proenkephalin mRNA in the rat striatum up to three hours after the initial 
injection, when compared to control animals. As in other studies, changes in 
the mRNA level have been correlated to changes in protein levels (Shiomi et 
al., 1986; O’Connell et al., 1987; Adler et al.. 1988). It may be assumed that 
fluphenazine does not #fect enkephalin protein levels in either the rostral or 
caudal region of the rat striatum up to three hours after administration. The 
dosage used would be expected to bind to greater than 50% of D2 dopamine 
receptors in vivo according to the reported affinity of fluphenazine for D2 
dopamine receptors (Van Toi et al.. 1991). As the number o f animals per group 
were particularly small, this may have introduced a greater error, and thus 
masked any small changes in proenkephalin gene expression that may have 
occurred, at any one time point. In a previous report it has been suggested that 
a single acute injection of haloperidol can induce proenkephalin mRNA in some 
animals by fifteen minutes, and in all animals tested by forty-five minutes 
(Konradi et al.. 1993). Similarly the mRNA levels of other peptidergic 
transmitters, for example, neurotensin, can be affected by acute treatment with 
dopaminergic D2 receptor antagonists (Augood et al.. 1991). The lack of an 
induction of proenkephalin mRNA after acute treatment with fluphenazine may 
reflect a slower drug action of this typical neuroleptic. A longer time period
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may be necessary for fluphenazine to penetrate the blood-brain barrier and thus 
have an effect on the levels of proenkphalin mRNA.
3.12 The effect of Antipsvchotic drug treatment on Proenkephalin mRNA 
levels twentv-four hours after administration
In this study the effect of the typical neuroleptics haloperidol and 
fluphenazine, which have relatively high affinities for D2-like dopamine 
receptors and moderate potency at Dl-like dopamine receptors (Christensen et 
al., 1984), were compared with the atypical neuroleptic clozapine, which has 
been demonstrated to show some selectivity for D4 dopamine receptors (Van 
Toi et a l. 1991) and with the 5-HT 1/2 receptor antagonist drug methiothepin, 
also known to bind to dopamine receptors, on the expression of proenkephalin 
rhRNA in the rat striatum twenty-four hours after drug administration.
From the results obtained it was observed that the typical neuroleptics 
haloperidol and fluphenazine increased the expression of proenkephalin mRNA 
in the rat striatum after twenty four hours. These antipsychotic drugs are 
known to induce enkephalin mRNA and enkephalin protein after chronic 
administration (Hong et al.. 1978; S aboi et al.. 1983; Tang et al.. 1983; Angulo 
et al.. 1986; Sivam et al.. 1986; Romano et al.. 1987; Morris et al.. 1988). At 
present it is generally accepted that the clinical therapeutic effects of these 
antipsychotic drugs are mediated through blockade of dopamine D2-like 
receptors (Creese et al. 1976; Seeman et al.. 1976; Baldessarini, 1985). The 
primary evidence for this hypothesis is two-fold. Firstly, most of the available 
antipsychotic drugs are dopamine D2-like receptor antagonists (Carlsson, 
1978; Peroutka and Snyder, 1980; Baldessarini, 1985). Evidence for this comes 
Rom an increased dopamine turnover and antagonism of dopamine D2 -like
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agonist effects, during acute administration, and an increase in D2-like 
dopamine receptor density following chronic administration (Carlsson, 1978;
Secondly it has been shown that there is a strong correlation between the
Muller and Seeman, 1978; Baldessarini, 1985; Wilmot and Szczepanik, 1989).
I
relative potencies of antipsychotic agents in competing for dopamine D2 sites 
in vitro and the doses of antipsychotic drugs used in the clinical treatment of 
psychoses (Peroutka and Snyder, 1980; Seeman, 1980; Cohen and Lipinski,
1981). However, it should be noted that the drugs and doses used would 
distinguish poorly between D2, D3 and D4 dopamine receptor subtypes.
Furthermore, the antipsychotic activity of neuroleptic drugs may, in fact, be 
related to the interaction of neuroleptics with other transmitter systems in the 
brain. At clinically effective doses, neuroleptics interact with a high degree of 
affinity with the a-adrenergic, histamine, muscarinic acetylcholine and 
serotonin receptors (Peroutka and Snyder, 1980).
A similar induction of pro enkephalin mRNA was observed twenty-four 
hours after treatment with the non-selective 5-HT1/2 receptor antagonist 
methiothepin. Recently, it has been suggested that potent serotonin 5-HT2 
receptor antagonism could alleviate negative symptoms in, schizophrenia.
Moreover, 5-HT2 antagonists have been shown to reduce neuroleptic-induced
catalepsy in rats (Balsara et al.. 1979; Hicks, 1990), to increase neuroleptic- |
induced dopamine turnover (Sailer et al.. 1990), to cause a slight, indirect
activation of midbrain dopaminergic neurons (Ugedo et al.. 1989), restoring
phasic rather than tonic activity, and to reduce neuroleptic-induced
extrapyramidal side effects (Reyntjens et a l. 1986; Bersani et a l. 1990). As
methiothepin has previously been shown to possess the ability to block
dopaminergic receptors in binding studies (Lloyd and Bartholini, 1974; j
Erijalbert et al.. 1978; Nelson et al.. 1979; Christensen, 1985), it is likely that
the methiothepin-induced increase in proenkephalin mRNA levels in the rat
striatum may be due its actions at dopamine D2-like receptors in vivo. :
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Although the possibility still remains that a S-EHT receptor blockade
may also be contributing to this effect. Both haloperidol and fluphenazine are i
known to possess 5-HT2 receptor binding properties, but with much lower
affinity than methiothepin (Meltzer et al.. 1989). i
The atypical neuroleptic drug clozapine, which is known to be 
associated with a low incidence of extrapyramidal side effects, a property that i
as yet has not been attributed to any one physiological effect of the drug, was 
shown to have no effect on proenkephalin mRNA levels twenty-four hours 
after administration. Previous studies have revealed that chronic treatment with 
clozapine does not increase the density of dopamine D1 or dopamine D2 
receptors (Seeger et al.. 1982; Severson et al.. 1984; Lee and Tang, 1984;
Rupniak et al.. 1984; Cohen and Lipinski, 1986). It has been suggested that the 
atypical antipsychotic agents exert preferential effects on the mesolimbic (AlO) 
dopamine system in vivo (Borison et al.. 1983; Borison and Diamond, 1983).
These results are the first observations indicating that striatal 
proenkephalin mRNA is induced after acute treatment, not only with certain 
typical neuroleptics, but also with the 5-HT 1/2 receptor antagonist compound, 
methiothepin, and not with the atypical neuroleptic drug clozapine. It may be 
suggested that the extrapyramidal side-effects associated with typical 
neuroleptic drug treatment could be partially attributed to the rapid induction 
of the enkephalin gene in the striatum shortly after drug administration and the 
subsequent sustained elevation with chronic use. This would be consistent with 
evidence that, in rodents with dopamine lesions, the degree of extrapyramidal 
motor deficit is related to the magnitude of the change in proenkephalin gene 
expression (Cadet et al.. 1992). The induction o f proenkephalin mRNA 
following acute typical neuroleptic drug treatment is most likely due to 
blockade of D2 or D3 dopamine receptor subtypes in vivo, rather than the D4 
dopamine subtype, as clozapine, having some selectivity for the D4 receptor 
over the D2 or D3 receptor subtypes (Van Toi et al.. 1991), was ineffective.
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Although in contrast to this, a previous study has demonstrated z . decrease in 
proenkephalin gene expression after chronic treatment with high doses of 
clozapine (Mercugliano and Cheeselet, 199t ). It must also be considered that 
5-HT receptor blockade may contribute to this effect, since the non-selective 5- 
HT receptor antagonist metliiothepin, together with both the typical 
neuroleptics fluphenazine and haloperidol, share the ability to block 5-HT2 
receptors.
Short-term Regulation of Preprotachvkinin mRNA Expression in vivo
3.13 The effect of Antipsvchotic drug treatments on the levels of 
Preprotachvkinin mRNA in the rat striatum twenty-four hours after 
administration
In this study the typical neuroleptic haloperidol clearly reduced the 
level'o^preprotachykinin mRNA in the rat rostral striatum after twenty-four 
hours, whilst both haloperidol and fluphenazine were shown to decrease 
preprotachykinin mRNA levels in the rat caudal striatum after acute treatment.
These results are in agreement with previous studies demonstrating that 
the level of protachykinin mRNA, the anceciiAj for substance P, is
reduced in the rat striatum after chronic treatment with the antipsychotic drug 
haloperidol (Hong et al.. 1983; Bannon et al.. 1986). This is the first 
observation for an acute effect of these neuroleptics on preprotachykinin 
mRNA levels in vivo. There was no significant change in preprotachykinin 
mRNA levels in the striatum, twenty-four hours after administration of the 
atypical neuroleptic, clozapine. This is in agreement with previous reports
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findicating that the atypical neuroleptic clozapine does not alter 
preprotachykinin mRNA in the rat striatum following chronic treatment (
Bannon et al.. 1987; Shibata et al.. 1990). The dose of clozapine used here 
would be expected to be blocking 80% of a-1 receptors, approximately 65% 5-
■■ ■
HT2 receptors, with relatively little blockade of D2 dopamine receptors
(Schotte et al.. 1993). Since clozapine has a decreased propensity for inducing
extrapyramidal side-effects, it is conceivable that decreased tachykinin gene
expression in the basal ganglia is somehow related to the production of these
adverse effects. It is known that chronic administration of most antipsychotic
drugs causes a depolarisation inactivation of dopamine neurons innervating the
rat striatum. This results in a decreased number of spontaneously active
dopamine cells and a diminished release of striatal dopamine (Chiodo, 1988). It
is the decrease in dopamine neurotransmission that apparently causes decreased
tachykinin biosynthesis similar to that seen after experimental dopamine cell 
.lesioning or in post-mortem material fi-om Parkinson’s disease patients (
Mauborgne et al., 1983; Tenovno et al.. 1984; Young et al.. 1986; elevens and 
Beal, 1989). In contrast, atypical antipsychotic drugs elicit neither 
depolarisation inactivation of dopamine cells innervating the striatum nor 
decreased tachykinin biosynthesis. However, both typical and atypical 
antipsychotic drugs induce depolarisation inactivation of those dopamine 
neurons innervating primarily limbic targets (Chiodo, 1988), leading to 
speculation that decreased limbic dopamine influence is the common 
mechal^ism of antipsychotic drug action. Although various typical and atypical 
antipsychotic agents may differ somewhat in their affinities for various 
dopamine receptor subtypes, some other property or properties o f atypical 
drugs ( such as antiadrenergic or antiserotoninergic effects) may be responsible 
not only for the differing propensities for induction of adverse side effects, but 
also for additional therapeutic effects (Chiodo, 1988; Meltzer, 1988). The dose 
of clozapine used in this study was chosen with the knowledge that clozapine
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has a particularly high affinity for the D4 dopamine receptor compared to most 
typical neuroleptics (Van Toi et a l. 1991). Doses of clozapine o f lOmg/kg and 
above have been shown to bind to striatal D2 binding sites in rats (Sailer et al.. 
1987; Audinot et al.. 1993). It is therefore likely that the lower dose of 3mg/kg 
used here is preferentially blocking D4 sites in vivo rather than D2 sites. 
Therefore, it appears unlikely that the D4 receptor is involved in mediating the 
decrease in preprotachykinin mRNA in the rat striatum, following acute 
treatment with either haloperidol or fluphenazine.
Similarly, the antipsychotic methiothepin did not alter the levels o f
preprotachykinin mRNA in this study. As it is most likely that the typical
neuroleptic agents studied caused a reduction in preprotachykinin gene
expression through a mechanism involving blockade of dopamine receptors, a
possible explanation for the lack of effect with methiothepin may be that the
affinity o f methiothepin for the dopamine D1 and D2 receptors is not
sufficiently strong to decrease preprotachykinin gene expression in the striatum
of the rat after acute administration. Another possible explagiation could be
that combined 5-HT antagonism together with dopamine receptor blockade is
preventing the reduction of preprotachykinin mRNA. , Haloperidol
and fluphenazine also possess 5-HT receptor antagonistic properties, but
perhaps the blockade of dopamine neurotransmission by t h ^  typicalop
neuroleptics overrides thetfserotonin receptor blockade.
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Short-term Regulation of Preprosomatostatin gene expression in vivo
3.14 The effect of Antipsvchotic daig treatments on the level of  
Preprosomatostatin mRNA twentv-four hours after administration
In this study the typical neuroleptic drugs haloperidol and fluphenazine 
did not significantly alter the levels of preprosomatostatin mRNA in the caudal 
striatum or in the nucleus accumbens of the rat, twenty-four hours after 
administration. However, it has previously been reported that haloperidol can 
decrease somatostatin gene expression in the striatum, nucleus accumbens and 
in the frontal cortex of the rat after chronic treatment (Beal and Martin, 1984; 
Radke et al.. 1988; Salin et al.. 1989). It has also been suggested that dopamine 
may be involved in the regulation of somatostatin mRNA levels after chronic 
treatment (Salin et al.. 1989). The lack of effect with haloperidol or
fluphenazine after twenty-four hours may reflect the time course necessary to
gftect the levels of this brain neuropeptide. It seems most likely that the 
.decrease in somatostatin gene expression in the rat striatal and accumbens
regions, observed after chronic treatment with the typical neuroleptic agent 
.haloperidol arises after a prolonged time period, and thus may be associated 
with the appearance of extrapyramidal side effects, which also appear after 
prolonged drug use ( Creese et al.. 1976; Seeman et al.. 1976; Baldessarini,
1985).
In contrast to tins, a low dose o f the atypical neuroleptic clozapine 
caused a significant increase in the levels of preprosomatostatin mRNA in both 
the caudal region o f the striatum and in the nucleus accumbens of the rat after 
twenty-four hours. In chronic studies, it has previously been suggested that 
high doses of clozapine can cause an induction of preprosomatostain mRNA in 
the rat nucleus accumbens (Salin et al.. 1989). These results provide the first 
evidence for a differential regulation o f preprosomatostatin gene expression
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after acute treatment with typical versus atypical antipschotic drugs. It appears
that the time course for the atypical agent, clozapine, to induce somatostatin
gene expression is relatively more rapid than the time course for haloperidol,
the typical neuroleptic, to cause a reduction in somatostatin mRNA levels. The
underlying mechanisms involved in the clozapine-induced expression of
somatostatin may be due to blockade of dopamine receptors. The low dose of
clozapine used in this study may reflect the possibilty that the D4 dopamine
receptor is involved in this effect, as clozapine has a ten-fold higher affinity for
the D4 receptor than for the D2 or D3 dopamine receptors, previously
demonstrated in in vitro binding studies (Van Toi et al.. 1991). High doses of
clozapine (greater than lOmg/kg) have been shown to bind to striatal D2 sites
in rats (Sailer et al.. 1987; Audinot et al.. 1993). The low dose o f 3mg/kg used
here, is preferentially blocking D4 sites in vivo rather than D2 sites. The
atypical neuroleptic clozapine is also known to have relatively high affinity for
some serotonin receptor subtypes, in particular the serotonin 5-HT2A and 5-
HT2C receptors (Zifa and Pillion, 1992; Canton et al.. 1993). The distribution
of the receptor mRNA’s encoding both the 5-HT2A and the 5-HT2C serotonin
receptors in the rat, has previously been demonstrated. Intermediate levels of»
both subtypes have been shown in the caudate-putamen, nucleus accumbens 
and substantia nigra pars compacta. However, in the caudate-putamen their 
distributions Qfê. quite different. The 5-HT2A receptor is most abundant in the 
medial striatum, and the 5-HT2A receptor mRNA has been shown to increase
<if
in the mediolateral direction.  ^ 5-HT2C receptor mRNA, present 
in the medial striatum has been shown to decrease in a mediolateral direction, 
and in addition, it was expressed in patches of higher density rather than an 
even distribution (Pompeiano et al.. 1993). Thus the possibility that clozapine is 
acting via a serotoninergic mechanism to increase somatostatin gene expression 
in both the striatum and nucleus accumbens, after acute treatment, is not 
unlikely. However, both haloperidol and fluphenazine have been shown to have
92
some affinity for 5-HT2A/2C receptors, but with much less potency than 
clozapine (Canton et al.. 1993). Also, it has recently been reported that
intracerebroventricular injection of 5,7-dihydroxytryptamine, a selective 
.serotonin neurotoxin, can increase preprosomatostatin mRNA levels in the rat
striatum. From this, it has been suggested that serotonin has an inhibitory effect
on the biosynthesis of somatostatin in the striatum (Bendotti et al.. 1993).
.Antipsychotic drugs which have strong affinities for 5-HT2 binding sites
are known to be associated with a low incidence of extrapyramidal side effects
(EPS) (Meltzer, 1988). The role of the 5-HT2A and 5-HT2C receptor sites are
at present unclear. However, the antagonism of these sites could contribute to 
.clozapine’s low EPS profile. Clozapine has also been reported to antagonise 
.the inhibitory effect o f 5-HT3 receptor agonists on the firing of cortical 
receptors in the rat (Ashby et al.. 1989). Blandina et al (1988) have shown that 
5-HT3 receptor stimulation may facilitate striatal dopamine release. However, 
the extent to which the clozapine-induced release of striatal dopamine involves 
5-HT3 receptor mechanisms is at present uncertain.
A similar induction o f preprosomatostatin mRNA was seen in both the 
rat striatum and nucleus accumbens regions after treatment  ^ with the non- 
selective 5-HT1/2 receptor antagonist, methiothepin. This result ftirther 
substantiates the possibility of a role for a 5-HT receptor subtype in tliis 
response. Methiothepin has previously been demonstrated to have a very high 
affinity for the 5-HT2A/2C receptors, as shown in binding studies (Leysen et 
al., 1982; Conn and Sanders-Bush, 1986). Since the atypical antipsychotic drug 
clozapine also has a high affinity for both the 5-HT2A and 5-HT2C, it could be 
hypothesised that the blockade of either or both of these serotonin receptor 
subtypes is a contributing factor to the increase in preprosomatostatin mRNA 
observed after acute administration of clozapine and methiothepin.
A short time course of the effect of low doses of clozapine on 
preprosomatostatin mRNA, in the rat striatum was thaiperfbrmed in order to
93
I
further address this drug-specific acute effect. However, we observed no 
significant changes in the levels o f preprosomatostatin mRNA up to three hours 
after the drug was administered.
3.15 Effect of Chronic Antipsvchotic treatment on Preprosomatostatin mRNA 
levels
In this study we have also demonstrated that low doses of clozapine can 
induce preprosomatostatin mRNA in the rostral and caudal regions of the rat
striatum and in the olfactory tubercles, after chronic administration. Previous»
evidence demonstrating an induction of somatostatin gene expression in the 
accumbens, involved the administration of much higher doses of clozapine than 
the dose used here. The low dose of 3 mg/kg clozapine may be reflecting a 
preferential D4 dopamine receptor blockade rather than D2 receptor blockade 
in order to increase the levels of preprosomatostatin mRNA. However, in 
previous studies the typical antipsychotic drug haloperidol has been shown to 
have an opposite effect on somatostatin mRNA levels. Chronic treatment with 
haloperidol was shown to decrease somatostatin mRNA levels in the striatum, 
nucleus accumbens and frontal cortex in the rat (Salin et al.. 1989). This effect 
is thought to be the result o f blockade of a stimulatory action o f dopamine on 
somatostatinergic neurons mediated through dopamine D2-Iike receptors 
(Sailer and Salama, 1986). Therefore, it seems unlikely that the effect of low 
doses of clozapine to increase somatostatin mRNA is mediated by blockade of 
dopaminergic transmission at D2 or D3 receptors. There is also evidence for an 
opposing action of typical versus atypical neuroleptics on muscarinic receptors 
in the striatum. The typical neuroleptic fluphenazine, has been shown to 
decrease muscarinic receptor density in the striatum, whereas in contrast, the 
atypical neuroleptic clozapine was shown to elevate muscarinic binding
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densities in the striatum, cortex and in the hippocampus in the rat (Friedman et
ai., 1983). The effect of clozapine to induce somatostatin gene expression is
likely to involve blockade of the D4 dopamine receptor or blockade o f another
neurotransmitter system in the brain. A possible candidate would be the
serotoninergic system. As previously mentioned, clozapine is a very potent 
.antagonist at certain serotonin receptor subtypes, in particular the 5-HT2A/2C 
subtypes. The effect of clozapine to induce somatostatin gene expression in the
■olfactory tubercles may also be mediated by a serotonin receptor blockade. It 
has been shown that the olfactory tubercles have intermediate levels of mRNA 
for both the 5-HT2A and 5-HT2C receptor subtypes in the rat (Pompeiano et 
al., 1993). Recently clozapine has also been demonstrated to have a relatively 
high affinity for the 5-HT6  and 5-HT7 serotonin receptor subtypes and it has 
been shown that the 5-HT6 receptor is expressed at high levels in the rat 
striatum (Monsma et a l. 1993). Since a number of atypical neuroleptics have 
been shown to possess a high affinity for the 5-HT6  receptor, it has been
suggested that this receptor subtype may be involved in mediating the
antipsychotic actions of certain neuroleptic drugs (Monsma et al.. 1993). In a
recent report, fluphenazine has been demonstrated to have a high affinity for
the cloned 5-HT6 subtype, with a Ki value of less than 20nM, although
haloperidol had essentially no affinity for the 5-HT6 receptor (Roth et al.. 
. .1993). In addition to its known affinity for certain 5-HT receptor subtypes, 
.clozapine is well known to have an antagonising action on many different 
.receptors, including a-adrenergic receptors and muscarinic receptors, which 
must still be considered in this effect of the drug.
It has been hypothesised that a disruption of somatostatin gene 
regulation may have a role in a number of identified psychoses in man, such as 
schizophrenia, parkinsonism, Huntington’s disease and alcohol dementia. It has 
been demonstrated that individuals with Parkinson’s disease have lower levels 
of somatostatin-like immunoreactivity in lumbar spinal fluid than their control
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counterparts (Cramer et a l. 1989). Similarly a recent study has shown the 
reduction of somatostatin peptide in the neocortex of Parkinson’s disease 
sufferers (Leake and Ferrier, 1993). A fiinctional interaction between central 
nervous system somatostatin and dopamine systems ha^ been implicated, as 
fluphenazine treatment has been shown to reduce cerebrospinal fluid 
somatostatin levels in patients with schizophrenia (Doran et al.. 1989). Another 
study has demonstrated a decrease in somatostatin-like immunoreactivity in the 
cerebrospinal fluid of chronic schizophrenic patients with a cognitive 
impairment (Reinikainen et al.. 1990). The development of schizophrenia has 
previously been suggested to involve autoimmune processes, such that blood 
serum samples taken from schizophrenic patients manifest a higher level of 
immune responsiveness to somatostatin, as compared to the control group 
(Rogaeva et al.. 1990). A further level o f complexity in the development of 
schizophrenia has been implicated in this study, since the increased immune 
responsiveness in blood serum to somatostatin was evident in patients suffering 
from malignant and paranoid schizophrenia, but was not evident in patients 
suffering from a slow-progressive form of schizophrenia (Rogaeva et al.. 
1990). This would suggest that different forms of the disease can differentially 
affect somatostatin levels. From this, it would appear that a number of 
physiological changes are necessary for the manifestation of schizophrenia, 
although the ‘chemical balance’ may be affected differently in different forms of 
the disease. In Huntington’s chorea, a marked down-regulation of somatostatin 
receptors in the human striatum has been shown (Palacios et al.. 1990). It has 
been postulated that the down-regulated somatostatin receptors may be 
localised on a population of neurons which are at risk in Huntington’s chorea 
(Palacios et al.. 1990). A reduction in cerebrospinal fluid somatostatin levels 
has also been demonstrated in alcoholic amnestic disorder or Korsakoff’s 
psychosis (Martin et al.. 1989) and in senile dementia of the Alzheimer’s type 
(Leake and Ferrier, 1993). Therefore it would seem that a decrease in
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somatostatin levels is one of the major physiological changes that takes place in 
a number of cognitive disorders.
Short-term Regulation of Neuropeptide Y gene expression in vivo
3.16 The Effect of Antipsvchotic drug treatment on the levels of 
Proneuropeptide Y gene expression twentv-four hours after administration
NeuropeptideY, a peptide which shows many o f the properties 
characterisitic of a neurotransmitter or neuromodulator is known to be highly 
abundant in mammalian brain. It has previously been detected in the same 
neurons as catecholamines and enkephalins (Hunt et a l. 1981; Hokfelt et al.. 
1983; Everitt et al.. 1984), and many neurons in the forebrain have been shown 
to contain both neuropeptide Y and somatostatin (Vincent and Johansson, 
1983; Chan-Pallay, 1987), In the striatum a small population of neurons are 
known to express both neuropeptide Y and somatostatin (praybiel, 1990; 
Vuillet et al.. 1990). Therefore we were interested in the effect of acute 
treatment with the atypical neuroleptic clozapine and the serotonin receptor 
antagonist, methiothepin, on the levels o f proneuropeptide Y mRNA in the 
striatum, as these drugs have previously been demonstrated to increase 
somatostatin mRNA levels in the striatum.
However, the results obtained indicate a lack of effect o f both clozapine 
and methiothepin on proneuropeptide Y mRNA levels in either the rostral or 
caudal regions in the rat striatum. Due to the small number of animals per 
treatment group, any small changes in the level of neuropeptide mRNA may 
remain undetected despite a possible drug effect.
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3.17 The effect of chronic neuroleptic drug treatment on dopamine D1 receptor 
expression
In previous studies selective D1 dopamine receptor blockade has been
demonstrated to increase cellular levels of neuropeptide Y mRNA in the rat
striatum (Morris, 1992). This is in contrast to the decrease in somatostatin
mRNA levels that have been reported in the same population of neurons
following chronic D2 receptor blockade (Weiss and Cheeselet, 1989; Salin et
al., 1989). It has therefore been suggested that dopamine is tonically and
simultaneously exerting an opposite control on neuropeptide Y and
somatostatin gene expression in the striatum (Morris, 1992). In view o f this, it
may not be surprising that both clozapine and methiothepin had no effect on
neuropeptide Y gene expression. If neuropeptide Y and somatostatin are
differentially regulated within the same cell, it would perhaps have been more
likely to see a decrease in proneuropeptide Y mRNA levels, although our
results did not show this to occur. Similarly the neuropeptides dynorphin and 
. .preprotachykinin which are expressed in striatonigral neurons have previously 
been shown to be differentially regulated by dopamine in the same cell 
population (Gerfen et al.. 1991 ).
It has long been known that chronic treatment with antipsychotic drugs
can up-regulate dopamine receptor subtypes. The class of drugs known as 
‘typical neuroleptics’ such as haloperidol, have previously been demonstrated 
to increase the mRNA encoding the DIA, the D2 and the D3 dopamine 
receptor subtypes (Buckland et al.. 1992). The levels of mRNA encoding the 
D1B/D5 receptor in the rat have been reported to remain unchanged after 
chronic haloperidol treatment (Buckland et al.. 1992). The results obtained 
from this study demonstrate that the typical neuroleptic fluphenazine, when
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given chronically, can significantly increase DIA receptor mRNA levels in the
rostral region , in the rat striatum. This is in accordance with previous reports
suggesting that blockade of dopamine D 1 receptors can increase D 1 receptor
mRNA (Creese et al.. 1992). The effect o f fluphenazine did not prove to be 
. . .significant in the caudal region of the striatum, despite a tendency towards an 
increase in D IA  mRNA expression.
With the ‘atypical’ neuroleptic drug clozapine an elevation of DIA  
receptor mRNA levels was also observed in the rostral striatum, although the 
increase was less than that seen with fluphenazine. The dose of clozapine used 
in this study would not be expected to be occupying more than 30-35% of D1 
receptors in vivo, according to the demonstrated affinities o f clozapine at D1 
compared to D4 dopamine receptors (Van Toi et al.. 1991). This therefore 
makes the observed induction D 1 receptor mRNA in the striatum after chronic 
clozapine treatment relatively difficult to interpret. However, it is not 
impossible that only a small percentage of D1 receptors need to be occupied in 
order to increase D1 mRNA. In previous reports chronic treatment with high 
doses of clozapine has been shown to both increase (O’ Dell et al.. 1990) and 
have no effect on the density of dopamine DIA receptors (Seeger et al.. 1982; 
Severson et al.. 1984; Lee and Tang, 1984; Rupniak et al.. 1984; Cohen and 
Lipinski, 1986; Buckland et al.. 1993). Other workers have studied the effect of 
clozapine on D2 receptor mRNA and receptor numbers. Wilmot and 
Szczepanik, (1989) found no increase in D2 receptor numbers in any rat brain 
regions. Similarly Van Toi et al (1991) found no increase in D2 receptor 
mRNA levels in rat striatum following chronic treatment with clozapine. 
Although, chronic clozapine treatment has recently been associated with an 
increase in D3 receptor mRNA levels. Buckland et al.. (1993) have 
demonstrated that high doses of 30mg/kg clozapine can increase D3 receptor 
mRNA levels by five-fold after four days of treatment. In addition, they also 
found that the levels of D3 receptor mRNA dropped back to basal levels after
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thirty-two days of treatment. In the previous studies that suggest clozapine has 
no effect on the levels of DIA receptor mRNA, it is likely that monitoring of 
mRNA levels occurred after twenty days or more. It is possible that the 
increase in DIA receptor mRNA levels that we observed after five days of 
treatment has declined back to basal levels after three weeks o f treatment, 
similar to that observed for the D3 receptor. Therefore it would be necessary to 
monitor the level of DIA receptor mRNA more closely, over a prolonged time 
period, in order to clarify this result.
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3.18 The effect of chronic neuroleptic drug treatment on the expression of the 
5-HT6 receptor mRNA
Clozapine has previously been reported to have a high affinity for the 
serotoninergic 5-HT6 receptor in binding studies (Monsma et al.. 1993), 
Therefore we were interested to see the effects of clozapine and the typical 
neuroleptic fluphenazine on the levels of 5-HT6 receptor mRNA in the rat 
striatum, following chronic drug treatment.
However, in this study both clozapine and fluphenazine had little effect 
on the levels of 5-HT6  mRNA in vivo after five days o f chronic treatment. This 
would suggest that the 5-HT6  receptor is not up-regulated by chronic blockade 
with both typical and atypical neuroleptic drugs. Also it may indicate that the 
serotoninergic control of this receptor subtype is low, in that there may be a 
low tonic activation of 5-HT6  receptors in the striatum.
Chapter 4
Regulation of Immediate Early Genes
in vivo
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INTRODUCTION
4.0 Neuroleptic Modulation of Immediate Early Genes In Vivo
At present, immediate early genes are thought to function by altering
the rate of transcription of a target gene, by binding to a specific site on the late
response gene. There has been a large amount of evidence gained to suggest
that modulation of the level of dopaminergic activity can induce the immediate
early genes c-fos and zif/268. Systemic treatment with dopaminergic agonists,
in particular SKF38393, increases the levels of c-fos and zifi268 after a 6-
hydroxydopamine-induced lesion (Robertson et al.. 1990; Cole et al.. 1992),
whereas evidence also exists showing that they are induced in the rat striatum 
. . .after administration of haloperidol, a dopaminergic D2 receptor antagonist 
(Dragunow et al.. 1990; Nguyen et al.. 1992). This induction of both c-fos and
i
zifi268 by typical neuroleptics is likely to b^ e mediated by the blockade of either
D2 or D4 dopamine receptors, because drU s^ active on these receptors share 
. . .the ability to increase the expression of these immediate early genes (Dragunow 
et al.. 1990; Cole et al., 1992; Nguyen et al.. 1992; Robertson and Fibiger, 
1992). By using the neuroleptic drug clozapine, wliich has a ten fold higher 
affinity for the dopamine D4 receptor than for the D2 receptor, given at low
doses , we have attempted to investigate further the nature of the receptor 
involved in these responses.
Currently there is very little evidence to demonstrate the hypothesis that 
immediate early genes may provide the link to changes in late response genes. 
However, it has been suggested that there is a link between the haloperidol 
induction o f c-fos and the subsequent increase in the levels of preproenkephalin 
mRNA (Sonnenberg et al.. 1989; Donovan et al.. 1992). More recently this 
circumstantial evidence has been questioned by results obtained by Konradi and
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1992), we have been interested in the effects of typical and atypical neuroleptic 
drug administration on the expression of these two genes in the rat striatum.
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colleagues (1993). At present there is no indication as to the mechanisms
leading to a decrease in preprotachykinin gene expression.
It is known that c-fos forms dimers with members o f the jun family of
immediate early genes to affect target gene transcription. The mRNA encoding
two members of this family, c-jun and jun-D, is present constitutively in striatal
neurons, and the corresponding proteins are likely to be available to form
complexes with c-fos once it is synthesised. The mRNA encoding another
immediate early gene belonging to this family, jun-B, is not normally detectable
in striatal neurons. However, jun-B is potentially of interest, because in primary
rat embryo ceils it has been linked to the suppression, rather than the
.enhancement of downstream gene transcription (Chiu et al.. 1989; Schutte et
:.y
al., 1989). We were therefore interested to determine whether jun-B and jun-D 
.is induced in the striatum and nucleus accumbens, by neuroleptic
administration. ^probams encoded ^
The newly cloned POU-domain -containing gene, RHS2 and the A.
HNF/3 fork head gene BF-1, have recently been shown to possess a
transcription regulatory region. However, as yet there has been very littleproduct^
research done on these genes. As both gene have been shown to be present in
A
the region of the striatunu (Le Moine and Scott-Young, 1992; Tao and Lai,
 : g'i:
RESULTS
4.1 Time course of Fluphenazine effect on c-fos mRNA levels in the region of 
rostral and caudal striatum
It is known that the immediate early gene c-fos can be induced by 
administration of the relatively non-selective, typical neuroleptic drug 
haloperidol (Nguyen et al ,1992). Therefore in this study we have investigated 
the effects over time of the typical neuroleptic drug fluphenazine (6 mg/kg), 
having high affinity for, and being a potent antagonist of the D2 dopamine 
receptor.
Following intraperitoneal administration of fluphenazine (6 mg/kg) to 
male wistar rats (n= 3), it was observed that the levels of c-fos mRNA were 
increased significantly in the rostral striatum 15 minutes [ F (4,20) =7.60, p= 
0.008, p< 0.01] and 45 minutes, p< 0.01, after drug treatment compared to the
animals treated at corresponding time points with physiological saline (n=2 ) 
[Figure 4.1.1]. After 45 minutes the levels of c-fos mRNA declined back to 
basal levels. ,
In the caudal striatum , a maximal and significant induction of c-fos 
mRNA levels after fluphenazine treatment occurred 45 minutes afl;er drug 
administration. [Figure 4.1.2] The levels of c-fos mRNA were significantly 
different such that F (4,20) =8.67, p= 0.0067, p< 0.01, from saline treated 
animals. A similar decline back to basal levels was observed after 45 minutes. 
The pattern of induction of c-fos mRNA was primarily observed in the 
dorsolateral striatum.
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Figure 4.1.1 : Effect of fluphenazine (6 mg/kg) on c-fos mRNA levels in the rat 
rostral striatum. Fluphenazine (6 mg/kg; n= 3) or vehicle (0.9% saline; n= 2) 
was injected i.p. and the animals killed after the specified time intervals. 
Results, obtained from film autoradiographs are expressed as mean relative 
optical density ± s.e.m. The open triangle = saline treated groups, closed 
triangle = fluphenazine (6 mg/kg) treated groups for the respective time periods. 
Significance was determined by one-way ANOVA, followed by the student's t- 
test. *p< 0.05.
Figure 4.1.2 : Effect o f fluphenazine (6 mg/kg) on c-fos mRNA levels in the rat 
caudal striatum. Fluphenazine (6 mg/kg; n= 3) or vehicle (0.9% saline; n= 2) 
were injected i.p. and the animals killed after the specified time intervals. 
Results, obtained from film autoradiographs, are expressed as mean relative 
optical density ± s.e.m. The open triangles = saline treated groups, closed 
triangles = fluphenazine (6 mg/kg) treated groups for the respective time 
periods. Significance was determined by one-way ANOVA, followed by the 
student's t-test. *p< 0.05
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Figure 4.2.1 : Effect of fluphenazine (6 mg/kg) on zif'268 mRNA in the rat 
rostral striatum. Fluphenazine (6 mg/kg; n= 3) or vehicle (0.9% saline; n= 2) 
were injected i.p. and the animals killed after the specified time intervals. 
Results, obtained fi*om film autoradiographs, are expressed as mean relative 
optical density ± s.e.m. The open triangles = saline treated groups, closed 
triangles = fluphenazine (6 mg/kg) treated groups for the respective time 
periods. Significance was determined by one-way ANOVA, followed by the 
student's t-test. * p < 0.05
Figure 4.2.2 : Effect of fluphenazine (6 mg/kg) on zifi268 mRNA levels in the 
rat caudal striatum. Fluphenazine (6 mg/kg; n= 3) or vehicle (0.9% saline; n= 2) 
were injected i.p. and the animals killed afi;er the specified time intervals. 
Results, obtained from film autoradiographs, are expressed as mean relative 
optical density ± s.e.m. The open triangles = saline treated groups, closed 
triangles = fluphenazine (6 mg/kg) treated groups for the respective time 
periods. Significance was determined by one-way ANOVA, followed by the 
student's t-test. * p< 0.05.
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4.2 Time course o f Fluphenazine effect on zi^268 mRNA levels in the regions 
of the rostral and caudal striatum
Zif'268, a zinc-finger containing protein, is also known to be induced by 
treatment with the typical neuroleptic haloperidol in the striatum (Nguyen et al. 
1992). Therefore the time course effect on zi£^268 mRNA induction by 
fluphenazine (6 mg/kg, n= 3) was investigated.
The levels of zif^268 mRNA were significantly induced compared to 
saline treated animals, [ F (4,20) =4.89, p= 0.04, p< 0.05] after 45 minutes in 
the rostral striatum. [Figure 4.2.1]. However , in the caudal striatum it was 
observed that zifi268 mRNA levels were induced 30 minutes after fluphenazine 
(6 mg/kg, n= 3) administration. This increase was significantly different fi-om 
saline treated animals (n= 2) at the corresponding time point, such that F (4,20) 
=3.50, p= 0.047, p< 0,05, DF= 1 [Figure 4.2.2], Induction of zif/268 was 
significantly different from saline treated animals 45 minutes after drug 
administration, p< 0.05, following which, a gradual decline back to basal levels 
was observed. [Figure 4,2.2], Again, the pattern of induction was primarily 
observed in the dorsolateral regions of the rat striatum. ^
,it'
:
I
4.3 Effect of acute neuroleptic drug administration on c-fos mRNA and zif/268 
mRNA expression in the rat striatum and nucleus accumbens
Drug Treatment Striatum Nucleus accumbens
Saline
Haloperidol
Fluphenazine
Clozapine
26.80±5,70 
144.00±19.00 * 
60.60±21.10 * 
23.70±6.30
25.50±5.50 
101.70±24.50  ^
18.50±2.10 
20.703=3.70
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Table 1: The expression of c-fos mRNA levels in the rat striatum and nucleus 
accumbens following treatment with vehicle (physiological saline), or the 
typical neuroleptics haloperidol (Img/kg), and fluphenazine (3mg/kg) or the 
atypical neuroleptic clozapine (3mg/kg). Results, obtained from film 
autoradiographs, are expressed as mean relative optical density x 1 0  ^± s.e.m., 
n=3-5. Significance was determined by one-way ANOVA, followed by the 
post-hoc Mann-Whitney U test. p< 0.05*
Drug treatment Striatum Nucleus accumbens
Saline
Haloperidol
Fluphenazine
Clozapine
46.75±5.76 
152.30±13.30 * 
203.703=42.10 * 
64.303=15.70
41.703:5.42 
95.303=14.90 
152.003=36.30 * 
43.303=17.80
Table 2: The expression of ziF268 mRNA levels in the rat striatum and nucleus 
accumbens following treatment with vehicle (physiological saline), or the 
typical neuroleptic drugs haloperidol (1  mg/kg), and fluphenazine (3mg/kg), or 
the atypical neuroleptic clozapine (3mg/kg). Results, obtained from film 
autoradiographs, are expressed as mean relative optical density x 10^  3= s.e.m., 
n=3-5. Significance was determined by one-way ANOVA, followed by the 
post-hoc Mann-Whitney U test. p< 0.05*
Animals were intraperitonealy injected with saline (n= 3), the typical 
neuroleptic drugs haloperidol (1 mg/kg, n= 3) and fluphenazine (6 mg/kg, n= 5)
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and the atypical neuroleptic drug clozapine (3mg/kg; n= 3). After 30 minutes 
the levels of mRNA were measured using in situ hybridisation histochemistry. 
Prior to the use of the above drug concentrations, a lower dose of Img/kg was 
used for both fluphenazine and clozapine, however no induction o f either c-fos 
or zift268 mRNA was observed. The effects of a higher dose of 6 mg/kg 
fluphenazine were also examined in rats, in the event that a higher dose may 
cause much more potent inductive effects. However, it was demonstrated that 
6 mg/kg fluphenazine caused a comparable increase in c-fos and zift268 mRNA 
levels to the induction observed with the lower dose of 3mg/kg fluphenazine 
(data not shown).
The above tables demonstrate that low levels of both c-fos mRNA 
[Table 2 ] and zif/268 mRNA [Table 3] are observed following treatment with 
physiological saline, the basal zif/268 hybridisation signal being approximately 
double that for c-fos mRNA. in both the rat striatum and nucleus accumbens.
The levels of c-fos mRNA in the striatum 30 minutes after treatment 
with the typical neuroleptic haloperidol (Img/kg) were significantly increased 
compared to animals treated with saline, such that F =50.56, p=0.011, p< 0.05 
[Table 2]. Haloperidol had a tendency to increase c-fos mRNA expression in 
the nucleus accumbens, and the increase was significantly different from saline 
treated animals (F=15.58, p< 0.05). Similarly fluphenazine (3mg/kg) 
significantly induced c-fos mRNA levels in the striatum (F=10.16, p< 0.05), but 
not in the nucleus accumbens. Clozapine (3mg/kg) had no effect on the 
expression of c-fos in both the striatum and nucleus accumbens. [Table 2].
A similar pattern of induction was observed for zif/268 mRNA in the 
striatum. The increase in zift268 mRNA levels after administration of 
haloperidol (Img/kg) for 30 minutes was significantly different from control 
rats (F=42.63, p< 0.01) [Table 3]. A tendency towards induction of ziff268 was 
observed in the nucleus accumbens following haloperidol (Img/kg), although 
this increase failed to reach significance. Fluphenazine (3 mg/kg) caused a
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significant induction of zifi268 mRNA in both the striatum (F=8.85, p< 0.05) 
and nucleus accumbens (F=7.94, p< 0.05). Clozapine (3mg/kg) had no effect 
on the levels of zifi268 mRNA in both the striatum and the nucleus 
accumbens. [Table 3].
The expression of c-fos and ziff268 mRNA had a tendency towards
slightly higher levels in the dorsolateral region of the striatum, although a 
general induction was observed throughout the striatum. The levels expressed 
in the nucleus accumbens were distributed homogeneously over core and shell
.regions.
4.4 The effect of acute treatment with neuroleptics on the expression of iun-B 
mRNA and iun-D mRNA in the rat striatum and nucleus accumbens
In saline treated animals a very low hybridisation signal for jun-B
■'imRNA was observed in all brain regions, similar to the low levels of c-fos 
.mRNA following saline treatment. Following administration of the typical 
neuroleptic haloperidol (Img/kg; n= 3), a dramatic increase in the levels of jun- 
B mRNA was observed 30 minutes after drug treatment, in the rat striatum 
(F=60.41, p< 0.05). [Figure 4.4.1]. A clear induction of jun-B mRNA was also 
observed in the nucleus accumbens (F=15.80, p< 0.05), following haloperidol 
(Img/kg). [Figure 4.4.2]. Similarly fluphenazine (3mg/kg, n= 8 ), a typical 
neuroleptic having a high affinity for the dopamine D2 receptor, was shown to
»cause a significant induction in the expression of jun-B mRNA levels in the rat
striatum (F=4.22. p< 0.05) [Figure 4.4.1, 4.4.5], and in the nucleus accumbens
(F=35.15, p< 0.05) [Figure 4.4.2]. The pattern of jun-B expression in the 
.striatum was primarily in the dorsolateral regions, whilst in the nucleus 
accumbens the tendency was towards a homogeneous distribution of jun-B 
mRNA . The atypical neuroleptic clozapine (3 mg/kg, n= 6 ) had no effect on the
I
Figure 4.4.1: Effect of acute administration of neuroleptic drugs on jun-B 
mRNA levels in the rat striatum. Haloperidol (Img/kg), or fluphenazine 
(3mg/kg), or clozapine (3mg/kg), or vehicle (0.9% saline) were injected l.p. 30 
minutes before sacrifice. Results, obtained fi*om film autoradiographs, are 
expressed as mean relative optical density + s.e.m.; n=3-8. Significance was 
determined by ANOVA followed by the post-hoc Mann-Whitney U test. * p< 
0.05 relative to saline group.
Figure 4.4.2: Effect of acute administration of neuroleptic drugs on jun-B 
mRNA levels in the rat nucleus accumbens. Haloperidol (Img/kg), or 
fluphenazine (3mg/kg), or clozapine (3 mg/kg), or vehicle (0.9% saline) were 
injected i.p. 30 minutes before sacrifice. Results, obtained from film 
autoradiographs, are expressed as mean relative optical density + s.e.m.; n=3-8. 
Significance was determined by ANOVA, followed by the post-hoc Mann- 
Whitney U test. *p< 0.05 relative to saline group.
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Figure 4.4.3: Effect o f acute administration of neuroleptic drugs on jun-D 
mRNA levels in the rat striatum. Haloperidol (Img/kg), or fluphenazine 
(3mg/kg), or clozapine (3mg/kg) or vehicle (0.9% saline) were injected i.p. 30 
minutes before sacrifice. Results, obtained from film autoradiographs are 
expressed as mean relative optical density + s.e.m.; n=3-8. Significance was 
determined by ANOVA, followed by the post-hoc Mann-Whitney U test. * p< 
0.05 relative to saline group.
Figure 4.4.4 : Effect o f acute administration of neuroleptic drugs on jun-D 
mRNA levels in the rat nucleus accumbens. Haloperidol (Img/kg), or 
fluphenazine (3mg/kg), or clozapine (3mg/kg), or vehicle (0.9% saline) were 
injected i.p. 30 minutes before sacrifice. Results, obtained from film 
autoradiographs, are expressed as mean relative optical density + s.e.m.; n=3-8. 
Significance was determined by ANOVA followed by the post-hoc Mann- 
Whitney U test. * p< 0.05 relative to saline group.
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Figure 4.4.5 : Effect of fluphenazine on the expression of jun-B mRNA in the 
rat striatum. Photomicrographs show the distribution of silver grains over cell 
bodies in the caudal striatum. On the left, the animal was treated with vehicle 
(0.9% saline) (A), and on the right, with fluphenazine (3mg/kg), injected i.p. 
The animals were killed 30 minutes later. Scale bar represents 25^m.
Figure 4.4.6 : Effect o f haloperidol on the expression of jun-D mRNA in the rat 
striatum. Photomicrographs show the distribution of silver grains over cell 
bodies in the caudal striatum. On the left, the animal was treated with vehicle 
(physiological saline) (A), and on the right , with haloperidol (Img/kg) (B), 
administered i.p. The animals were killed 30 minutes later. Scale bar represents 
25/xm.
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expression of jun-B mRNA levels in either the striatum or nucleus accumbens
compared to saline treated control animals.
Another member of the jun family o f immediate early genes, jun-D, was 
investigated. In comparison to the other lEGs under investigation, jun-D is 
anomolous in that it is basally expressed in much higher levels throughout the 
brain.The expression of jun-D mRNA was shown to be increased in the 
striatum 30 minutes after treatment with haloperidol (Img/kg, n= 3) [Figure 
4.4.3, 4.4.6], compared to saline treated control animals. This induction was 
shown to be statistically significant relative to control (F=20.70, p< 0.05). 
Likewise a similar increase in jun-D mRNA levels were seen in the nucleus 
accumbens after haloperidol (Img/kg, n= 3) (F-19.00, p< 0.05) [Figure 4.4.4]. 
However fluphenazine (3mg/kg, n= 8 ) and clozapine (3 mg/kg, n= 6 ) had no 
observed effect on the expression of jun-D mRNA in either the striatum or 
nucleus accumbens.
4.5 Effect of acute treatment with neuroleptics on the transcription factor genes 
BF-1 and RHS2.
The recently cloned homeobox genes BF-1 and RHS2 have been shown 
to be expressed at moderate levels in the striatum. ( Tao and Lai, 1992; Le 
Moine and Young, 1992). Therefore, we have investigated the effect of 
neuroleptic drugs on the levels of expression of these genes in the rat striatum.
The hybridisation signal obtained for BF-1 and RHS2 gene expression 
was quite high in saline treated animals (n= 3). Thirty minutes after the 
administration of the typical neuroleptic drug fluphenazine ( 3  mg/kg, n= 3 ) or 
the atypical neuroleptic clozapine (3 mg/kg, n= 3), there was no significant
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Figure 4.5.1 : Effect of neuroleptic drug treatment on the expression of BF-1 
mRNA in the rat caudal striatum. Three animals per group were injected i.p. 
with vehicle (0.9% saline), fluphenazine (3mg/kg) or with clozapine (3mg/kg). 
After 30 minutes the animals were killed and their brains processed for in situ 
hybridisation. Results, obtained from autoradiographic film, are expressed as 
mean relative optical density + s.e.m. The number of animals per group is 
shown in parentheses.
Figure 4.5.2 : Effect of neuroleptic drug treatment on the expression of RHS2 
mRNA in the rat caudal striatum. Three animals per group were injected i.p. 
with vehicle (0.9% saline), or fluphenazine (3mg/kg), or with clozapine 
(3mg/kg). After 30 minutes their brains were processed for in situ 
hybridisation. Results, obtained from autoradiographic film, are expressed as 
mean relative optical density + s.e.m. The number of animals per group is 
shown in parentheses.
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change in the levels o f expression of BF-1 mRNA [Figure 4.5.1] or RFIS2
mRNA [Figure 4.5.2] compared to saline treated control animals.
4.6 Effect of acute neuroleptic drug treatment on the expression of BF-1 
mRNA in the rat striatum 24 hours later.
The levels of BF-1 mRNA expressed in saline treated animals were 
generally distributed in relatively high levels throughout the brain, particularly 
in the forebrain regions. Following treatment with haloperidol (Img/kg, n= 3), 
fluphenazine (3mg/kg, n= 3), or clozapine (3mg/kg, n= 3), the levels of BF-1 
mRNA in the rostral striatum were unchanged compared to the levels 
expressed in saline treated control animals. [Figure 4.6.1]. However, in the rat 
caudal striatum, it was observed that intraperitoneal injection o f clozapine 
(3 mg/kg, n= 3) caused an increase in the levels of BF-1 mRNA after 24 hours. 
This induction by clozapine was shown to be significantly different from saline 
treated animals [ F (3,8) =4.93, p=0.038, p< 0.05 ] [Figure 4.6.2]. Haloperidol 
(Img/kg, n= 3) and fluphenazine (3mg/kg, n= 3) had no effect on BF-1 mRNA 
levels in the caudal striatum 24 hours after drug administration. [Figure 4.6.2].
4.7 Effect of acute neuroleptic drug treatment on the expression of the POU- 
domain containing gene RHS2 in the rat striatum
Low levels of RHS2 mRNA were expressed in both the rostral and 
caudal striatum, in saline treated rats. Treatment with haloperidol (Img/kg, n= 
3), fluphenazine (3mg/kg, n= 3) or clozapine (3mg/kg, n= 3) had no significant 
effect on the levels of RHS2 mRNA in the rostral striatum of the rat [Figure 
4.7.1]. Similarly in the rat caudal striatum, treatment with haloperidol (Img/kg, 
n= 3), fluphenazine (3 mg/kg, n= 3) or with clozapine (3 mg/kg, n= 3) caused no
1 1 0
Figure 4.6.1 : Effect of acute neuroleptic drug treatment on the expression of 
BF-1 mRNA in the rat rostral striatum. Animals were injected i.p. with vehicle 
(0.9% saline), or haloperidol (Img/kg), or fluphenazine (3mg/kg), or with 
clozapine (3mg/kg). After 24 hours, the animals were killed and their brains 
processed for in situ hybridisation. Results, obtained from autoradiographic 
film, are expressed as mean relative optical density + s.e.m.; the number of 
animals per group is shown in parentheses.
Figure 4.6.2: Effect of acute neuroleptic drug treatment on the expression of 
BF-1 mRNA in the rat caudal striatum. Animals were injected i.p. with vehicle 
(0.9% saline), or haloperidol (Img/kg), or fluphenazine (3mg/kg), or with 
clozapine (3mg/kg). After 24 hours, the animals were killed and their brains 
processed for in situ hybridisation. Results, obtained from autoradiographic 
film, are expressed as mean relative optical density + s.e.m.; the number of 
animals per group is shown in parentheses. Statistical significance was 
determined by one-way ANOVA, followed by post-hoc Dunnett’s test, p < 
0.05* relative to saline group.
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Figure 4.7.1 : Effect of acute neuroleptic drug treatment on the expression o f  
RHS2 mRNA in the rat rostral striatum. Animals were injected i.p. with vehicle 
(0.9% saline), or haloperidol (Img/kg), or fluphenazine (3mg/kg), or with 
clozapine (3 mg/kg). After 24 hours, the animals were killed and their brains 
processed for in situ hybridisation. Results, obtained from autoradiographic 
film, are expressed as mean relative optical density + s.e.m.; the number of 
animals per group is shown in parentheses.
Figure 4.7.2 : Effect of acute neuroleptic drug treatment on the expression of
RHS2 mRNA in the rat caudal striatum. Animals were injected i.p. with vehicle»
(0.9% saline), or haloperidol (Img/kg), or fluphenazine (3mg/kg), or with 
clozapine (3mg/kg). After 24 hours, the animals were killed and their brains 
processed for in situ hybridisation. Results, obtained from autoradiographic 
film, are expressed as mean relative optical density + s.e.m.; the number o f  
animals per group is shown in parentheses.
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significant changes in the levels of RHS2  mRNA compared to saline treated 
animals in the rat [Figure 4.7.2],
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DISCUSSION
Regulation of Immediate Early Genes in vivo
4.8 Time Course of fluphenazine effect on c-fos and zifr268 mRNA levels
.The typical neuroleptic drug fluphenazine, having a high affinity for
dopaminergic D2 receptors, was shown to maximally induce c-fos mRNA
levels in the rat striatum forty-five minutes after the drug was given, and the
levels were reduced back to basal levels after three hours. This finding is similar
to previous reports that suggest a peak induction of c-fos can occur from thirty 
.to sixty minutes after an acute treatment with psychostimulants or neuroleptic
drugs (Robertson et al.. 1989; Cole et al.. 1992; Nguyen et al.. 1992; Bhat et
al., 1992). Our results also showed a significant increase in c-fos mRNA after
fifteen minutes in the rostral region of the rat striatum, but not in the caudal
regions. In a former study, zif/268 mRNA levels have been shown to be
significantly increased after fifteen minutes (Cole et al.. 1992), and therefore
the observed induction of c-fos mRNA fifteen minutes after fluphenazine
treatment is not unlikely. It may be that the drug fluphenazine is absorbed
more quickly, and thus an induction of c-fos gene expression is occurs more
rapidly. Differences in the rate at which drugs are absorbed across the blood-
brain barrier are likely to reflect small differences in peak expression time.
The immediate early gene zifi268 was also demonstrated to be induced
maximally in the caudal region of the striatum after thirty minutes, and the
levels declined back to basal levels after three hours. In the rostral regions of 
.the rat striatum maximal zif/268 expression was observed after forty-five 
minutes which then decreased back to basal levels over a three hours time 
period. In previous reports it has been shown that zift268 is induced maximally 
by thirty to forty-five minutes after neuroleptics (Cole et al.. 1992; Nguyen et
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al., 1992 ), although an induction can be measured as early as fifteen minutes 
(Cole et al.. 1992). Our results are therefore consistent with previous studies 
(Cole etal., 1992: Nauven et al.. 1992; Bhat et a l. 1993).
These studies were undertaken in order to reproduce the current 
evidence suggesting that ‘typical* neuroleptics can induce both c-fos and 
zifr268 gene expression in the rat striatum and accumbens regions. In addition 
we were interested in the effects of certain ‘typical* and ‘atypical* antipsychotic 
drugs on the expression of two members of the jun family of immediate early 
genes, namely jun-B and jun-D, and to elucidate the receptor mechanisms that 
precede the induction of these immediate early genes.
4.9 Effect of acute Tvpica! Neuroleptic drug treatment on c-fos and zifi268 
gene expression in the rat striatum and nucleus accumbens
The results of this study show that acute injections of the typical
antipsychotic drugs haloperidol and fluphenazine can cause the induction o f a
»number o f immediate early genes including c-fos and zifi268 in the striatal 
region of the rat brain. A considerable induction of zifi268 mRNA, and to a 
lesser extent c-fos mRNA, was observed in the striatum. The induction of both 
c-fos and zifi268 mRNA by these typical antipsychotics followed a dorsolateral 
pattern. In addition, haloperidol was also shown to induce c-fos mRNA levels 
homogeneously in the nucleus accumbens. This is in agreement with previous 
reports suggesting that haloperidol can induce fos protein in both the core and 
shell regions, as well as in the striatum (Deutch et al.. 1992; Robertson and 
Fibiger, 1992), However, the level of c-fos mRNA was considerably less in the 
accumbens region after fluphenazine, compared with the levels seen in the 
striatum after fluphenazine administration. Merchant and Dorsa (1993),
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observed no induction of c-fos mRNA in the nucleus accumbens after 
administration of typical antipsychotic agents. Conversely, zift268 mRNA was 
dramatically induced by fluphenazine in the nucleus accumbens, the effect being 
quantitatively greater than that of haloperidol. It is clear from this that the 
immediate early genes under investigation have different induction patterns 
after typical neuroleptic drug administration. This may reflect stimulation of 
different cell populations within the caudate-putamen. The inductive effect of 
haloperidol on both c-fos and zif/268 is consistent with previous reports 
demonstrating an increase in the expression of these immediate early genes by 
haloperidol in the caudate-putamen (Dragunow et al.. 1990; Miller, 1990; 
Nguven et al.. 1992: Robertson et al.. 1992).
As many antipsychotic drugs are known to be potent dopamine receptor 
antagonists, it has been suggested that the induction of certain immediate early 
genes such as c-fos and zift268 may be mediated by blockade o f dopamine 
neurotransmission.
II »More recent evidence also indicates that the late response gene
dynorphin acting through kappa opioid receptors can inhibit the cocaine- 
induced expression of c-fos, mediated by stimulation of D1 receptors, in 
striatonigral neurons (Steiner and Gerfen, 1995). This suggests that the striatal 
dynorphin system acts to inhibit the dopamine input to striatonigral neurons, 
implying that endogenous feedback mechanisms can control the level of the 
immediate early gene, c-fos, that is expressed. This reveals a further complexity 
to cellular events, and in the future may provide an insight into the 
manifestation of certain disease states.
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4.10 Effect of acute Typical Neuroleptic drug treatments on iun-B and iun-D 
gene expression in the rat striatum and nucleus accumbens
observed in both the striatum and nucleus accumbens o f the rat. High basal
:
We report here for the first time that haloperidol can dramatically 
induce the expression of jun-B mRNA in the rat striatum and nucleus Iaccumbens. The level of expression of jun-B mRNA in the striatum was similar 
to the levels expressed for c-fbs mRNA and zifi268 mRNA after administration 
of haloperidol, compared with the very low levels expressed in saline-treated 
control animals. The large proportion of cells positively labelled for jun-B in 
the striatum suggest that jun-B is induced primarily in the medium-sized spiny 
neurons, because this cell type is known to represent 95% of striatal neurons
(Graybiel et al.. 1986).The induction due to haloperidol followed a rostral- 
caudal decline that matches the proposed rostral-caudal decline in the density
of D2 dopamine receptors in the striatum fBoysen et al.. 1986). Therefore, this 
evidence suggests that the induction of jun-B is predominantly modulated by 
D2 dopamine receptors.
»Whereas this is the first demonstration that jun-B is induced by 
neuroleptic treatment, there is some evidence for the induction o f jun-B afi;er 
acute administration of cocaine (Hope et al.. 1992), amphetamine, and 
apomorphine (Cole et al.. 1992). It is well known that these drugs have agonist 
properties at a number of receptors, including dopamine receptors. Therefore 
our evidence suggests that the expression of jun-B is regulated according to the 
level of dopamine activity.
This study has also revealed another member of the jun family of 
immediate early genes to be induced by typical neuroleptic drug administration.
s
After haloperidol, a small but significant induction of jun-D mRNA was
115
levels o f jun-D mRNA exist throughout the brain, which makes this immediate 
early gene different from jun-B. Similar to jun-D, high levels o f basal 
expression of c-jun are also present in certain brain areas. This is the first 
evidence that the level o f expression of the jun-D gene can be modulated by 
neurotransmitter activity. The induction of jun-D after haloperidol 
administration suggests that jun-D, as well as jun-B, may be interacting with 
fos proteins to regulate the expression of downstream genes. In a manner 
similar to jun-B, expression of jun-D mRNA followed a dorsolateral pattern of 
distribution in the striatum and a homogeneous distribution in the nucleus 
accumbens after haloperidol administration.
The effect of fluphenazine, also having a typical antipsychotic drug 
profile, was clearly very similar to that of haloperidol. Fluphenazine, given at 
relatively high doses was shown to induce jun-B mRNA. A dramatic induction 
of jun-B expression was observed in the striatum and a similar level of 
induction was observed for jun-B mRNA in the nucleus accumbens after 
fluphenazine. As typical neuroleptics are potent dopamine receptor antagonists 
in vivo, this further suggests that blockade of dopamine transmission may be 
involved in mediating this effect.
4.11 Effect of the Atypical neuroleptic, clozapine on the expression on the 
immediate earlv genes c-fos. zif/268. iun-B and iun-D and the possible receptor 
mechanismfs] mediating immediate early gene induction bv antipsychotic drugs
The results obtained demonstrate that low doses of clozapine have no 
effect on the expression of c-fos, zif/268, jun-B, or jun-D mRNA levels in 
either the rat striatum or nucleus accumbens after acute administration.
Previous reports have demonstrated that higher doses of the atypical 
antipsychotic clozapine can induce fos-immunoreactivity in the shell region of 
the nucleus accumbens, but not in the striatum (Deutch et al.. 1992; Robertson
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and Fibiger, 1992). It is currently thought that the accumbens is associated with 
the mesolimbic system and is one of the prime targets for neuroleptic drugs. 
Behaviuoral studies have shown that chronic clozapine treatment selectively 
enhances apomorphine-induced locomotor activity, behaviour associated with 
dopamine nesolimbic activation. Whereas, treatment with haloperidol 
significantly enhanced apomorphine-induced chewing and sniffing stereotypies, 
thought to be associated with dopamine nigrostriatal activation (Seeger et al.. 
1982). The extrapyramidal side effects associated with many typical neuroleptic 
drug treatments may be attributed to their activity on motor systems within the 
caudate-putamen. Therefore, the pattern of expression of c-fos and other 
immediate early genes may provide an important insight into the regional 
mechanisms of atypical antipsychotics. In this study low doses of the atypical 
antipsychotic drug clozapine had no effect on the levels of expression of c-fos, 
zifi268, jun-B and jun-D mRNA in either the striatum or nucleus accumbens of  
the rat brain. It has previously been shown through in vitro binding studies that 
fluphenazine has a greater affinity for the D2 dopamine receptor than the D4 
dopamine receptor (Van Toi et al.. 1991). Clozapine, however, has a ten-fold 
greater affinity for the D4 site compared with the D2  site (Van Toi et al.. 
1991). Clozapine has been shown to bind appreciably to striatal D2 sites in rats 
only at doses of lOmg/kg and above (Sailer et al.. 1987; Audinot et al.. 1993). 
It is therefore likely that the lower dose of 3 mg/kg used in these acute 
experiments is preferentially blocking D4 sites in vivo rather than D2 sites. This 
is supported by the evidence that a dose of 3mg/kg clozapine blocks a 
substantial proportion of the serotonin 5-HT2 receptors in vivo (Canton et al.. 
1993). Indeed clozapine has a similar affinity for D4 and 5-HT2 sites (Van Toi 
et al.. 1991; Zifa and Fillion, 1992), implying that this dose will produce D4 
antagonism in vivo. At higher doses of clozapine ( 1 0 -2 0 mg/kg), an induction of 
zifi268 has been reported in the caudate-putamen (Nguyen et al.. 1992).This 
therefore suggests that at higher doses, clozapine is acting at D2 receptors to
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produce this effect. As clozapine had no effect on the immediate early genes 
under investigation, this would imply that the increased expression observed 
after typical neuroleptic drug administration is most likely due to a D2 
dopamine receptor blockade rather than a D4 effect.
D 1 dopamine receptor blockade may be considered to have negligible 
contribution to the effect on immediate early gene expression by any of the 
neuroleptics used in these studies. It has been shown that low doses o f 
fluphenazine occupy primarily D2 dopamine receptors in vivo (Sailer et al.. 
1987). Dragunow et al. (1990), have demonstrated previously that the specific 
D1 dopamine receptor antagonist SCH23390 did not induce c-fos protein in 
striatal neurons. Therefore, it is likely that the effect of haloperidol, 
fluphenazine or clozapine on D1 or D5 dopamine receptors does not contribute 
to the clear induction of the immediate early genes c-fos, zifr268, jun-B, and 
jun-D seen after drug administration. However, the affinity of fluphenazine for 
D 1 receptors is relatively high; therefore, it may be considered possible that the 
induction of jun-B mRNA after fluphenazine treatment is reduced in 
comparison with the induction observed after haloperidol, due to the ability of 
fluphenazine to antagonize D 1 receptors.
Despite their high affinity for dopamine receptors, neuroleptics also 
have considerable affinity for many serotonin receptors. From both in vivo and 
in vitro binding studies, clozapine is known to be a potent antagonist at 
serotonin 5-HT2 and 5-HT 1C receptors (Zifa and Fillion, 1992; Canton et al., 
1993). It is likely that clozapine administered at a dose of 3mg/kg would be 
blocking approximately 50% of 5-HT2/1C receptors (Canton et al.. 1993). 
Likewise the typical neuroleptics haloperidol and fluphenazine were shown to 
have some antagonist binding properties at 5-HT2 receptors, but with much 
lower affinity than clozapine. The relative potencies o f these drugs, together 
with a lack of effect of clozapine at a dose likely to be blocking 5-HT2/1C 
receptors in vivo, would therefore suggest that 5-HT receptors are not
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involved in the effects reported here. Nevertheless, the consequences of 
neuroleptics having simultaneous effects on multiple transmitter systems must 
be taken into consideration.
A number of mechanisms have been proposed that could explain the 
increased expression of many immediate early genes by typical neuroleptic drug 
administration. One possible interpretation of these results is that haloperidol 
and fluphenazine produce their effects by increasing the release of dopamine 
from nigral-striatal terminals, which then acts on D1 dopamine receptors to 
induce immediate early genes. Related to this idea is the more likely possibility 
that D2 dopamine antagonists induce immediate early gene mRNA in striatal 
neurons by allowing unopposed D1 receptor stimulation. After a 6 - 
hydroxydopamine lesion, the specific D1 dopamine receptor agonist SKF 
38393 has been shown to increase c-fos in striatal neurons of the rat brain 
(Robertson et al.. 1990). The link between D1 receptor activation and the 
induction of immediate early genes, has been further supported by Cole et al. 
(1992), who have demonstrated that administration of SKF 38393, but not the 
specific D2 receptor agonist LY171,555, causes an induction of c-fos, zif/268 
and jun-B in the caudate-putamen after a 6 -hydroxydopamine lesion, and this 
can be abolished by pretreatment with SCH 23390. Recent evidence also 
suggests that SCH 23390 decreases the mRNA levels of zifr268 in the adult 
intact striatum of the mouse (Mailleux et al.. 1992). Therefore the current 
evidence implies strongly that the induction of a number of immediate early 
genes including c-fos, zifr268 and jun-B may be the result of a stimulation of 
the D1 dopamine receptor. Previous reports have also demonstrated that 
destruction of mesotelencephalic dopaminergic neurons with 6 - 
hydroxydopamine abolishes the increase in fos expression in the striatum and 
nucleus accumbens produced by haloperidol (Robertson and Fibiger, 1992). 
This provides fiirther support for the induction of c-fos after D1 dopamine 
receptor activation. However, it should be noted that SCH23390 does not
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4.12 Effect of acute neuroleptic drus treatment on the expression of BF-1 and 
RHS2 transcription factor genes
Our results show that the expression of the recently cloned transcription 
factor genes RHS2 and brain factor-1 (BF-1) were not Aftected thirty minutes 
after treatment with either the typical neuroleptic drug fluphenazine, or the 
atypical neuroleptic drug clozapine, compared to saline treated controls. 
However, the expression of BF-1 mRNA after twenty -four hours was 
significantly induced by low doses of the atypical neuroleptic clozapine in the
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block the induction of c-fos by D2 receptor antagonism (Robertson et al.. 
1992; Merchant and Dorsa, 1993). Therefore the precise mechanisms operating 
remain unclear.
Our results suggest that neuroleptic drug administration induce a
pattern o f immediate early gene induction more complex than has been
appreciated until now. This includes the induction, at the mRNA level, o f two
members of the jun family of leucine zipper proteins, jun-B and jun-D. The
results also suggest that these effects occur in response to blockade of D2
rather than D4 receptors. It would appear that a fine balance exists in vivo
between D 1 and D2 receptor stimulation. When the balance is disturbed, as in
psychotic disorders, the expression of a number of immediate early genes may
be affected. As yet, the consequences of these transient changes on the
expression o f downstream genes is not fully understood. However, a link has
been suggested between c-fos and proenkephalin gene regulation (Sonnenberg
et al.. 1989). Although, more recently, this idea has been argued against, as it 
.has been implied that it is not the fos protein that interacts with the enkephalin 
enhancer (Konradi et al.. 1993). As the protein CREB has also been shown to 
act as a transcription factor, this may be a more likely candidate.
medial striatum, but not by fluphenazine. There was a tendency towards an 
induction of RHS2 mRNA in the striatum after clozapine treatment, although 
the levels failed to reach significance. These results provide the first evidence 
that neuroleptics can induce BF-1 gene expression, at the mRNA level, in the 
adult rat brain.
In the developing mammalian brain, three separate regions known as 
the forebrain, midbrain and hindbrain are initially formed from the rostral part 
o f the neural tube. The most rostral forebrain region, the telencephalon, gives 
rise to the structures of the cerebral hemispheres, which include the cerebral 
cortex and basal ganglia. Previous studies have demonstrated that the 
expression of BF-1, a member of the HNF-3/fork head gene family, is restricted 
to the telencephalon region in the developing rat brain (Tao and Lai, 1992). 
Therefore it has been suggested that BF-1 may have a role as a transcriptional 
regulator in the complex signalling system that coordinates the precise temporal 
and spatial patterns of diiferential gene expression in multicellular organisms. 
Northern blotting analysis has shown that the BF-1 gene is expressed in the 
cortex, olfactory bulb, hippocampus and caudate-putamen in the adult rat brain, 
the levels of expression being four-fold lower than in the fetal rat brain (Tao 
and Lai, 1992). More recently, the identification of a gene in human fetal tissue 
having high homology at the nucleotide level to brain factor- 1 in the rat, has 
been shown to be expressed in the telencephalon, with strong expression being 
observed in the dentate gyrus and hippocampus. The expression of human BF- 
1, also referred to as HFKl, was also found to be restricted to neuronal cells in 
the telencephalon (Murphy et al.. 1994). The basal expression of BF-1 mRNA 
in the adult rat striatum showed that a large proportion of cells were positively 
labelled for BF-1, which suggests that BF-1 is expressed primarily in the 
mediun-spiny neurons, because this cell type has previously been demonstrated 
to represent 95% of striatal neurons (Graybiel et a l. 1986). Therefore, it may
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be suggested that the induction o f BF-1 mRNA seen after clozapine treatment 
is primarily in the medium-spiny neuronal cell poulation within the striatum.
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The low dose of clozapine used in this study may reflect a mechanism
Ï
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involving either a dopamine D4 receptor stimulation or a 5-HT receptor subtype
stimulation, which has previously been discussed in earlier studies using the same
dosage o f clozapine. Although clozapine is known to have a high affinity for
many receptor types, including adrenergic, histaminergic and muscarinic
receptors and therefore a variety of different receptors may be contributing to 
.the observed induction of BF-1 after low doses of clozapine.
This is the first evidence that the a member of the HNF-3/ fork head
, ■
gene family, brain factor-1, can be modulated by neuroleptic drug administration.
Since the atypical neuroleptic, clozapine, but not the typical neuroleptic
fluphenazine was able to induce BF-1 mRNA in the striatum, this may reflect a
previously undiscovered role for BF-1 in the control of antipsychotic disorders,
,and a possible contributory factor in the lack of extrapyramidal side effects 
observed clinically after clozapine treatment. However, the potential target 
genes, whose level of expression is dependent on BF-1 induction, remains to be 
identified.
Chapter 5
Striatal Neuronal Cultures
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INTRODUCTION
5.0 Striatal Neurone Morphology
As our understanding of the molecular mechanisms regulating cellular 
activity has grown, the information that can be obtained from in vivo 
experiments has become more difficult to interpret, and the importance of in 
vitro systems has consequently increased. The intercellular and subcellular 
processes which coordinate and control the activity of neurones in particular 
brain regions such as the striatum can frquently only be studied in tissue 
maintained in vitro, where reagents can be applied in known concentrations, 
directly onto the cells. This has been emphasised by the recent identification of 
novel dopamine and serotonin receptors which are expressed at relatively high 
levels in striatal tissue (Sunahara et al.. 1991; Van Toi et al.. 1991; Monsma et 
d., 1993). The absence of selective ligands for these receptors means that their 
role in regulating the activity of striatal neurons can essentially only be studied 
in vitro, where the drugs can be applied in precise concentrations, and hence 
relative selectivity can be calculated exactly.
It has been clear for some years that striatal neurons, dissociated fi-om 
embryonic rat brain and maintained under cell culture conditions, can survive 
well in vitro for a number of weeks (Messer, 1981; Kessler, 1986; Weiss et al., 
1986; Surmeier et al.. 1988). These primary striatal neuron cultures have 
proved to be a useful system for electrophysiological and second messenger 
studies, looking at the effects of stimulation of receptors for dopamine, GAB A, 
glutamate and growth factors (Murphy et al.. 1987; Dumuis et al.. 1988; 
Dubinsiy-, Misgeld and Dietzel, 1989; Sproson and Woodruff, 1990; 
Marin-et al.. 1992; Simpson and Morris, 1994). However, there is evidence that 
dopamine is likely to have different effects on the different classes of neuron in 
the striatum in vivo (Morris et al., 1988; Le Moine et al., 1991; Pollack and
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Wooten, 1992). It is clearly o f considerable importance to know which o f the 
neuronal types normally present in the striatum are also present in the primary 
cultures. It may be that some classes o f neuron do not survive at all, and that 
the intracellular effects that can be studied are those occuring in only one or 
two different neuronal types. Conversely, all casses of neuronal types may be 
present in vitro, in which case these primary cultures may provide a suitable 
model for studing the regulation of activityof the whole range of striatal 
neurons.
Approximately 95% of striatal neurons in vivo are thought to be 
GABA-ergic projection neurons additionally containing either enkephalin 
peptides or dynorphin and tachykinin peptides (Bolam et al.. 1985; Graybiel, 
1990; Besson et al.. 1990). The remainder comprise possibly three populations 
of intemeurons releasing acetylcholine, or GABA and neuropeptide Y, or 
somatostatin, neuropeptide Y and nitric oxide (Bolam et al.. 1984; Phelps et 
al-, 1985; Graybiel, 1990; Vuillet et al.. 1990). Despite the importance of a 
comprehensive phenotypical characterisation of striatal neurons in culture, 
there is to date only limited evidence as to what classes of neurons are present 
in vitro. Extracts of primary striatal cultures have previously been shown to 
contain immunoreactive somatostatin and substance P (Kessler, 1986), and 
proenkephalin mRNA (Schwartz and Simantov, 1988; Vilijn et al.. 1988), while 
analysis at the cellular level has shown the presence of GABA (Messer, 1981; 
Weiss et al.. 1986; Surmeier et al.. 1988), along with immunoreactive leu- 
enkephalin ISurmeier et al.. 1988), which could arise from either the expression 
of the prodynorphin gene, or the proenkephalin gene, and immunoreactive 
somatostatin (Williams et a l. 1991). Of these, only GABA, immunoreactive 
leu-enkephalin and immunoreactive somatostatin have been localised to 
neurons rather than glia (Surmeier et al.. 1988; Williams et al.. 1991). Striatal 
glia in culture are known to express the enkephalin gene at high levels (Vilijn et
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al., 1988), so it remains an open question to what extent the other neuroactive 
substances detected in culture extracts are derived from non-neuronal cells.
Therefore, before striatal neurons in culture can be used as a model for 
the in vivo situation, it is important to characterise the cell types that are 
present in vitro.
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RESULTS
5.1 Characterisation o f rat striatal neuronal cultures
In striatal neurone cultures grown in DMEM, a high proportion o f cells 
were identified as astrocytes on the basis of their large, flat morphology and 
their characteristic immunoreactivity for glial fibrillary acidic protein (GFAP), 
revealing large unstained nuclei, as shown in figure 5.1.1. To reduce astrocytic 
contamination o f the cultures, a range of different concentrations of cytosine 
arabinoside was added to the culture medium. It was found that cytosine 
arabinoside (20/iM), optimally reduced astrocytic contamination of the cultures 
to less than 5% of the total cell population without dramatically affecting the 
numbers of neurones. Cytosine arabinoside treatment was therefore included in 
all subsequent experiments. Neuronal cells were clearly distinguishable from 
astrocytes on the basis of their morphology. However, their identity was 
confirmed by using neurone-specific enolase (NSE)- immunostaining, together 
with in situ hybridisation with an oligonucleotide probe specific for 
microtubule-associated protein 2 (MAP 2) mRNA, found only in neuronal cell 
types. A variety of neuronal morphologies could be identified in neurones 
stained with the anti-NSE antiserum, including bipolar cells with oval somata, 
multipolar cells with oval somata, and cells with triangular somata giving rise to 
large numbers of dendritic processes. [Figure 5.1.2] revealing the diversity of 
cell types within the striatum. Following in situ hybridisation with an 
oligonucleotide probe for MAP 2 mRNA, neuronal cells counterstained with 
cresyl violet, can be seen to express MAP 2 message, compared to the 
complete absence of MAP 2 mRNA following hybridisation of cultures with a 
MAP 2 sense oligonucleotide probe (not shown).
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A large number of cells in culture, approximately 30-40%, were stained 
using the met-enkephalin antiserum [Figure 5.1.3], characteristically staining 
the cell soma. Cells from each o f the morphological groups were identified as 
met-enkephalin immunoreactive neurons. In accordance with this result, a 
relatively high proportion of neurones in culture ( 30-40%), were found to 
contain proenkephalin (Penk) mRNA, when assayed by in situ hybridisation 
histochemistry [Figure 5.1.4]. After hybridisation with a 25-fold excess o f  
unlabelled Penk oligonucleotide included in the hybridisation buffer, no 
labelling was observed, confirming the specificity of the hybrisation reaction. 
The cells containing immunoreactive-met-enkephalin or those expressing Penk 
mRNA were generally of medium size (12-20fim diameter). In comparison, 
cortical cultures grown under the same conditions contained no met-enkephalin 
immunoreactive neurons (not shown).
A smaller number of neurones were also found to express 
preprotachykinin (PPT) mRNA [Figure 5.1.5], although the hybridisation signal 
was much weaker than with the Penk probe. No specific signal could be 
detected with an oligonucleotide probe specific for prodynorphin mRNA at any 
time point from 7 DIV to 21 DIV.
Following hybridisation o f striatal cultures with the somatostatin 
antisense probe, only a small proportion of neurones were labelled, but the 
intensity of the hybridisation signal was very strong. [Figure 5.1.6]. Cells 
labelled with the somatostatin probe were generally larger (15-25 fim), than 
those labelled for Penk or PPT. Again, the hybridisation signal was completely 
removed by the inclusion of a 25-fold excess of unlabelled somatostatin 
oligonucleotide in the hybridisation reaction. No specific signal was seen when 
sense probes were used under identical conditions [Figure 5.1.7]. The NPY 
probe was expressed in the same number of cells as the somatostatin probe, 
although the hybridisation signal was considerably weaker than that observed 
for the somatostatin probe [Figure 5.1.8], and similarly a 25-fold excess of
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unlabelled probe when added to the hybridisation reaction, abolished the 
hybridisation signal.
A very small number of striatal neurons in culture also stained positively 
for acetylcholinesterase [Figure 5.1.9]. These cells tended to be larger than 
average (20-25jum diameter) and stained very darkly for acetylcholinesterase. 
Characteristically, these cells gave rise to a number of heavily-stained processes 
that appeared to make contact with many neighbouring cells.
A relatively small percentage (< 5%) o f cultured striatal neurons were 
demonstrated to contain NADPH-diaphorase activity [Figure 5.1.10]. These 
cell types generally had large triangular or oval somata (20-25^m diameter), 
and appeared similar in terms of their gross morphology to the neurones 
exhibiting NADPH-diaphorase activity in sections of adult rat striatum [Figure 
5.1.11]. The cultured NADPH-diaphorase-positive neurones gave rise to long 
processes with axon-like morphology, with an extensive plexus o f connections 
with neighbouring cells. These “axons” were characterised by the presence of  
pronounced variscosity-like swellings along their length, which loosely 
resembles the appearance of the diaphorase-positive fibres in adult rat striatal 
tissue.
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Figure 5.1.1 : Primary striatal cultures ,in the absence of cytosine arabinoside, 
processed for immunocytochemistry using antisera against glial fibrillary acidic 
protein (GFAP). The stained cells are large and flat with unstained nuclei. Scale 
bar represents 25^m.
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Figure 5.1.2: Primary striatal cultures processed for immunocytochemistry 
using antisera against neurone specific enolase (NSE). Groups of neurones 
show strong intensity staining for NSE, including a variety o f different 
morphological types ( bipolar, multipolar, triangular). Scale bar represents 
25/xm.

Figure 5.1.3 : Primary rat striatal cultures processed for immunocytochemistry 
using antisera against met-enkephalin. The cell bodies of neurones in culture 
stained positively for met-enkephalin. The characteristics of enkephalin positive 
neurones tended to be those with oval somata and a bipolar morphology. Scale 
bar represents 25^m.
Figure 5.1.4 : Cultured striatal neurones following hybridisation with a probe 
specific for proenkephalin (Penk) mRNA,. Exposure time 2 weeks. 
Photomicrographs show cultured striatal neurones expressing the Penk gene, as 
seen by the distribution of silver grains over certain cell bodies. Approximately 
40-50% of cells were labelled positively with the Penk probe. Scale bar 
represents 25^m.
&
Figure 5.1.5 : Cultured rat striatal neurones following hybridisation with a 
radiolabelled probe specific for preprotachykinin (PPT) mRNA. Exposure time 
approximately 6 days. Photomicrographs show striatal neurones counterstained 
in cresyl violet. Approximately 25-35% of cells were labelled positively for 
PPT mRNA. Scale bar represents 25^m.
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Figure 5.1.6 : Cultured rat striatal neurones following hybridisation with a 
radiolabelled probe specific for preprosomatostatin mRNA. Exposure time 4 
days. Photomicrographs show striatal neurones counterstained in cresyl violet. 
A relatively small percentage of cells in culture were labelled positively for 
preprosomatostatin mRNA, as shown by an increase in the density of silver 
grains over certain cell bodies. Characteristically, the positively labelled cells 
were of larger size. Scale bar represents 25/*m.
Figure 5.1.7 : Cultured rat striatal neurones following hybridisation with a 
radiolabelled somatostatin ‘sense’ probe. Exposure time 5 days. 
Photomicrographs show striatal neurones counterstained in cresyl violet. Scale 
bar represents 25fxm.
I- - ■'.'I'.i "J, i ,. •'--4i_= Vir- L ('•r^  ^ z^ 'f-:.
¥
d
"''I:?
rf|
%
} \
Figure 5.1,8 ; Cultured rat striatal neurones following hybridisation with a 
radiolabelled probe specific for proneuropeptide Y mRNA. Exposure time 5 
days. Photomicrographs show striatal neurones counterstained in cresyl violet. 
A small percentage of cells were labelled positively for proneuropeptide Y  
mRNA, as shown by an increase in the number of silver grains over certain cell 
bodies. However the intensity of labelling was generally much lower than for 
preprosomatostatin mRNA. Scale bar represents 25/xm.
• %
I% J
\  #k ——
■I
Figure 5.1.9 : Primary rat striatal neurone cultures processed for 
acetylcholinesterase staining. A small percentage o f cells stained positively for 
acetylcholinesterase in culture, observed as a brown stain. Again both cell soma 
and dendrites were stained intensely and characteristically the labelled cells 
were much larger with many dendritic processes. Scale bar represents 25^m.
I
Figure 5.1.10 : Primary rat striatal neurone cultures processed for NADPH- 
diaphorase staining. Cultures were incubated with phosphate buffer containing 
NADPH and nitro blue tétrazolium for 1 hour at 37°C. A small percentage of 
cells in culture stained positively for NADPH-diaphorase, which can be seen 
here as a blue stain. Both the cell soma and dendrites stained positively. The 
population of cells that were NADPH-diaphorase positive tended to be large 
with numerous dendritic processes. Scale bar represents 25/im.
Figure 5.1.11 : Adult rat cryostat sections of caudal striatum processed for 
NADPH-diaphorase staining. Sections were incubated with phosphate buffer 
containing NADPH and nitro blue tétrazolium for 1 hour at 37°C. A small 
percentage of cells in adult rat sections stained positively for NADPH- 
diaphorase, seen here as a blue stain. Both cell soma and dendrites stained 
positively. Scale bar represents 25fxm.
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DISCUSSION
5.2 Phenotypic characterisation of rat striatal neurones in primary culture
Striatal neurones in primary culture have already proven to be a useful 
model system for studying the molecular events associated with striatal 
function. The use o f primary cultures may be of particular importance with the 
rapid discovery of newly cloned receptors, many of which are known to be 
expressed in striatal tissue, such as the newly cloned dopaminergic D4 receptor 
(Van Toi et al.. 1991) and serotoninergic 5-HT6 receptor (Monsma et al,. 
1993). In this study we have therefore examined primary striatal cultures for 
the presence of the vaiib us neurochemical phenotypes which are found in the 
rat striatum in vivo. The use of in situ hybridisation, rather than 
immunohistochemistry, allows the unequivocal identification of the pattern of 
gene expression in these cultured neurons.
The specificity of the hybridisation protocol is suggested in various 
pieces of evidence. We have shown repeatedly that in normal tissue, our 
hybridisation sequences allow the specific localization of the mRNA sequences 
to which the probes are complementary (Morris, 1989; Morris et al.. 1990; 
Sirinathsinghji et al.. 1990; Morris and Hunt, 1991; Morris, 1992). The high 
stringency conditions we employ prevent the hybridisation of the probes to any 
related sequences in the tissue. The lack o f any signal in striatal cultures when 
sense probes are used, and the observation that the hybridisation signal with the 
antisense probes can be inhibited competitively by a 25-foId excess of the 
unlabelled oligonuleotide, provide further evidence that the hybridisation 
signals that we detect represent the authentic complementary mRNA.
Previous work has established that a high proportion of cultured striatal 
neurons are GABA-ergic (Messer, 1981; Weiss et al.. 1986; Surmeier et al..
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1988). This is consistent with the in vivo situation. The majority of these 
GABA-ergic neurons in vivo are thought to be projection neurons, where 
GABA coexists with either dynorphins and tachykinins, or enkephalins (Besson 
et al.. 1990). It could therefore be predicted that the cultures should obtain a 
high percentage of neurons expressing the preproenkephalin, preprotachykinin 
and prodynorphin genes.
In primary striatal neuron cultures, it was observed that many neurons 
stained positively with an antiserum raised against met-enkephalin and there 
was negligible cross-reactivity to any of the peptide products of the 
prodynorphin (Proenkephalin B) gene. Since these cells closely resemble those 
demonstrated by Surmeier et al.. (1988), to contain immunoreactive-leu- 
enkephalin, this suggests that these neurons express the pro enkephalin rather 
than the prodynorphin gene. This was confirmed by in situ hybridisation 
analysis using a proenkephalin oligonucleotide. These results indicate that a 
high proportion of cells in these cultures express the proenkephalin phenotype.
An exact determination of the percentage op neurons expressing a 
particular phenotype in vitro is impossible. Although many neurons remain 
spread evenly over the substrate after seeding, other neurons migrate at an 
early stage to form regions where the neurons are clumped together, (Schwartz 
and Simantov, 1988; Surmeier et al.. 1988), and accurate counting cannot be 
performed. However, a rough estimate of the proportion o f neurons containing 
either proenkephalin mRNA or immunoreactive-met-enkephalin in culture 
suggests that enkephalinergic cells are the predominant cell type in vitro, as in 
vivo, although the proportion is rather lower than the 60% of striatal neurons 
that are known to be enkephalinergic in vivo. On the basis of the number of 
cells involved, it is likely that these cultured neurons expressing the 
proenkephalin phenotype are identical to the GABA-ergic cells already 
identified in primary culture (Messer, 1981; Weiss et al.. 1986; Surmeier et al.,
1988).
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A considerable number of neurons in culture were also found to 
expresss preprotachykinin mRNA, although the proportion appears to be 
slightly lower than the proportion which are enkephalinergic. Considering the 
impossibility of making exact determinations o f the percentage o f labelled 
neurons in primary striatal culture, this would be approximately consistent with 
the reports that roughly 40-50% of striatal neurons in vivo contain 
immunoreactive substance P (Besson et al.. 1990). It therefore seems clear that 
neuronal rather than non-neuronal cells are the source of immunoreactive- 
substance P detected in extracts of primary striatal cultures (Kessler, 1986).
In situ hybridisation is not a truly quantitative technique, in the sense 
that the kinetics and equilibrium position of the hybridisation reaction are 
unknown for each oligonucleotide. The absolute levels of a particular mRNA 
species cannot be determined, and so it is not possible to compare the 
abundance of different mRNA species, unless it is assumed that the 
hybridisation reaction has an identical efficiency for each probe/mRNA 
combination. This assumption is likely to be valid, but a formal proof would be 
essentially impossible. If this assumption is made, then the results suggest that 
the neuronal levels of preprotachykinin in cultured striatal neurons are 
markedly lower than the levels of preproenkephalin mRNA. This appears to be 
the situation in vivo (Young et al.. 1986; Sirinathsinghji et al.. 1990), although 
the relative difference between the hybridisation signals with the two probes is 
probably greater in the cultures. Removal of the dopaminergic innervation of 
the striatum In vivo increases the levels o f proenkephalin mRNA and decreases 
the levels of protachykinin mRNA (Young et al.. 1986; Morris et al.. 1989). 
This potentially exaggerated difference (based on the above assumption) 
between the apparent levels of proenkephalin mRNA and preprotachykinin 
mRNA in culture may, if correct, be due to the absence of dopamine in the 
environment o f the cultured neurons.
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We found that no striatal neurons in culture contained detectable levels 
of prodynorphin mRNA. This is in agreement with an earlier study analysing 
extracts o f primary cultures (Vilijn et al.. 1988). This is interesting, when it is 
considered that striatal tachykinins and dynorphins are thought to be located 
predominantly in the same population of neurons (Besson et al.. 1990). The 
presence of neurons expressing the preprotachykinin phenotype in vitro 
suggests that this class of neurons is able to survive under these conditions. It 
may be that some developmental signal, for example the secretion o f a 
particular growth factor, is required for the appearance of the prodynorphin 
phenotype in the cells, and that this signal is not present in our culture medium. 
Alternatively, prodynorphin mRNA may be expressed, but at levels below the 
limit o f sensitivity of the hybridisation reaction. However, this is unlikely, given 
that the protocol is highly sensitive (Morris, 1992).
The medium aspiny neurons which represent only a few percent o f the 
total number o f neurons in the normal striatum, are thought to contain 
somatostatin, neuropeptide Y and NADPH-diaphorase (Vincent and 
Johansson, 1983; Smith and Parent, 1986; Graybiel, 1990). We report here that 
neurons expressing the somatostatin gene are present in primary striatal 
cultures. We also observe many neurons that express the neuropeptide Y gene, 
and in so far as comparisons of the amounts of different mRNA species are 
possible, the neuropeptide Y gene appears to be expressed, at the mRNA level, 
at a lower level than the somatostatin gene. This parallels the situation in the 
normal striatum (Morris, 1989; 1992). Equally, within the limitations outlined 
above, it appears that considerably fewer neurons in culture contain 
somatostatin mRNA or neuropeptide Y mRNA, as compared to proenkephalin 
mRNA.
These results provide the first evidence that neurons in striatal culture 
also contain NADPH-diaphorase. While it has yet to be shown that 
somatostatin mRNA, neuropeptide Y mRNA and NADPH-diaphorase are all
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contained in the same cell in vitro, our data demonstrate that the cultures 
contain neurons expressing each of these phenotypes. It now seems clear that 
the NADPH-diaphorase reaction detects the enzyme responsible for nitric 
oxide synthase (Hope et al.. 1991). Release of nitric oxide from primary striatal 
cultures following glutamate receptor stimulation has recently been described, 
(Marin et al.. 1992). Our results confirm that the origin of this release is likely 
to be neuronal. Nitric oxide is synthesised in the cytoplasm by the nitric oxide 
synthase/NADPH-diaphorase enzyme, and is then thought to diffuse randomly 
across membranes to effect any cells in the surrounding area. The evidence that 
nitric oxide is involved in a number of biochemical and physiological processes 
in the central nervous system, is increasing rapidly (Garthwaite, 1991).
The morphology of the NADPH-diaphorase-positive neurons appears 
to correspond surprisingly closely to the morphologies identifiable in intact 
tissue. The intense Golgi-like staining of the processes of the neurons 
containing NADPH-diaphorase enabled us to ascertain the extent of their 
connections with other cells in the culture wells. In every case, the diaphorase- 
positive neurons gave rise to a complex branching network of fibres covered in 
varicosity-like swellings. This reproduces closely the appearance of intact 
striatal tissue, which is a dense interwoven mesh of diaphorase-positive fibres 
with varicosities. We were able to observe these variscosities in contact with 
unstained neurons. For traditional neurotransmitters, evidence of synaptic 
specialisations, both pre- and post-synaptic, in electron micrographs, would be 
required for evidence of cell-cell communication in culture. However, the non- 
synaptic release of nitric oxide, and its ability to cross cellular membranes, 
means that a rough proximity of NADPH-diaphorase-containing fibres with 
another cell would be sufficient to allow intercellular communication of signals. 
These results therefore provide strong evidence that nitric oxide release from 
these cells may affect other neurons in culture.
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MThe adult intact striatum also contains relatively rare cholinergic cells, 
larger than the other striatal neurons, and thought to be intemeurons (Bolam et 
al., 1984; Phelps et al.. 1985; Graybiel, 1990). In primary striatal culture we 
found that a very small percentage of striatal neurons stained heavily for 
acetylcholinesterase, which is an indication, although not an absolute proof that 
the cells are cholinergic. In other brain regions there are neurons which contain 
acetylcholinesterase, but no choline acetyl-transferase, and therefore do not 
synthesise the transmitter acetylcholine. However, in the striatum in vivo, it 
appears that acetylcholinesterase is expressed only in cholinergic neurons
: ;■(Walker et al.. 1987). The use of acetylcholinesterase as a marker for 
cholinergic neurons has the advantage that, in contrast to choline acetyl- 
transferase-immunostaining, the entire neuritic structure o f the neurons is 
revealed.
The acetylcholinesterase-positive neurons that we observed in culture
were larger than most of the other neurons, consistent with the situation in the
intact striatum. The entire neuropil in normal striatal tissue stains very heavily
for acetylcholinesterase, suggesting that neurites containing acetylcholineterase 
.in vivo are virtually ubiquitous. It was noticeable that a small number of
acetylcholinesterase-positive cells in culture displayed an intricate and
widespread array of neurites, extending potentially to affect large areas of the
culture well. It is therefore possible that this feature of the acetylcholinesterase-
positive neurons in vitro mirrors an aspect of the fimctional cytoarchitecture of
similar neurons in vivo.
The results shown here suggest that both NADPH-diaphorase-positive
and the acetylcholinesterase-positive neurons make extensive connections with 
.other neurons in culture. There is electrophysiological (Misgeld and Dietzel,
1989; Dubinsky, 1989) and biochemical (Weiss et al.. 1986) evidence to 
support the presence of synaptic interactions between cultured striatal neurons.
It should therefore be remembered that any neurotransmitter effects being
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Studied in such cultures may occur trans-synaptically, as well as directly on the 
cells under investigation.
Overall, these results suggest that primary cultures of striatal neurons 
may provide a surprisingly good model o f the intact striatum. Neurons 
expressing proenkephalin mRNA, protachykinin mRNA, somatostatin mRNA 
and neuropeptide Y mRNA are all present, along with neurons staining for 
NADPH-diaphorase and acetylcholinesterase. The only neurotransmitter gene 
that apparently fails to be expressed from the striatal repertoire is the 
prodynorphin gene. Therefore primary cultures are a relatively good model of 
the intact striatum and will provide a suitable model for the identification of 
factors regulating the expression of these genes in culture.
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Chapter 6
Dopaminergic Regulation of Immediate 
Early Genes in vitro
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INTRODUCTION
6.0 Dopaminergic Regulation of Immediate Early Genes In Vitro
Many cell types in the mature central nervous system respond to 
changes in their local neurochemical environment by altering their pattern of 
gene expression (Goodman, 1990; Morris, 1993). These alterations in gene 
expression then persist for some time, allowing the cells to sustain a long-term 
response to the original stimulus. Perturbation of the normal level of 
dopaminergic transmission in the rat striatum, either by the administration of 
neuroleptics, which antagonise the actions of dopamine, or by lesioning the 
nigrostriatal pathway, results in sustained changes in the levels of peptide 
neurotransmitter mRNAs (Bannon et al.. 1986; Merchant and Dorsa, 1993; 
Morris et al.. 1988; Morris and Hunt, 1991; Young et al.. 1986), associated 
with parallel changes in the rate of neuropeptide release (Lindefors et al..
1989).
Immediate early genes encode proteins whose structures fall into a 
number of distinct classes. They are rapidly induced in response to a variety of 
different stimuli such as growth hormones, increased synaptic activity and drug 
administration, and their proteins are thought to bind to specific sites in the 
genome to modulate the rate of transcription of downstream genes (Morgan 
and Curran, 1987; Sheng and Greenberg, 1990). Induction of immediate early 
genes is likely to provide a link between events at the cell membrane and long 
term alterations in neuronal gene expression. The immediate early genes c-fos 
(Morgan and Curran, 1987) and ziE268 (Millbrandt, 1987), also known as 
ergl, Krox 24, and NGFIA, are thought to be involved in functional plasticity 
in rat striatal neurons, in that they are induced in vivo by treatment with 
neuroleptic drugs (Dragunow et aL 1990; Nguyen et al.. 1992; Robertson and
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determine the mechanisms through which dopamine receptors are linked to the
Fibiger, 1992; see also chapterj|). It is therefore of considerable interest to
that glutamate can increase c-fos, c-jun, jun-B, and zifr268 mRNAs by binding 
to selective glutamatergic receptor subtypes in cultured cortical and striatal 
neurons, and this induction is thought to be mediated by the enzyme PKC
regulation of gene expression. A number of different dopamine receptors are 
known to be present in the striatum. The D1 and D5 (Dlb) dopamine receptors 
correspond to the traditional Dl-like receptors (Monsma et al.. 1990; Sunahara 
et al.. 1991; Tiberi et al.. 1991) in that they show high affinity for the agonist 
SKF38393 and the antagonist SCH23390, and low affinity for D2 “selective”
■ :drugs such as quinpirole and eticlopride. Both D1 and D5 receptors aie 
.positively coupled to adenylate cyclase. Therefore the stimulation of Dl-like
receptors results in an increase in intracellular cAMP levels, with the
consequent activation of cAMP-dependent protein kinase (PKA). However,
there is also evidence that Dl-like receptors can be linked to a stimulation of
phospholipase C and consequently protein kinase C (PKC) activation (Felder et
a l, 1989; Mahan et al.. 1990; Frail et al.. 1993). The D2, D3, and D4
dopamine receptors correspond to the traditional D2-like receptor, in that they
show relatively high affinity for the agonist quinpirole and the antagonist
eticlopride, along with low affinity for SKF38393 and SCH23390. The D2 and
D4 receptors are coupled to an inhibition of adenylate cyclase activity (Seeman
and Van Toi, 1993).
At present there is very little evidence on the dopaminergic regulation
of gene expression in striatal neurons maintained in cell culture, although there
is some evidence for neurotransmitter regulated induction of immediate early 
*genes in cell culture conditions. Stimulation of the N-methyl-D-aspartate
receptor in primary cultures of cerebellar neurons has been shown to trigger the 
.induction of c-fos and other immediate early genes (Szekely et a l. 1987;
Szekely et al.. 1989; Szekely et al.. 1990). More recently it has been shown
1
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(Vaccarino et al.. 1992). Several neurotransmitters activate phosphoinositide 
hydrolysis in central nervous system neurons as the first step o f a 
transmembrane signalling cascade that may lead to neuronal circuit modulation 
(Berridge et al.. 1982; Gonzales and Crews, 1984; Battv et al.. 1985; Schoepp 
and Johnson, 1988). Ambrosini and Meldolesi (1989) have shown that 
quisqualate and muscarinic receptor-induced phosphoinositide hydrolysis in 
primary cultures of striatal and hippocampal neurons involves differential 
mechanisms of activation. Activators of the cAMP second messenger pathway 
in primary cultures of neurons from rat cerebral cortex have also been shown to 
induce c-fos and other immediate early gene transcription factors directly 
(Vaccarino et al.. 1993). Indeed, the D1-dopaminergic agonist, SKF38393, 
administered for short time periods, has been demonstrated to increase mRNA 
levels for the immediate early genes c-fos, jun-B, and zifr268 in cortical 
neurons (Vaccarino et al.. 1993). Stimulation of glutamatergic NMDA 
receptors and metabotropic quisqualate receptors in cultured striatal neurons 
has previously been shown to increase the release of arachidonic acid, and 
therefore activate the arachidonic acid cascade (Dumuis at al.. 1988; 1990).
There is little information on the regulation of late response genes in 
cell culture. However, Giraud and colleagues (1991) have demonstrated that 
preproenkephalin gene transcription can be activated by the cAMP-dependent 
protein kinase A and protein kinase C pathways in striatal cell cultures, with the 
use of selective drugs to target the respective enzymes. Similarly, treatment o f  
striatal astrocytes with isoprenql'n^ or with forskolin or 8-bromo-cAMP, agents 
which directly increase intracellular cAMP, have been shown to elevate the 
level of preproenkephalin mRNA (Batter and Kessler, 1991).
Therefore in this study, we have attempted to reproduce the 
dopaminergic stimulation of c-fos and zif/268 gene expression in primary 
cultures o f embryonic rat striatal neurons, in order to identify the intracellular 
pathway(s) and second messenger system(s) involved. As much controversy
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surrounds the location of dopaminergic D1 and D2 receptors in the caudate- 
putamen. Two proposals are currently well supported. Firstly, that the two 
subtypes of dopamine receptor are located on separate populations o f cells, on 
the basis that certain neuropeptides have been colocalised with a particular 
subtype but not the other and secondly that both D1 and D2 subtypes are 
expressed on the same cell. In the following studies we have addressed this 
question using the cultured striatal neuron model.
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RESULTS
6.1 The time course effect of haloperidol on zifr268. iun-B and c-fos mRNA 
levels in cultured rat striatal neurons
Therefore we have investigated the effect of haloperidol on these lEGs in a
Many lEGs including ziF268, jun-B and c-fos are known to be induced 
. .in vivo by the dopaminergic antagonist drug haloperidol (Nguven et al. 1992).
cultured striatal neuron system.
:Neuronal cultures were exposed to dopamine (SjaM) for two days.
Haloperidol (2/iM), when supplemented into the medium, was shown to induce 
.the expression of zifr268 mRNA in vitro in a time-dependent manner. A
dramatic increase in the levels of zifr268 mRNA was observed after 30 minutes,
although a significant induction of zift268 mRNA compared to the levels of
expression at time zero, occurred only after 45 minutes [F(2, 16) = 153.22, p<
0.05] [Figure 6.1.1 ]. This maximal induction of zif/268 mRNA remained
significantly high up to 60 minutes after haloperidol administration, p< 0.05 
.[Figure 6.1.1], and thereafter declined back to basal levels.
A similar, but more gradual induction of jun-B mRNA levels was 
observed with haloperidol (2jaM). The induction of jun-B mRNA levels were 
significantly higher 20 minutes after treatment with haloperidol [ F(2,16) = 
27.46, p= 0.006 p< 0.01 ], than the levels expressed at time zero. A similar 
level o f induction was observed 30 minutes after drug administration, p< 0.01. 
After 45 minutes the expression of jun-B mRNA remained significantly higher 
than at time zero, such that p< 0.05, after which the levels were not
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Figure 6.1.1 : Effect of haloperidol on zifr268 mRNA levels in striatal cultures. 
Haloperidol (2/iM) was added to cultures for 90, 60, 45, 30, 20, 10, and 5 
minute time intervals before fixation in buffered formalin. Results, obtained 
from film autoradiographs, are expressed as mean relative optical density ± 
s.e.m,; n=3. Significance was determined by one-way ANOVA, followed by 
post-hoc Dunnett’s test. * p< 0.05
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significantly induced compared to the levels of jun-B mRNA at time zero (not 
shown).
Haloperidol (2/xM), also had a tendency to increase the levels of c-fos 
mRNA in striatal neuronal cultures, although the increase was generally 
variable, and proved not to be significantly different from the levels expressed 
at time zero (not shown).
6.2 Effect of dopamine receptor activation on the levels of c-fos and zifr268 
mRNA in cultured rat striatal neurons.
The previous experiment established that maximal induction of zifr268 
mRNA occurred 45 minutes after drug application. Since the induction o f jun- 
B mRNA and c-fos mRNA followed a similar pattern, this time point was 
consequently used for all subsequent experiments. The probes used in the 
following studies have all been extensively characterised under the conditions 
used (Wisden et al. 1990). .Nevertheless, the specificity o f each probe used was 
confirmed in a number of preliminary experiments. Hybridisation of sense 
probes labelled to the same specific activity, gave no signal, and addition o f a 
25-fold excess o f unlabelled antisense oligonucleotide to the hybridisation 
buffer completely displaced the hybridisation signal (refer to chapter 5).
The hybridisation signal representing c-fos mRNA was generally low in 
unstimulated cells. In unstimulated cultures a small percentage of neurons were 
labelled for c-fos following treatment with vehicle alone (Hank's balanced salts 
solution).[Figure 6.2.1]. This was assumed similar to the low levels expressed 
in vivo when the cells remain unstimulated. Following treatment with dopamine
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(5^M) a dramatic increase in the hybridisation signal for c-fos mRNA was 
.observed. [Figure 6.2.1], This induction was highly significant compared to the
Ilow levels of c-fos mRNA expressed in vehicle treated cultures [ F(3, 22) =
s18.57, p= 0.0007, p< 0.001 ]. The magnitude of induction was related to the i
concentration of dopamine applied. The levels of c-fbs mRNA were induced by
3^'lOOnM dopamine (not shown) , but a maximal induction was obtained at SfxM
dopamine. Coadministration of the selective D1/D5 receptor antagonist,
SCH23390 (1/aM) with dopamine (5/^M), clearly caused a reduction in the
hybridisation signal due to c-fbs mRNA.. This decrease was demonstrated to be
significantly different from the signal due to dopamine alone [ F (3,22) =18.57,
p< 0.05 ] [Figure 6.2.1]. However ,coadministration of eticlopride (1/xM), the
selective dopamine D2 receptor antagonist, with dopamine proved not to be
significantly different from dopamine alone, but was significantly different fi-om
vehicle alone [ F (3,22) =18.57, p< 0.05 ] [Figure 6.2.1].
A very similar pattern of induction was observed for zifi268 mRNA in a
cultured striatal neurons. Low levels o f zifi268 mRNA were expressed in
vehicle treated cultures, which was assumed similar to the low levels expressed
in vivo when the cells are unstimulated. Addition of a 25-fbld excess of
unlabelled probe to the hybridisation buffer, abolished the hybridisation signal
completely (not shown), confirming specificity of the probe. Dopamine (5/aM),
clearly increased the hybridisation signal due to zif/268 mRNA , and this
increase was significantly different from vehicle alone (n= 8) [ F(3,16) = 12.11,
p= 0.0007, p< 0.001] [Figure 6.2.2]. By coadministering SCH23390 (1/tM)
along with dopamine (5/*M) a dramatic reduction in the hybridisation signal
was observed, such that the reduction was different from dopamine alone [
F(3,16) = 12.11, p< 0.001 ] [Figure 6.2.2]. , Coadministration of
eticlopride (ljuM) with dopamine clearly did not reduce the signal rapAiSAnbunq
Wabtnenb■ths-bfelef zifi268 mRNA compared to dopamine alone, but was significantly different 
from vehicl^alone [ F (3,16) = 12.11, p< 0.001 ] [Figure 6.2.2].
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Figure 6.2.1 : Effect o f dopamine receptor stimulation on c-fos mRNA levels in 
striatal cultures. Cultures were treated with vehicle or dopamine (5/^M), or 
treated by coadministration of dopamine / SCH23390 (l|iM ), or
coadministration of dopamine / Eticlopride (1/tM) for 45 minutes. Results 
,obtained from film autoradiographs, are expressed as mean relative optical 
density units x 100 +s.e.m. from the number o f different cultures shown in 
parentheses. * p< 0.05, *** p< 0.001, relative to vehicle alone; +++ p< 0.001 
relative to dopamine alone.
Figure 6.3.1 : Effect of dopamine D1 receptor stimulation on c-fos mRNA 
levels in striatal cultures. Cultures were treated with vehicle, or SKF38393 
(l^M), or treated by coadministration of SKF38393 / SCH23390 (IjuM), or 
coadministration of SCH23390 / Eticlopride (IjaM) for 45 minutes. Results, 
obtained from film autoradiographs, are expressed as mean relative optical 
density units x 100 +s.e.m. from the number of different cultures shown in 
parentheses. * p< 0.05, *** p< 0.001, relative to vehicle alone; -H-+ p< 0.001 
relative to SKF38393 alone.
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Figure 6.2.2 : Effect of dopamine receptor stimulation on zifr268 mRNA levels 
in striatal cultures. Cultures were treated with vehicle, or dopamine (5jnM), or 
treated by coadministration of dopamine / SCH23390 (1/iM), or
coadministration of dopamine / Eticlopride (1/^M) for 45 minutes. Results are 
expressed as mean number of pixels / unit area +s.e.m. from the number o f  
different cultures shown in parentheses. *** p< 0.001, relative to vehicle alone; 
p< 0.001, relative to dopamine alone.
Figure 6.3.2 : Effect of dopamine D1 receptor stimulation on zifr268 mRNA 
levels in striatal cultures. Cultures were treated with vehicle, or SKF38393 
(1/iM), or treated by coadministration of SKF38393 / SCH23390 (l^M), or by 
coadministration of SKF38393 / Eticlopride (l^M) for 45 minutes. Results are 
expressed as mean number of pixels / unit area +s.e.m. from the number of 
different cultures shown in parentheses. *** p< 0.001, relative to vehicle alone; 
+++ p< 0.001, relative to SKF38393 alone.
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■'i6.3 Effect of D1/D5 dopamine receptor stimulation on the levels o f c-fos and
'1'
zif/268 mRNA in cultured striatal neurons
#
Low levels of both c-fos and zif/268 mRNA were expressed in vehicle 
treated cultures. Following the addition of the D1/D5 receptor agonist,
SKF38393 (1/xM) a dramatic induction of c-fos mRNA was observed, and this 
increase was significantly different from vehicle alone [F (3,26) = 33.83, p=
0.0006, p< 0.001 ] [Figure 6.3.1]. Similarly, treatment with SKF38393 (1/aM) 
caused a massive induction of zif/268 mRNA in these cultures [F (3,26) =
33.83, p< 0.001] [Figure 6.3.2, 6.4.3]. SCH23390 (1/xM) when coadministered
with SKF38393, was demonstrated to reduce the hybridisation signal for both /■'Ï
c-fos and zifr268 [Figure 6.4.3] respectively. This decrease in the hybridisation 
signal was significantly different from SKF38393 alone for both c-fos [ F (3,26)
= 33.83, p< 0.001 ] [Figure 6.3.1] and zifr268 [ F (3,26) = 33.83, p< 0.001]
[Figure 6.3.2, 6.4.3]. However, coadministration of eticlopride (IjaM) with 
SKF38393 was shown to cause an induction of c-fos mRNA [ F (3,26) =
33.83, p< 0.05 ] [Figure 6.3.1] and zif/268 mRNA [ F (3,26) = 33.83, p<
0.001 ] [Figure 6.3.2, 6.4.3], compared to vehicle alone (n= 14), but there was 
no significant decrease in the signal when compared to SKF38393 alone (n= 8).
In every case the increase in silver grain density was found to occur 
over the smaller, more intensely counterstained cells in the cultures. These were 
identified in preliminary immunocytochemical experiments as neurons. Despite 
a large percentage of neurons being labelled following application of 
dopaminergic agonists, there were still many neurons that did not show a
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significant accumulation of silver grains. No increases in silver grain density 
were detected over the larger, more weakly counterstained non-neuronal cells.
6.4 Effect of inhibition of protein kinase A on c-fos and zif/268 mRNA levels 
in striatal cultures
The second messenger systems involved in the induction of the lEGs c-
fos and zif/268 mRNA were investigated using selective inhibitors of
serine/threonine protein kinases. The selective protein kinase A inhibitor,
KT5720 (2jlcM) (Kase et al.. 1987), when applied alone to striatal cultures had
no effect on the expression o f either lEG when compared to vehicle treated
cultures (not shown). However pretreatment of the cultures for 30 minutes
with KT5720, prior to the addition of SKF38393 (IjuM) caused a small but
significant reduction in the ability of SKF38393 to induce c-fos mRNA levels [
F (3,26) = 14.23, p= 0.0033, p< 0.01 ] [Figure 6.4.1, 6.3.4]. In the presence of
KT5720, the levels of c-fos mRNA due to indirect stimulation via SKF38393,
were still significantly higher [ F (3,26) = 14.23, p<0.001 ], than the levels
expressed in vehicle alone. Pretreatment with a relatively non-selective inhibitor
of all protein kinases, H7 (50^M), caused a more dramatic reduction in the
tohybridisation signal due^the induction of c-fos mRNA by SKF38393 [ F (3,26) 
= 14.23, p< 0.001 ] when compared to SKF38393 alone [Figure 6.4.1]. This 
information suggests the involvement of a protein kinase other than protein 
kinase A.
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Figure 6.4.1 : Effect of inhibition of protein kinase A on c-fos mRNA levels in 
striatal cultures. KT5720 (2^M), or H7 (50^M) or vehicle, were added 30 
minutes prior to treatment with SKF38393 for 45 minutes. Results are
expressed as mean number of pixels / unit area + s.e.m. from the number o f  
different cultures shown in parentheses. *** p< 0.001, relative to vehicle alone; 
++ p< 0.01, +-H- p< 0.001, relative to SKF38393 alone.
Figure 6.4.2 : Effect of inhibition of protein kinase A on zif/268 mRNA levels 
in striatal cultures. KT5720 (2/iM), or H7 (50/xM), or vehicle were added 30 
minutes prior to treatment with SKF38393 (l^M), for 45 minutes. Results are 
expressed as mean number of pixels / unit area + s.e.m. from the number of 
different cultures shown in parentheses. * p< 0.05, *** p< 0.001, relative to 
vehicle alone; -H -+  p< 0.001, relative to SKF38393 alone.
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Figure 6.4.3 : Induction of zif^268 mRNA by Dl-like dopaminergic agonists. 
Cultured rat striatal neurones are shown following hybridisation with the probe 
to detect ziC^ 268 mRNA. Black silver grains overlying counterstained cell 
bodies represent the hybridisation signal. Cells were treated \\dth (a) vehicle 
(HESS) (b), SKF38393 (l^M) (c) SKF38393 (1/iM) + eticlopride (1/xM), (d) 
SKF38393 (1/iM) + SCH23390 (1/iM), (e) SKF38393 (l/^M) after 
pretreatment with KT5720 (2;uM). Scale bar represents 20/im.
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Pretreatment of the cultures with KT5720 (2/tM), dramatically inhibited 
the ability of SKF38393 to induce zif/268 mRNA by approximately 90%. This 
decrease in signal was shown to be significantly different from SKF38393 
treatment alone, such that F (3,16) =66.40, p= 0.00076, p< 0.001, [Figure 
6.4.2, 6.4.3]. Similarly, pretreatment with H7 (SOfiM) caused a significant 
reduction in the levels of zif/268 mRNA due to stimulation by SKF38393 [ F 
(3,16) =66.40, p< 0,001 ] [Figure 6.4.2].
:'
I6.5 Effect of inhibition of protein kinase C on the levels of c-fos and zif/268 1
mRNA in rat striatal cultures
From the previous experiment, it is clear that the role o f protein kinase 
enzymes in the induction of c-fbs and of zif/268 mRNA is relatively complex.
Therefore we went on to investigate the role of protein kinase C (PKC) in these 
responses using the selective PKC inhibitor, calphostin C (Bruns et al.. 1991).
This PKC inhibitor has been reported to be activated only by exposure to light 
(Bruns et al, 1991).
Initially the efficiency of PKC inhibition in striatal cultures was 
monitored by observing the ability of calphostin C to reduce the activation of c- 
fbs and zif/268 gene expression by phorbol-12-myristate-13-acetate (PMA). A 
significant induction in the levels of c-fbs mRNA [ F (2,13) = 23.42, p= 0.007,
SiIp< 0.01 ] [Figure 6.5.1] and zif/268 mRNA [ F (2,9) = 36.19, p= 0.0006, p<0.001 ] [Figure 6.5.3], compared to treatment with vehicle alone,were 
.observed following treatment with lOOnM PMA. Pretreatment for 30 minutes 
with the selective PKC inhibitor, calphostin C, caused a marked reduction in 
the levels of c-fbs and zifi268 mRNA (approximately 70%). The decrease in c-
Figure 6.5.1: Eftect of calphostin C on the phorbol ester-induced expression o f  
c-fos mRNA in striatal cultures. Calphostin C (ImM), or vehicle were added 30 
minutes prior to treatment with phorbol-12-myristate-13-acetate (10"^M) for 
45 minutes. Results obtained from film autoradiographs, are expressed as mean 
relative optical density units x 100 +s.e.m..from the number of different 
cultures shown in parentheses. ** p< 0.01, *** p< 0.001, relative to vehicle 
alone; + p< 0.05 relative to phorbol-12-myristate-13-acetate alone.
Figure 6.5.2 : Effect of calphostin C on the SKF3 8393-induced expression of 
c-fos mRNA in striatal cultures. Calphostin C (IfxM), or vehicle were added 30 
minutes prior to treatment with of SKF38393 (l/xM) for 45 minutes. Results, 
obtained from film autoradiographs, are expressed as mean relative optical 
density units x 100 +s.e.m. from the number of different cultures shown in 
parentheses. *** p< 0.001, relative to vehicle alone; +++ p< 0.001 relative to 
SKF38393 alone.
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Figure 6.5,3 : Effect of calphostin C on phorbol ester-induced zifr268 rhRNA 
levels in striatal cultures. Calphostin C or vehicle were added to the
cultures 30 minutes prior to treatment with phorbol-12-myristate-13-acetate 
(10"^M) for 45 minutes. Results, obtained from film autoradiographs, are 
expressed as mean relative optical density units x 100 +s.e.m. from the number 
of different cultures shown in parentheses. *** p< 0.001, relative to vehicle 
alone; + p< 0.05, relative to phorbol-12-myristate-13-acetate alone.
Figure 6.5.4 : Effect of calphostin C on the SKF38393-induced expression of 
2dfr268 mRNA levels in striatal cultures. Calphostin C (l/tM), or vehicle were 
added 30 minutes prior to treatment with SKF38383 (1/iM) for 45 minutes. 
Results, obtained from film autoradiographs, are expressed as mean relative 
optical density units x 100 +s.e.m. from the number of different cultures shown 
in parentheses. *** p< 0.001, relative to vehicle alone.
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6.6 Effect of quinpirole on c-fos and zif/268 mRNA expression in cultured rat 
striatal neurons
Low levels of c-fos and zifr268 mRNA were expressed in vehicle 
treated cultures compared to the highly significant induction of both c-fos 
mRNA [ F (3,19) = 33.14, p= 0.0006, p< 0.001] [Figure 6.6.1] and zifr268 
mRNA [ F(3,16) = 28.23, p== 0.0009, p< 0.001) [Figure 6.6.2] after SKF38393
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fbs mRNA levels was shown to be significantly different from cultures treated
■with phorbol ester alone [ F (2,13) = 23.42, p< 0.05 ] [Figure 6.5.1], and 
similarly the reduction in zifr268 mRNA levels was also significantly different 
from phorbol ester stimulated cultures alone [ F (2,9) = 36.19, p< 0.05 ]
[Figure 6.5.3].
As in previous experiments, SKF38393(l/iM) was shown significantly 
to induce the expression of c-fos mRNA [ F (2,17) = 36.06, p= 0.00033, p<
0.001 ] [Figure 6.5.2]. Following pretreatment with calphostin C (I/liM) for 30 
minutes,the ability o f SKF38393 to induce the c-fos gene was
dramatically inhibited. This reduction was demonstrated to be significantly 
different from SKF38393 treatment alone [ F (2,17) = 36.06, p< 0.001] [Figure
6.5,2], such that the levels o f c-fos mRNA were not significantly different from 
basal levels. The expression of zifr268 mRNA was also shown to be increased 
to significant levels after SKF38393 (l^tM) treatment [ F (2,12) = 37.14, p=
0.00086, p< 0.001 ] [Figure 6.5.4], as in previous experiments. However, 
pretreatment with calphostin C (l/^M) was unable to cause a significant 
reduction in the increase in zif/268 mRNA after treatment with SKF38393 
[Figure 6.5.4].
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treatment. Coadministration of SKF38393 (IjuM) together with quinpirole 
(1/xM), the selective D2 dopamine receptor agonist, caused a marked fall in the Ihybridisation signal representing c-fbs mRNA, due to SKF38393 treatment. This 
decrease was significantly different fi'om SKF38393 alone [ F (3,19) = 33.14, p<
0.01 ] [Figure 6.6.1]. A similar suppression of the hybridisation signal for zifr268
%mRNA was observed when quinpirole was coapplied with SKF38393, and this
■!|
was significantly different fi'om cultures treated with SKF38393 alone [ F (3,16)
■= 28.23, p< 0.001 ]. [Figure 6.6.2]. Quinpirole (IjuM) when applied alone had
-no effect on the levels of zif/268 mRNA expressed in these cultures [Figure
6.6.2]. However, the levels of c-fbs were slightly increased in the presence of î
quinpirole alone. This increase was shown to be significantly different from 
vehicle treated cultures [ F (3,19) = 33.14, p< 0.05 ] [Figure 6.6.1].
Figure 6.6.1: Effect o f quinpirole on the SKF38393-induced expression o f c- 
fos mRNA levels in striatal cultures. Quinpirole (IjuM), or vehicle was added 
30 minutes prior to treatment with SKF38393 (1/aM), for 45 minutes. Results, 
obtained from film autoradiographs, are expressed as mean relative optical 
density units x 100 + s.e.m. from the number of different cultures shown in 
parentheses. * p< 0.05, *** p< 0.001, relative to vehicle alone; +++ p< 0.001, 
relative to SKF38393 alone.
Figure 6.6.2 : Effect of quinpirole on the SKF38393-induced expression of 
zifr268 mRNA levels in striatal cultures. Quinpirole (ImM), or vehicle were 
added 30 minutes prior to treatment with SKF38393 (ImM), for 45 minutes. 
Results, obtained from film autoradiographs, are expressed as mean relative 
optical density units x 100 + s.e.m. from the number of different cultures shown 
in parentheses. *** p< 0.001, relative to vehicle alone; -H4- p< 0.001, relative 
to SKF38393 alone.
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Initially it was necessary to determine the time course of induction o f
DISCUSSION
the immediate early genes under investigation. Previous in vivo studies have 
suggested that peak induction of the immediate early genes c-fos and zifr268 fi::;
mRNAs occurs thirty to sixty minutes after the initial injection of both 
psychostimulants or neuroleptic drugs in vivo (Robertson et al.. 1989; Cole et 
al.. 1992; Nguyen et al.. 1992; Bhat et al.. 1992). In agreement with this our 
results show that the immediate early gene zif/268 is maximally induced in
primary culture approximately forty-five minutes after the addition of 
haloperidol to the culture medium. The rise in zif/268 mRNA levels in vivo, has
been shown to be apparent as early as fifteen minutes after the injection (Cole 
et al.. 1992). The lack of an induction of zift268 mRNA at early time points in 
vitro, is likely to reflect differences in the neuronal environment such as 
temperature, and thus may be responsible for delayed signal transduction 
processes. Similar to the in vivo situation (Cole et al.. 1992; Nguyen et al.. 
1992), zifi268 mRNA levels in vitro, decline back to basal levels by 
approximately three hours.
6.7 Dopaminergic Regulation of Immediate Early Genes In Vitro
:'r
In this study we have demonstrated that exposure of rat striatal primary 
cultures to dopamine resulted in dramatic increases in the levels of c-fos and 
zift268 mRNAs. The use o f in situ hybridisation to monitor these changes has 
the advantage that the cell types where the changes in gene expression occur 
can be identified with some confidence. It is worth noting that despite the small
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proportion of non-neuronal cells in such cultures, some pharmacological agents 
can stimulate dramatic increases in immediate early gene expression in the glial 
cells. The induction o f c-fos and zifr268 mRNA levels that we observed in 
these studies, following dopamine receptor stimulants appears to occur in the 
same population of cells that exhibit immunoreactivity for neuron-specific 
enolase. Therefore this induction of immediate early gene expression is 
occurring in the striatal neurons.
'
We have previously shown that a high proportion of striatal neurons in 
primary culture express either the proenkephalin gene or the preprotachykinin 
gene, and therefore are likely to represent the medium spiny projection neurons 
characterised in the mature striatum (Graybiel, 1986). Intemeurons are thought 
to constitute only a small percentage of the number of neurons in the normal 
striatum (Graybiel, 1986), and we have shown earlier that the corresponding 
neurochemical phenotypes represent a similarly small proportion of striatal 
neurons in primary striatal culture. The high proportion o f neurons containing 
c-fos mRNA or zifr268 mRNA in these experiments after dopaminergic
stimulation suggests that immediate early gene induction is taking place in the 
culture counterpart of the medium spiny neuron. This is consistent with 
evidence suggesting that the induction of immediate early gene expression in 
striatal neurons in vivo following manipulation of the level o f dopaminergic 
activity occurs in medium spiny neurons (Dragunow et al.. 1990; Graybiel et 
al., 1990; Robertson et al.. 1990; Robertson et al.. 1992 ). The induction of c- 
fos or zifi268 following dopamine stimulation was observed with a doseage 
ranging from lOOnM to 5/xM, concentrations which would be expected to 
stimulate all dopamine receptor subtypes.
In rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal 
pathway, there is evidence that the induction of c-fos by SKF38393 occurs 
primarily in the medium spiny neurons expressing the preprotachykinin gene 
and projecting to the substantia nigra (Robertson et al.. 1989; Robertson et al..
S1992). The number of neurons showing increased c-fos expression in culture
after treatment with the dopaminergic D1 agonist, SKF38393, means that the 
. . . .preprotachykinin-containing neurons must be involved, but we would not rule 
out the possibility that enkephalinergic neurons in culture also respond to 
SKF38393 with an increased level of c-fos expression.
Since the addition of SKF38393 to the culture medium was able to 
reproduce the dopaminergic stimulation of c-fos and zift268 mRNA, but the
:
addition of quinpirole had no effect on zift268 and a minor inductive effect on
c-fos, it is most likely that tliis response is mediated by stimulation of a D l/ D5-
like receptor. This is further supported by the observation that SCH23390, the 
.D l selective antagonist, was able to attenuate the inductive effect of
.SKP38393, but the selective D2 antagonist, eticlopride was unable to effect
these responses. This is in accordance with previous work in vivo, which also 
.suggests that the induction of c-fos and zif/268 after administration of
dopaminergic agonists is likely to occur via stimulation of Dl-like dopamine
receptors (Robertson et al.. 1989; Robertson et al.. 1990; Graybiel et al.. 1990;
Amauld et al.. 1993; Cole et al.. 1992; Mailleux et al.. 1992; Moratalla et al..
1992). The effects of dopaminergic agonists on immediate early gene
expression in primary cultures reported here therefore appedr to reflect the
corresponding in vivo actions very closely.
. . .Significant increases in c-fos and zift268 mRNA levels in striatal 
neurons were detected following treatment with SKF38393 at concentrations 
between 30nM and SfxM. The EC50 value obtained is very close to the Kq 
values reported for the binding of SKF38393 to striatal membranes (Seeman 
and Van Toi, 1993). This suggests that there is a low receptor reserve for 
SKF38393 in stimulating these changes, consistent with the biochemical 
evidence that, in striatal tissue, SKF38393 acts as an agonist with only 
moderate efficacy (Setler et al.. 1978).
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It is clear that, in a number of different cell types, increased 
transcription of both the c-fos and zifr268 genes can be observed following 
activation o f either protein kinase A (PKA) or protein kinase C (PKC) (review 
by Sheng and Greenberg, 1990). This is in line with the presence o f cyclic 
AMP- responsive enhancers and phorbol ester- responsive enhancers in the 
promoter regions of these genes. The biochemical evidence suggests that D l-  
like dopamine receptors can be coupled either to stimulation of adenylate 
cyclase or phospholipase C, with consequent activation of PKA or PKC 
respectively (Mahan et al.. 1990; Monsma et al.. 1990; Sunahara et al.. 1991; 
Tiberi et al.. 1991; Frail et al.. 1993). The dopaminergic stimulation of c-fos 
and zifr268 gene expression in striatal neurons could therefore potentially be 
mediated via either PKA or PKC.
Highly selective inhibitors are now available which allow the 
intracellular actions of different serine / threonine kinases to be distinguished. 
The highly selective inhibitor of PKA, namely KT5720 (Kase et al.. 1987), 
blocked the ability of SKF38393 to stimulate zifr268 expression by 90%. The 
Ki value for KT5720 against PKA is approximately 60nM, whereas its Ki value 
against other kinases such as PKC is greater than 2/xM (Kase et al.. 1987). The 
concentration of KT5720 used in this study would therefore'be predicted to 
cause a 95% inhibition of PKA and less than 50% inhibition of PKC. The 
degree of attenuation of the effect of SKF38393 on zifr268 induction observed 
with KT5720 therefore strongly implicates protein kinase A in this effect.
Calphostin C is a highly selective inhibitor of PKC, which shows 
negligible activity against other serine/ threonine kinases (Kobayashi et al.. 
1989). The concentration of ljuM calphostin C used in these experiments, 
should consequently inhibit PKC by more than 90%, with only minimal effects 
on other serine/ threonine kinases. However, an important aspect concerning 
the use o f calphostin C, is that its activity is dependent on exposure to light 
(Bruns et al., 1991). We observed that treatment of the cultures with the
153
phorbol ester, phorbol-12-myristate-13 acetate (PMA), resulted in a clear 
induction of both c-fos and zifr268 mRNA levels compared to controls. 
Pretreatment with calphostin C caused a 70% decrease in the ability o f PMA to 
induce expression of both c-fos and zifr268 mRNA levels. While this may imply 
that the activation of calphostin C was not quite maximal in our protocol, it 
provides a definite indication o f the degree of PKC inhibition achieved.
Consistent with the above evidence that the actions o f dopaminergic 
agonists on zifi268 expression were mediated entirely by PKA, calphostin C 
pretreatment had no significant effect on the stimulation of zifi268 mRNA 
levels by SKF38393. In contrast, calphostin C pretreatment caused a dramatic 
reduction in the ability o f SKF38393 to enhance c-fos expression. The 
relatively greater inhibition by calphostin C of the SKF38393 response as 
compared to the PMA response may simply reflect a sub-maximal activation of 
PKC by the endogenous intracellular pathway, subsequent to stimulation of 
Dl-like dopamine receptors. It is of some interest that the SKF38393-induced 
increase in c-fos gene expression was also reduced by inhibition of PKA. This 
implies that PKA activity also participates in the Dl-dopaminergic induction of 
c-fos expression.
These results therefore suggest that stimulation of c-fos expression by 
SKF38393 involves mainly PKC, but with an additional contribution fi'om 
PKA. Conversely, the stimulation of zif/268 gene expression by SKF38393 
appears to proceed almost entirely via PKA. However, it is important to 
remember that there are may be a further level of complexity involved in these 
effects, in that phosphorylation of cyclic AMP-response element binding 
proteins by PKA or PKC may affect their relative affinity for the cyclic AMP- 
reponsive and phorbol ester-responsive enhancers (Merino et al.. 1989). In 
other words, even when only a single kinase is activated, its ability to modulate 
gene expression may be affected by altering the basal level of activity of 
another kinase.
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Nevertheless, some important conclusions can be drawn from these 
results. The inratcellular pathways coupled to induction of lEGs vary in 
different cell types. It is clear that in non-neuronal cells and cell lines, both 
PKA and PKC are powerfril stimulants for the induction of both c-fos and 
zifr268 (reviewed by Sheng and Greenberg, 1989). The information available 
on neuronal cell responses is rather scarce, but it appears that in primary 
cultures of cerebellar granule cells, c-fos expression can be stimulated by PKC, 
but not by PKA (Szekely et al.. 1989). In contrast, in primary cultures of 
cerebral cortical neurons, activation o f PKA can produce a mild enhancement 
o f expression of the c-fos and zif/268 genes (Vaccarino et al.. 1993). Our 
results represent, to the best of our knowledge, the first indication that both 
PKA and PKC can be coupled to stimulation of c-fos and zif/268 expression in
striatal neurons. Furthermore, our data suggests that the population of Dl-like 
dopamine receptors on striatal neurons includes receptors coupled to both 
adenylate cyclase and to phospholipase C. Until now, the evidence for coupling 
of Dl-like receptors in the central nervous system to phospholipase C has been 
derived from in vitro experiments using translated endogenous and exogenous 
nucleic acids (Mahan et al.. 1990; Monsma et al.. 1990; Frail et al.. 1993), or 
from extrapolation of results from kidney cells (Felder et al.. 1989). The 
evidence reported here therefore provides a frinctional confirmation of the 
molecular evidence that Dl-like receptors on striatal neurons can couple to 
both second messenger systems.
The different relative contribution of PKC- and PKA-dependent
pathways to the dopaminergic induction o f c-fos and zifr268 expression may
have implications for the regulation of striatal gene expression by other
neurotransmitters. For example a receptor negatively linked to adenylate
cyclase might act to suppress zifr268 expression more than c-fos expression. It
appears that, when activation o f both PKC and PKA occurs in striatal neurons, 
.the rate of zif/268 transcription may be more sensitive to changes in PKA
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activity, while the rate of c-fos transcription may be more sensitive to changes 
in PKC activity. In the light of our results, investigations of the second 
messenger systems involved in the regulation of immediate early gene 
expression by other neurotransmitter receptors are clearly of some importance.
While we have shown that dopamine and SKF38393 are able to exert a 
powerful stimulatory influence on striatal immediate early gene expression by 
activating Dl-like dopamine receptors, we also detected a relatively small 
enhancement o f c-fos expression following treatment with the selective D2-like 
agonist quinpirole. This effect was specific for the c-fos gene, in that quinpirole 
did not affect zifr268 expression. At present the in vivo information suggests 
that D2-like agonists should act to supress immediate early gene expression. 
However, there are thought to be a relatively small number o f D3 receptors in 
the rat striatum, and quinpirole is known to be an effective agonist at D3 
receptors (Sokoloff et al.. 1990). It has recently been reported that stimulation 
of D3 dopamine receptors can activate c-fos in a transfected cell line (Pilon et 
al.. 1994). Our results raise the interesting possibility that stimulation of D3 
receptors may activate c-fos gene expression in a population of striatal neurons. 
However, further work would be necessary to expolre this possibility.
We also report that activation of D2-like dopamine receptots by quinpirole 
reduces the stimulation o f c-fos and zif/268 expression by SKF38393. Since the 
in vivo evidence suggests that tonic activity at D2-like receptors suppresses 
immediate early gene expression, (Dragunow et al.. 1990; Nguven et al.. 1992; 
Robertson and Fibiger, 1992) this action of quinpirole conforms more closely to 
expectations. There has been considerable debate as to whether individual striatal 
neurons express both Dl-like and D2-like dopamine receptors. Based on an 
inability to detect D l receptor mRNA and D2 receptor mRNA in the same 
population of neurons by in situ hybridisation (Gerfen et al.. 1990; Le Moine et 
al., 1991), it has been argued that these two receptor types are not colocalised in 
striatal neurons. In contrast functional and immunochemical evidence suggests
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%that medium spiny neurons contain both D l and D2 receptors (Lester et al..
1993; Surmeier et al.. 1992; Larson and Ariano, 1994).
Our results have demonstrated that quinpirole can act functionally to
antagonise the effects of SKF38393 on striatal neurons. If it is assumed that
ySKF38393 and quinpirole are not acting trans-synaptically in our studies, then
the data appears to confirm the coexpression of Dl-like and D2- like receptors 
in the same neuronal population. There is evidence that striatal neurons in 
primary culture form functional synapses (Pin et a l. 1986; Weiss et al., 1986:
Dubinsky, 1989; Misgeld and Dietzel, 1989). However, the synapses appear to 
be predominantly GABAergic (Pin et al.. 1986; Misgeld and Dietzel, 1989), so 
that an indirect action of quinpirole to inhibit synaptic activity would be 4
predicted to enhance immediate early gene induction rather than to suppress it. 4
Furthermore we have found that bicuculline does not influence c-fbs or zifr268 4
mRNA levels (data not shown), suggesting that intrinsic GABAergic activity is 
not a major factor regulating immediate early gene expression in striatal 
neurons. Our results therefore lend further weight to the theory that medium 
spiny neurons express both Dl-Iike and D2-like dopamine receptors, and that 
these two receptor classes are in functional opposition. ,
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Chapter 7
Antisense Oligonucleotide Strategies
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INTRODUCTION
7.0 Antisense Oligonucleotides
Single stranded oligonucleotides, complementary to a specific mRNA
are called antisense oligonucleotides. Several investigators have used "antisense
strategy" to block the synthesis of specific proteins (review by Dolnick, 1990;
Vand der Krol et al.. 1988). Although the exact mechanism of action of antisense
oligonucleotides is unknown, they can achieve a translational arrest of a target 
. . .mRNA when hybridisation occurs in vivo or in a cell-free translation system.
Effective anti sense oligonucleotides are generally of short length (15-20 bases).
It is believed that this length is short enough to be taken up by cells, but long
enough to provide specificity of binding to a unique base sequence o f mRNA
(Zamecnik and Stephenson, 1978; Zamecnik et al.. 1986; Holt et al.. 1988; Van
der Krol et al.. 1988; Dolnick, 1990). There is current evidence suggesting that
the mechanism of oligonucleotide uptake is predominantly fluid-phase
endocytosis (pinocytosis) (Stein and Cheng., 1993) which may be initiated by
receptor-mediated recognition (Yakubov et al.. 1989). The 'mechanisms of
potential oligonucleotide interactions with target nucleic acids are very complex.
According to the most popular theories, the antisense oligonucleotides exert
their effects by inducing translational arrest of protein synthesis either by
stimulating ribonuclease H-mediated degradation (Walder and Walder, 1988) or
preventing the translocation of the ribosome along the targeted mRNA sequence
(Boiziau et al.. 1991).
Two types of antisense oligonucleotides are presently in use as experimental 
.tools, either the unmodified phosphodiester oligonucleotides or the nuclease 
resistant phosphorothioate analogues. Different cell types have been shown to 
differ greatly with respect to oligonucleotide uptake as well as oligonucleotide
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degradation. It has been suggested that many neuronal systems have a very low 
capacity to degrade oligonucleotides and that they are therefore amenable to 
treatment with either phosphodiester oligonucleotides or nuclease-stable 
analogues (Wahlestedt et al.. 1993; Standifer et al.. 1993; Akabayashi et al.. 
1994). It has previously been shown that phosphodiester oligonucleotides can 
enter cultured neurons at a concentration of up to 5% in the media (Caceres and 
Kosik, 1990). Effective treatment with antisense oligonucleotides is entirely 
dependent on the gene type under study and the turnover rate o f the protein. In 
general, for receptor synthesis inhibition a minimum treatment time of two to 
five days has been shown necessary (Wahlestedt et al.. 1993; Erlinge et al.. 1993; 
Standifer et al.. 1993).
The potential uses of antisense oligonucleotides has gradually become 
clear and a considerable focus on experimental use is currently in progress. In 
the past decade antisense oligonucleotides have been effective in inhibiting 
herpes simplex virus replication (Zamecnik and Stephenson, 1978) and in 
blocking the synthesis of human immunodeficiency viral proteins (Zamecnik et 
al-, 1986). The anti sense strategy has also been used in studying the function of 
cellular oncogenes and other proteins on cell proliferation and differentiation in 
vitro (Holt et al.. 1988; Wickstrom et al.. 1988: Becker et a l. i989; Tortora et 
ai., 1990; Maier et al.. 1990; Venturelli et al.. 1990; Wang et al.. 1992). In 
clonal cell lines antisense oligonucleotides have been used to target specific 
proteins involved in second messenger systems (Wagner et al.. 1992). An 
antisense oligonucleotide has also been used against the NMDA receptor 
complex preventing NMDA receptor channel formation and functionally 
reducing neurotoxicity elicited by NMDA receptors in vitro (Wahlestedt et al..
1993). Both the muscarinic M2 and GABAg receptor proteins have been 
successfully decreased by more than 50% using antisense oligonucleotides and 
thus has eliminated the ability of these receptors when stimulated to inhibit 
cyclic AMP formation (Holpainen and Wojcik, 1992). Only a few reports have
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induction of both c-fos and zif/268 rhRNA, in striatal neurons, after treatment 
with SKF38393, 
receptor subtypes.
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shown the effectiveness o f antisense oligonucleotides in primary cultured 
neurons (Caceres and Kosk, 1990; Listerud et al.. 1991).
Direct administration o f antisense oligonucleotides in vivo has recently 
proved effective against certain lEGs and receptor proteins. Direct infiision 
into the striatum of an antisense oligonucleotide against the lEG c-fos, has been 
shown to reduce amphetamine-induced production of fos-like 
immunoreactivity, without affecting zifr268 expression (Chiasson et al.. 1992).
Similarly, the ability of cocaine to induce c-fos protein in striatum and also
■VÎ
locomotor stimulation was blocked when an antisense oligonucleotide against 
c-fbs was injected into the nucleus accumbens (Heilig et al.. 1993). Zhang and
Creese (1993) have shown that an intracerebroventricular infiision of D2 Iantisense selectively decreases striatal D2 receptors by 50% in the rat, while |
■not effecting D l, muscarinic and 5-HT2 receptor proteins. Direct infusion of
iD2 antisense has also been shown to inhibit rotational behaviour induced by 
quinpirole, aD2 agonist, but not that induced by the D l agonist SKF38393, or A
the muscarinic agonist oxotremorine in the striatum of rats previously treated |
Iwith 6 -hydroxy dopamine (Weiss et al.. 1993). The use of antisense strategy 
has also revealed a possible new subtype of D2 receptor on the basis of 
functional properties (Valerio et al.. 1994).
The aim of these experiments was therefbre to attempt to identify the 
functional dopamine receptor subtype, whose stimulation is involved in the
4ia non-selective agonist fbr both D l and D5 dopamine
RESULTS
7.1 Effect of blockade of dopamine D1 and D5 receptor synthesis on the levels 
of the lEGs c-fbs and zi£ 2^68 mRNA using antisense oligonucleotide strategies 
in rat striatal neuron cultures
The use of antisense oligonucleotides to arrest the translation of 
receptor mRNAs and thus reduce receptor synthesis has recently been 
employed to investigate receptor mediated responses. In this study we were 
interested in the nature of the receptor(s) involved in the induction o f c-fbs and 
zif'268mRNA after treatment of cultures with SICF38393, the selective D1/D5 
receptor agonist.
Initially the dose range of both the D1 and D5 antisense 
oligonucleotides was determined. We found that doses of 2fxM and above were 
toxic to the neurons in culture, whilst doses of IjaM appeared to be effective.
Addition o f SKF38393 (InM-S^iM) to cultured striatal neurons was
demonstrated to increase the expression of both c-fbs mRNA and zif/268
mRNA in a dose-dependent manner. The EC5 0  fbr the SKP38393-induced
stimulation of both c-fbs and zift268 mRNA was in the region of 95nM. There
was no difference in the basal level of expression of c-fbs mRNA in striatal :f|
cultures pretreated fbr 2  days with 15-mer antisense phosphorothioate
oligonucleotides (IfiM) complementary to a region of the dopamine D 1 and D5
receptors alone compared to vehicle treated cultures. However, in cultures
pretreated for 2 days with D 1 anti sense, followed by SKP38393 (lnM-5/iM)
treatment fbr 45 minutes, the slope of the dose response curve representing
induction of c-fbs mRNA had clearly shifted in a downward direction, implying
that the D1 receptor is involved in this response. This shift in the dose response
162
curve to SKF38393 was demonstrated to be significantly different from the the 
dose response curve to SKF38393 alone ( F - 118.64, p< 0.001, ANOVA 
minitab, n= 3). [Figure 7.1.1]. Less of a shift was observed in the presence of 
the dopamine D5 receptor antisense oligonucleotide, however, this overall shift 
was significantly different from the dose response curve to SKF38393 alone 
(F= 18.58, p< 0 .0 0 1 ) [Figure 7.1.2]. As an appropriate control for the effects 
of the D1 and D5 receptor antisense oligonucleotides, a 15-mer D1 'sense' 
phosphorothioate oligonucleotide was synthesised, having the same sequence
as a region of the D1 receptor mRNA. Pretreatment of the cultures with a 15-
/mer D1 sense oligonucleotide (1/xM) for two days , followed by acute 
treatment with SKF38393 (lnM-5/nM) for 45 minutes had no effects on the 
induction of c-fbs mRNA by SKF38393 [Figure 7.1,3], However, the dose 
response curve in the presence of the D1 sense oligonucleotide was 
significantly different from the dose response curve to SKF38393 in the 
presence o f the D1 antisense oligonucleotide (F=22.98, p< 0.05) and similarly 
was significantly different from the curve to SKF38393 in the presence of the 
D5 antisense (F= 18.17, p< 0.05) [Figure 7.1.3],
The induction of zifr268 mRNA following SKF38393 treatment showed 
a similar dose dependent profile, with an EC5 0  of 95nM, However, when 
cultures were pretreated for two days with the D 1 'sense' oligonucleotide, the 
dose response curve to SKF38393 (lnM-5^M) was clearly different from 
SKF38393 (lnM-5juM) alone, such that F= 37.55, p< 0.001, n= 3 [Figure 
7.1.4]. This would suggest that the sense oligonucleotide can effect the ability 
of SKF38393 to induce zif/268 under these conditions. Pretreatment with the 
D1 antisense oligonucleotide (1/aM) also caused a significant shift in the 
SKF38393 dose response curve (F= 81.57, p< 0.001, n= 3) [Figure 7.1.5] , and
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similarly pretreatment with the D5 antisense oligonucleotide (l^aM) resulted in 
a significant shift in the dose response curve to SKjF38393 (lnM-5juM) (F= 
159.51, p< 0.001, n= 3) [Figure 7.1.6], The effects observed with the sense 
oligonucleotide suggests that the reduction in response seen with the two 
antisense oligonucleotides is likely to be non-specific.
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Figure 7.1.1 : Effect of a dopamine D 1 antisense oligonucleotide on c-fbs 
mRNA levels in striatal cultures. Cells were pretreated for two days with a 15- 
mer phosphorothioate oligonucleotide corresponding to a D1 dopamine 
receptor antisense (ljuM, n= 3). Cells were then exposed to SKF38393 (InM- 
5^M, n= 5) alone or in the presence of D1 antisense (n= 3), or vehicle (HBSS) 
alone or in the presence of D1 antisense. After 45 minutes the ceils were fixed 
in buffered formalin and then processed for in situ hybridisation with a specific 
radiolabelled probe for c-fbs. Results are expressed as mean number of pixels 
per unit area ± s.e.m. The dose response curve in the presence of the D 1 
antisense was significantly different from SKF38393 treatment alone p< 
0.001*** (two-way ANOVA, Minitab).
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Figure 7.1.2 : Effect of a dopamine D5 antisense oligonucleotide on c-fbs 
mRNA levels in striatal cultures. Cells were pretreated for two days with a 15- 
mer phosphorothioate oligonucleotide corresponding to a D5 dopamine 
receptor anti sense (l^M, n - 3). Cells were then exposed to SKF38393 (InM- 
5juM, n= 5) alone or in the presence of D5 anti sense (n= 3), or vehicle (HBSS) 
alone or in the presence of D5 antisense. After 45 minutes the cells were fixed 
in buffered formalin and then processed for in situ hybridisation with a specific 
radiolabelled probe for c-fbs. Results are expressed as mean number of pixels 
per unit area ± s.e.m. The dose response curve in the presence o f the D5 
antisense was significantly different from SKF38393 treatment alone p< 
0.001*** (two-way ANOVA, Minitab).
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Figure 7.1.3 : Effect of a dopamine D1 sense oligonucleotide on c-fbs mRNA 
levels in striatal cultures. Cells were pretreated for two days with a 15-mer 
phosphorothioate oligonucleotide corresponding to a D1 dopamine receptor 
sense probe (1/aM, n= 3). Cells were then exposed to SKF38393 (InM-S^aM, 
n= 5) alone or in the presence of D1 sense (n= 3), or vehicle (HBSS) alone or 
in the presence o f D l sense. After 45 minutes the cells were fixed in buffered 
formalin and then processed for in situ hybridisation with a specific 
radiolabelled probe for c-fbs. Results are expressed as mean number of pixels 
per unit area ± s.e.m. The dose response curve in the presence of the D l sense 
was not significantly different from SKF38393 treatment alone (two-way 
ANOVA, Minitab).
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Figure 7.1.4 : Effect of a dopamine D l sense oligonucleotide on ziff268 mRNA 
levels in striatal cultures. Cells were pretreated for two days with a 15-mer 
phosphorothioate oligonucleotide corresponding to a D l dopamine receptor 
sense probe (ljuM, n= 3). Cells were then exposed to SKF38393 (lnM-5/iM, 
n= 5) alone or in the presence of D l sense (n= 3), or vehicle (HBSS) alone or 
in the presence of D l sense. After 45 minutes the cells were fixed in buffered 
formalin and then processed for in situ hybridisation with a specific 
radiolabelled probe for zifi268. Results are expressed as mean number of pixels 
per unit area ± s.e.m. The dose response curve in the presence o f the D l sense 
was significantly different from SKF38393 treatment alone p< 0.001 (two-way 
ANOVA, Minitab).
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Figure 7.1.5 : Effect of a dopamine D l antisense oligonucleotide on zij7268 
mRNA levels in striatal cultures. Cells were pretreated for two days with a 15- 
mer phosphorothioate oligonucleotide corresponding to a D l dopamine 
receptor antisense (1/xM, n= 3). Cells were then exposed to SKF38393 (InM- 
5juM, n= 5) alone or in the presence of D l anti sense (n= 3), or vehicle (HBSS) 
alone or in the presence of D l antisense. After 45 minutes the cells were fixed 
in buffered formalin and then processed for in situ hybridisation with a specific 
radiolabelled probe for zif^268. Results are expressed as mean number o f pixels 
per unit area ± s.e.m. The dose response curve in the presence o f the D l 
antisense was significantly different from SKF38393 treatment ajone p< 
0.001*** (two-way ANOVA, Minitab).
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Figure 7.1.6 : Effect o f a dopamine D5 antisense oligonucleotide on zif'268 
mRNA levels in striatal cultures. Cells were pretreated for two days with a 15- 
mer phosphorothioate oligonucleotide corresponding to a D5 dopamine 
receptor antisense (l^M, n= 3). Cells were then exposed to SKF38393 (InM- 
SfjM, n= 5) alone or in the presence of D5 antisense (n= 3), or vehicle (HBSS) 
alone or in the presence of D5 antisense. After 45 minutes the cells were fixed 
in buffered formalin and then processed for in situ hybridisation with a specific 
radiolabelled probe for zift268. Results are expressed as mean number of pixels 
per unit area ±  s.e.m. The dose response curve in the presence of the D5 
antisense was significantly different from SKF38393 treatment alone p< 
0.001*** (two-way ANOVA, Minitab).
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DISCUSSION
7.2 Effect of dopamine receptor antisense oligonucleotides on immediate early 
gene expression in striatal cultures
In previous results we have demonstrated that acute treatment with 
SKF38393 can induce the expression of the immediate early genes c-fbs and 
ziff268 in primary embryonic rat striatal cultures. This is in agreement with in 
vivo work where the induction of c-fbs by SKF38393 has been shown, 
following a unilateral 6 -hydroxydopamine lesion of the nigrostriatal pathway 
(Robertson et al.. 1989; Robertson et al.. 1992) and with in vitro research 
demonstrating the induction of c-fbs with SKF38393 treatment in cerebral 
cortical cultures (Vaccarino et al.. 1993).
SKF38393, a potent D l/ D5 dopamine receptor agonist, is thought to 
be producing this stimulatory effect on both c-fbs and ziff268 gene expression 
by activating Dl-like receptors in vivo and in vitro. Until now it has been 
impossible to distinguish Dl-mediated effects from D5-mediated effects, simply 
because there are no selective ligands to differentiate between these two highly 
homologous dopamine receptor subtypes. However, with the introduction of 
antisense oligonucleotides targeted towards particular receptor mRNAs, it is 
now possible to achieve a substantial degree of protein synthesis inhibition.
Two 15-nucleotide-long antisense oligonucleotides were designed to recognize 
a sequence of the D l and D5 dopamine receptor genes respectively, in an 
attempt to answer this question more fully.
In this study we have demonstrated that c-fbs mRNA can be dose-
■■dependency increased by SKF38393 in vitro, with an EC50 value of 
approximately 1 lOnM. This E C 5 0  value obtained is very close to the Kd values 
previously reported for the binding of SKF38393 to striatal membranes
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(Seeman and Van Toi, 1993). The levels of c-fbs mRNA reached a plateau at 
around 5jnM SKF38393. Pretreatment of primary striatal cultures with a D l 
sense phosphorothioate oligonucleotide, at a concentration not causing toxic 
effects, demonstrated by no change in D2 receptor binding and no obvious 
change in cell numbers, clearly had no effect on the dose-dependent induction 
of c-fbs gene expression by SKF38393, in rat striatal cultures. This would be 
expected, because the sense oligonucleotide is acting as a control here, in that it 
has the same sequence as part of the D l receptor mRNA and therefore no 
binding interaction to cellular mRNA will occur if conditions are optimal, with 
non-specific binding reduced to a minimum. In contrast, pretreatment with the 
D l phosphorothioate antisense oligonucleotide, at a concentration not causing 
toxicity, was clearly able to reduce the dose-dependent induction of c-fbs 
mRNA by SKF38393. The D l antisense caused a greater than 50% reduction 
of the maximum effect of SKF38393.
Similarly pretreatment with the phosphorothioate antisense 
oligonucleotide directed towards the D5 dopamine receptor protein reduced 
the overall effect of SKF38393, particularly at low concentrations of 
SKF38393. However, the maximum effect of SKF38393 was unaltered by 
pretreatment with the D5 antisense. In general, these results are suggesting that 
the D l dopamine receptor primarily mediates the inductive effect o f SKF38393 
on c-fbs gene expression in the rat striatum. However, there may be a smaller 
D5 component to this effect. It is known that the density of D5 dopamine 
receptors in the striatum is much lower than the density of D l dopamine 
receptors, and that the affinity for the endogenous ligand dopamine, is ten-fold 
higher for the D5 receptor (Van Toi et al.. 1991). These properties of the D5 
receptor may be thought to functionally represent a ‘fine control’ over the 
dopaminergic system. Therefore stimulation of D l and D5 dopamine receptors 
may contribute to the induction of c-fbs by SKF38393. The results also indicate
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that in rat primary striatal cultures, in the case of D l receptors, there appears to 
be little receptor reserve.
The results obtained for the SKF38393- induced expression o f ziff268 
mRNA in the presence of the antisense oligonucleotides are much more 
dijBScult to interpret. Similar to the results obtained for c-fbs, a dose-dependent 
increase in zif/268 mRNA was observed following acute treatment with 
SKF39383 alone,with a very similar EC50 value to that obtained for c-fbs 
induction, of around lOOnM. However, pretreatment with the D l sense 
oligonucleotide clearly inhibited the dose-dependent effect o f SKF38393 on 
ziff268 gene expression. This non-specific inhibitory effect of the D l sense 
makes any effect o f the D l or D5 antisense very difficult to interpret as a 
specific effect. Therefore the effects of the dopamine D l and D5 antisense on 
ziF268 expression after SKF38393 are likely to be non-specific in these 
experiments.
One of the major disadvantages in the use o f ‘knockdown’ approaches
such as antisense oligonucleotide inhibition, is the narrow experimental and
therapeutic windows that accompany antisense use. With the D l and D5
antisense a concentration of IjxM proved effective in reducing the SKF38393
'
effect on c-fbs gene expression by 50%. However, we found that
concentrations of 2 ^M and above proved toxic to the cells in primaiy striatal
culture. Therefore the existence o f a narrow window for effective
concentration may not always parallel the therapeutic window. In particular,
potential problems are associated with an incomplete effect o f oligonucleotide
treatment. If a biological phenomenon has a great deal of spare capacity or
redundancy, for example, then only a fraction of receptors have to be occupied
to elicit a full response, and the oligonucleotide treatment may become
functionally ‘silent’. In this study it would also be necessary to demonstrate ■
reductions in Dl-like receptor binding, and to rule out oligonucleotide effects
on proteins other than the targeted D l and D5 receptor proteins, by perfbrming
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appropriate ligand-binding experiments, which are at present still in progress in 
our laboratory. Further appropriate controls for these experiments would 
involve the use o f random sequence oligonucleotides and mismatch 
oligonucleotides.
However, the results from this study are the first to provide an insight 
into the specific receptor mechanism involved in the inductive effect of 
SKF38393 on c-fbs expression in the rat striatum. Antisense oligonucleotides 
targeted towards the D l and D5 dopamine receptor proteins have been used to 
reduce the respective receptor protein and thus establish which dopamine 
receptor subtype(s) contribute to the stimulatory effect of SKF38393 on c-fbs 
gene expression in rat striatal culture. We have produced evidence to suggest 
that D l receptor stimulation is primarily involved in this effect, with a minor 
D5 component. However, the evidence that non-specific effects occur on 
another cellular process- the induction of zifr268 expression, suggests that 
extreme caution should always be observed when using antisense 
oligonucleotides.
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Chapter 8
Serotoninergic Regulation of Immediate 
Early Gene Expression in vitro
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INTRODUCTION
8.0 Serotoninergic Modulation of Immediate Early Gene Expression in the 
Central Nervous System
The serotoninergic system is involved in numerous physiological 
functions. In the central nervous system, serotonin (5-HT) is known to be 
involved in the homeostatic regulation of fundamental physiological functions 
such as sleep, appetite, locoihotion, nociception, sexual activity and vascular 
contraction (Wilkinson and Dourish, 1991). Disruption o f the serotoninergic 
system has also been implicated as a critical factor in mental disorders such as 
schizophrenia, anxiety, depression, parkinsonism and obsessive-compulsive 
disorders (Lopez-Ibor, 1988). This biogenic amine neurotransmitter is 
synthesised by neurons in the raphe nuclei of the brain stem that project 
throughout the central nervous system, with the highest density in basal ganglia 
and limbic structures (Steinbusch, 1984).
At present, at least seven classes of serotonin receptor have been 
cloned, each class being supported by a number of receptor subtypes. The 
functional significance, if any, in terms of the physiological role of many of  
these newly cloned receptors is as yet to be identified and therefore is of great 
importance in understanding the role of 5-HT as a regulator of many 
behavioural responses.
The relatively new field of research into immediate early genes is 
currently expanding. However, there is very litttle research, as yet, into the 
serotoninergic modulation of immediate early genes in the central nervous 
system. Recent work has demonstrated , using cultured spinal cord neurons, 
that the induction of the immediate early gene c-fbs and subsequent 
transactivation of the prodynorphin gene, are coupled events triggered by 5-
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HTIA receptor agonists (Lucas et al.. 1993). Classical 5-HTlA receptor 
agonists are known to be inhibitory, although this induction of c-fbs following a 
5-HTl A receptor stimulation also resulted in a simultaneous increase in cAMP 
levels. This would appear to be an anomoly from the classical cloned 5-HTlA  
receptor subtype, suggesting the possibility of another subtype of the 5-HTlA  
receptor.
The serotoninergic system has also been implicated in the regulation of 
immediate early genes in the striatum. Recent in vivo research has suggested 
that the ability of cocaine to induce the expression of c-fbs and zifr268 in brain 
neurons is partly due to its characteristic property of 5-HT uptake inhibition. 
Using the selective inhibitors of 5-HT uptake, fluoxetine and citalopram, the 
ability of mazindol, a dopamine and noradrenaline uptake blocker, to induce 
zifr268 and c-fbs was shown to be potentiated (Bhat and Baraban, 1993). More 
recently, activation of the serotonin 2A/2C receptor has been demonstrated to 
cause a localised expression of the immediate early gene c-fbs in the frontal 
cortex, amygdala, globus pallidus, nucleus accumbens and dorsomedial 
striatum, and this induction could be selectively blocked with the 2A/2C 
antagonist ritanserin in vivo (Leslie et al.. 1993). There is also some evidence 
for the serotoninergic regulation of tachykinin gene expression in the rat 
neostriatum. A recent report has shown that by raising extracellular levels of 
serotonin with zimelidine, a 5-HT uptake inhibitor, the levels of 
preprotachykinin mRNA were increased (Walker et al.. 1991). This suggests 
that neostriatal tachykinin biosynthesis is sensitive to alterations in 5-HT 
neurotransmission.
At present there are several suggestions with regard to the involvement 
of central serotoninergic mechanisms in the actions of antipsychotic drugs. The 
recently cloned 5-HT6 and 5-HT7 receptor subtypes have been demonstrated 
to exhibit a particularly high affinity for some atypical neuroleptic drugs, 
including clozapine. The mRNA encoding the 5-HT6 receptor has been shown
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to be mainly present in the striatum, olfactory tubercles, nucleus accumbens 
and in the hippocampus (Monsma et al.. 1992). More recently it has been 
demonstrated that the 5-HT6 receptor is present in primary striatal neuron 
cultures and it is positively coupled to adenylyl cyclase activity (Sebben et al.. 
1994). Similarly the 5-HT7 receptor subtype has also been shown to be 
positively coupled to adenylyl cyclase (Tsou et al.. 1994). Therfore the 5-HT6 
and 5-HT7 receptor subtypes may have a functional role in the manifestation 
and clinical treatment of certain disease states such as schizophrenia and 
parkinsonism.
Therefore, it was decided to investigate the role of serotonin in the 
induction of the immediate early genes c-fbs and zifr268, and to elucidate the 
receptor mechanism(s) involved.
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RESULTS
Much research has been done on the dopaminergic regulation o f lEGs 
in the striatum. However, at present there is very little information on the 
serotoninergic modulation of lEGs in the striatum. Although there are 
implications for a serotoninergic stimulation o f zifr268 in the striatum (Bhat et 
al, 1993). Therefore in this study we were interested in the serotoninergic 
modulation of the lEGs zifr268 and c-fbs in rat striatal neuronal cultures and
8.1 Effect o f serotonin (5-HT) on the expression of the lEGs c-fbs and zifr268 
mRNA
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the receptor site(s) involved.
Serotonin (5-HT) (lnM-5/xM) was demonstrated to clearly increase the 
expression of both ziE268 and c-fbs mRNA in striatal cultures in a dose 
dependent manner. The induction of ziE268 mRNA forty-five minutes after 5- 
HT (300nM) can be seen in figure 8.1.19, as an increase in the number o f silver 
grains over cell bodies in striatal culture, compared to vehicle treated cultures. 
The EC5 0  o f 5-HT to stimulate both zifr268 and c-fbs mRNA in striatal culture 
was approximately lOOnM. The induction occured in a large proportion of the 
cultured cells, suggesting that the increase in mRNA was observed mainly in 
medium spiny neurons [Figure 8.1.19]. Pretreatment of striatal cultures with
I .
ondansetron (200nM), the selective 5-HT3 receptor antagonist, clearly had no 
effect on the levels of zifr268 mRNA being expressed in culture after addition 
of 5-HT (lnM-5juM). [Figure 8.1.1]. Although c-fbs mRNA levels due to 
stimulation by 5-HT were effected by the presence of ondansetron (200nM)
I
and this was shown to be significantly different from 5-HT (lnM-5/*M)
treatment alone (F= 9.73, p< 0.01; n - 3). [Figure 8.1,2].
The cultures were also pretreated with a number of 5-HT 1/2 receptor 
antagonists including cyproheptadine, methiothepin, mesulergine and 
spiperone. It was found that cyproheptadine (500nM) caused a dramatic 
reduction in the hybridisation signal representing the induction of zif/268 
mRNA by 5-HT, and this was demonstrated to be significantly different from 
the expression o f zifr268 mRNA due to 5-HT (lnM-5/iM) alone (F= 29.95, p< 
0.001; n= 3) [Figure 8.1.3, 8.1.19]. A similar reduction in the signal was 
observed for c-fbs mRNA (F= 19.57, p< 0.001; n= 3) [Figure 8.1.4]. 
Pretreatment with methiothepin (200nM) clearly decreased the hybridisation 
signal for zifr268 mRNA in culture and was significantly different from 5-HT 
alone (F= 39.95, p< 0.001; n= 3) [Figure 8.1.5]. A reduction in the 
hybridisation signal for c-fbs mRNA was also observed (F== 33.89, p< 0.001; 
n= 3) [Figure 8.1.6]. In cultures treated with mesulergine (lOOnM) prior to the 
addition of 5-HT (lnm-5juM) a marked decrease in zifr268 mRNA was 
observed and this was significantly different from 5-HT (lnM-5/tM) alone (F- 
28.71, p< 0.001; n= 3) [Figure 8.1.7]. Pretreatment with the lower 
concentration of 30nM mesulergine also resulted in a highly significant 
decrease in the levels of zif/268 mRNA in culture (F= 17.36, p< 0.001; n~ 3) 
following a 5-HT-induced stimulation [Figure 8.1.8]. Mesulergine (lOOnM) 
caused a reduction in the levels of c-fbs mRNA as a result of a 5-HT receptor 
stimulation. This decrease proved to be significantly different (F= 7.10, p< 
0.01; n= 3) from 5-HT alone (InM-S/^M) [Figure 8.1.9]. Spiperone (lOOnM) 
pretreatment was also demonstrated to cause a massive inhibition of the 5-HT- 
induced stimulation of zifr268 mRNA in striatal cultures, and this decrease was 
shown to be significant (F= 59.36, p< 0.001; n~ 3) compared to 5-HT (InM- 
5/xM) alone [Figure 8.1.10], as did the lower dose of 30nM spiperone (F= 
31.96, p< 0 .0 0 1 ; n - 3) [Figure 8 .1 .1 1 , 8.1.19]. As spiperone has very low
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affinity for the 5-HT 1C receptor, the low dose used in this study would suggest 
that the increase in zif'268 mRNA observed, is not due to stimulation o f the 5 
HT2C receptor. Pretreatment with spiperone (30nM) also resulted in a 
dramatic and highly significant inhibition o f the hybridisation signal for c-fos 
mRNA (F= 40.86, p<0.001; n= 3) compared to 5-HT treatment alone [Figure
8 .1 .1 2 ],
.
The effects of a number of 5-HT receptor agonists were investigated in 
striatal culture. Addition of the 5-HT2C receptor agonist mCPP (lnM-5^M) 
had no overall effects on the levels of both zifi268 mRNA [Figure 8.1.13] and 
c-fos mRNA [Figure 8.1.14]. Similarly the selective 5-HTlA receptor agonist
80H-DPAT (InM-SjaM) had no significant effect on the expression of the 
zifi268 [Figure 8.1.15] and c-fos genes [Figure 8.1.16]. Finally the selective 5- 
HT2A/2C receptor agonist, ±- DOI (lnM-5juM) was shown to have a slight 
effect on the levels of zifi268 and c-fos mRNA in striatal culture, but this 
induction did not prove to be significant [Figures 8.1.17 and 8.1.18 
respectively].
i
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Figure 8,1.1 : Effect o f selective inhibition of the serotononergic 5-HT3 
receptor on the levels o f expression of zifi268 mRNA in rat striatal neuron 
cultures. Cultures were pretreated for 30 minutes with ondansetron (200nM) 
prior to the addition of vehicle or 5-HT (lnM-5/xM) (n= 3) or treated with 
vehicle or 5-HT (lnM-5/iM) alone (n= 8 ). Results, obtained from film 
autoradiographs, are expressed as mean relative optical density x 1 0  ^± s.e.m. 
Significance was determined by ANOVA, General Linear Model, Minitab. The 
two dose response curves were not significantly different.
Figure 8.1.2 ; Effect of selective inhibition of the serotononergic 5-HT3 
receptor on the levels of expression of c-fos mRNA in rat striatal neuron 
cultures. Cultures were pretreated for 30 minutes with ondansetron (200nM) 
prior to the addition of vehicle or 5-HT (lnM-5/iM) (n= 3) or treated with 
vehicle or 5-HT (lnM-5^M) alone (n= 7). Results, obtained from film 
autoradiographs, are expressed as mean relative optical density x 1 0  ^±  s.e.m. 
Significance was determined by ANOVA, General Linear Model, Minitab. The 
two dose response curves were significantly different, p< 0 . 0 1  **.
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Figure 8.1.3 : Effect o f inhibition of serotoninergic 5-HT1/2 receptors on the 
levels of expression of zifi 2^68 mRNA in rat striatal neuron cultures. Cultures 
were pretreated for 30 minutes with cyproheptadine (500nM), prior to the 
addition of vehicle or 5-HT (lnM-5/iM) (n= 3) or treated with vehicle or 5-HT 
(lnM-5/nM) alone (n= 8 ). Results obtained from film autoradiographs, are 
expressed as mean relative optical density x 1 0  ^ ±  s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. The two dose 
response curves were significantly different, p< 0 .0 0 1  ***.
Figure 8.1.4 : Effect o f inhibition of serotoninergic 5-HT 1 / 2  receptors on the 
levels o f expression of c-fos mRNA in rat striatal neuron cultures. Cultures 
were pretreated for 30 minutes with cyproheptadine (500nM), prior to the 
addition of vehicle or 5-HT (lnM-5/tM) (n= 3) or treated with vehicle or 5-HT 
(lnM-5/xM) alone (n= 7). Results obtained from film autoradiographs, are 
expressed as mean relative optical density x 10  ^ ± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. The two dose 
response curves were significantly different, p< 0 . 0 0 1  ***.
70 1
o  o 60 -
w
SQ
'Sü
Aoo>
(DK
fla0S
X
mC0Q
13u
CLo
0>
0K
Ü0
0
50 -
40
30
20
1 0  -J
80 -,
r-H 70 -
60
50 -
40
30
20 O
O 5 -H T  a lo n e  
#  5 - H T /c y p ro h e p ta d in e  
(500nM)
- 9
log[5-H T ]
O 5 -H T  a lo n e  
#  5 -H T /c y p ro h e p ta d i:  
(500nM)
- 9 8 7 - 6 - 5
lo g [5 -H T ]
%;i.
î
Figure 8.1,5 : Effect of inhibition of serotoninergic 5-HT 1/2/6 receptors on the 
levels o f expression of zif/268 mRNA in rat striatal neuron cultures. Cultures 
were pretreated for 30 minutes with methiothepin (200nM), prior to the 
addition of vehicle or 5-HT (lnM-5^M) (n= 3) or treated with vehicle or 5-HT 
(lnM-5/tM) alone (n= 8 ), Results obtained from film autoradiographs, are 
expressed as mean relative optical density x 1 0  ^ ± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab,The two dose 
response curves were significantly different, p< 0 ,0 0 1  ***,
Figure 8,1,6 : Effect of inhibition of serotoninergic 5-HT 1/2/6 receptors on the 
levels o f expression of c-fos mRNA in rat striatal neuron cultures. Cultures 
were pretreated for 30 minutes with methiothepin (200nM), prior to the 
addition of vehicle or 5-HT (lnM-5^M) (n= 3) or treated with vehicle or 5-HT 
(lnM-5/iM) alone (n= 7). Results obtained from film autoradiographs, are 
expressed as mean relative optical density x 1 0  ^ ± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. The two dose 
response curves were significantly different, p< 0 . 0 0 1  ***.
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Figure 8.1.7 : Effect of inhibition of serotoninergic 5-HTlA /2A /2C receptors 
on the levels of expression of ziE268 mRNA in rat striatal neuron cultures. 
Cultures were pretreated for 30 minutes with mesulergine (lOOnM), prior to 
the addition o f vehicle or 5-HT (lnM-5/fM) (n- 3) or treated with vehicle or 5- 
HT (lnM-5^M) alone (n= 8 ). Results obtained from film autoradiographs, are 
expressed as mean relative optical density x 10  ^ ± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. The two dose 
response curves were significantly different, p< 0 . 0 0 1  ***.
Figure 8.1.8 ; Effect of inhibition o f serotoninergic 5-HTlA /2 A /2C receptors 
on the levels of expression of zifr268 mRNA in rat striatal neuron cultures. 
Cultures were pretreated for 30 minutes with mesulergine (30nM), prior to the 
addition o f vehicle or 5-HT (lnM-5^M) (n= 3) or treated with vehicle or 5-HT 
(lnM-5/iM) alone (n= 8 ), Results obtained from film autoradiographs, are 
expressed as mean relative optical density x 1 0  ^ ± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. The two dose 
response curves were significantly different, p< 0 . 0 0 1  ***.
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Figure 8.1.9 : Effect of inhibition of serotoninergic 5-HT 1A /2A /2C receptors 
on the levels of expression of c-fos mRNA in rat striatal neuron cultures. 
Cultures were pretreated for 30 minutes with mesulergine (lOOnM), prior to 
the addition of vehicle or 5-HT (InM-5/LcM) (n= 4) or treated with vehicle or 5- 
HT (lnM-5/tM) alone (n= 7). Results obtained from film autoradiographs, are 
expressed as mean relative optical density x 10  ^ ± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. p< 0.01 ***.
oo
X
-* ->
ü<uQ
lü
ü
ao
<D>ip
"qj
P
Cd
CD
O 5 —HT a lo n e  
#  5 —H T /  M e su le rg in e  
(lOOnM)
80
70
60
50
40
30
20
- 9 8 7 —  6 5
lo g [5 - H T ]
Figure 8.1.10: Effect o f inhibition of serotoninergic 5-HT 1A /2A /2C / 7 
receptors on the levels o f expression o f zif'268 mRNA in rat striatal neuron 
cultures. Cultures were pretreated for 30 minutes with spiperone (lOOnM), 
prior to the addition of vehicle or 5-HT (lnM-5/tM) (n= 3) or treated with 
vehicle or 5-HT (lnM-5f*M) alone (n= 8 ). Results obtained from film 
autoradiographs, are expressed as mean relative optical density x 1 0  ^± s.e.m. 
Significance was determined by ANOVA, General Linear Model, Minitab. The 
two dose response curves were significantly different, p< 0 . 0 0 1  ***.
Figure 8.1.11 : Effect of inhibition of serotoninergic 5-HT 1A /2A /2C / 7 
receptors on the levels of expression o f zifr268 mRNA in rat striatal neuron 
cultures. Cultures were pretreated for 30 minutes with spiperone (30nM), prior 
to the addition o f vehicle or 5-HT (lnM-5fiM) (n= 3) or treated with vehicle or 
5-HT (InM-S^iM) alone (n= 8 ). Results obtained from film autoradiographs, 
are expressed as mean relative optical density x 10^ ± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. The two dose 
response curves were significantly different, p< 0 .0 0 1  ***.
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Figure 8.1.12 : Effect of inhibition of serotoninergic 5-HT 1A /2A /2C / 7 
receptors on the levels of expression of c-fos mRNA in rat striatal neuron 
cultures. Cultures were pretreated for 30 minutes with spiperone (30nM), prior 
to the addition of vehicle or 5-HT (lnM-5/nM) (n= 3) or treated with vehicle or 
5-HT (lnM-5/nM) alone (n= 7). Results obtained from film autoradiographs, 
are expressed as mean relative optical density x 1 0  ^± s.e.m. Significance was 
determined by ANOVA, General Linear Model, Minitab. The two dose 
response curves were significantly different, p< 0 . 0 0 1  ***.
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Figure 8.1.13 : Effect o f a 5-HT2C receptor stimulation on the level of 
expression o f zif/268 mRNA in rat striatal neuron cultures. Cultures were 
treated for 45 minutes with vehicle (HBSS), mCPP (lnM-5^M, n= 5) alone or 
with 5-HT (lnM-5/iM, n= 8 ) alone for comparison. Result, obtained from film 
autoradiographs, are expressed as mean relative optical density x 1 0  ^± s.e.m.
Figure 8.1.14 : Effect of a 5-HT2C receptor stimulation on the level of  
expression of c-fos mRNA in rat striatal neuron cultures. Cultures were treated 
for 45 minutes with vehicle (HBSS), mCPP (lnM-5/^M, n= 3) alone or with 5- 
HT (lnM-5;iM, n= 7) alone for comparison. Results, obtained from film 
autoradiographs, are expressed as mean relative optical density x 1 0  ^± s.e.m.
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Figure 8.1.15 : Effect o f a 5-HT 1A receptor stimulation on the level o f 
expression of zif'268 mRNA in rat striatal neuron cultures. Cultures were 
treated for 45 minutes with vehicle (HBSS), 80HDPAT (lnM-5/iM, n= 4) 
alone or with 5-HT (lnM-5/tM, n= 8 ) alone for comparison. Results, obtained 
from film autoradiographs, are expressed as mean relative optical density x 10^ 
± s.e.m. No significant induction of zifi268 mRNA was observed.
Figure 8.1.16 ; Effect of a 5-HTlA receptor stimulation on the level o f  
expression of c-fos mRNA in rat striatal neuron cultures. Cultures were treated 
for 45 minutes with vehicle (HBSS), 80HDPAT (lnM-5/*M, n= 4) alone or 
with 5-HT (lnM-5/iM, n= 7) alone for comparison. Results, obtained firom film 
autoradiographs, are expressed as mean relative optical density x 10^ ± s.e.m. 
No significant induction o f c-fos mRNA was observed.
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Figure 8.1.17 : Effect of a 5-HT2A/ 2C receptor stimulation on the level of  
expression of ziF268 mRNA in rat striatal neuron cultures. Cultures were 
treated for 45 minutes with vehicle (HBSS), ± DOI (lnM-5^M, n= 3) alone or 
with 5-HT (lnM-5^M, n= 8 ) alone for comparison. Results, obtained from film 
autoradiographs, are expressed as mean relative optical density x  10^ ± s.e.m. 
No significant induction of zifr268 mRNA was observed.
Figure 8.1.18 : Effect o f a 5-HT2A/ 2C receptor stimulation on the level o f 
expression of c-fos mRNA in rat striatal neuron cultures. Cultures were treated 
for 45 minutes with vehicle (HBSS), ± DOI (lnM-5/nM, n= 3) alone or with 5- 
HT (InM-SgM, n= 7) alone for comparison. Results, obtained from film 
autoradiographs, are expressed as mean relative optical density x 1 0  ^± s.e.m. 
No significant induction of c-fos mRNA was observed.
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Figure 8.1.19 : Effect of serotoninergic antagonists on the level of expression 
of zif/268 mRNA in rat striatal neuron cultures. Photomicrographs show 
neuronal cultures treated with (A) vehicle, (B) 5-HT (l^M), (C) 
cyproheptadine (SOOnM)/ 5-HT (l^M) and (C  ^ spiperone (30nM)/ 5-HT 
( 1/xM). An induction of7»f/45gcan be seen as an increase in the number o f silver 
grains over the cell bodies. Scale bar represents 25^m.
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DISCUSSION
8.2 Regulation o f immediate earlv genes bv serotonin in vitro
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It has been known for some time that serotonin may play an important 
role in the manifestation of certain pathological disorders, including pain, 
anxiety, schizophrenia and parkinsonism. With recent evidence suggesting that 
serotonin may be involved in the modulation of immediate early gene 
expression both in vivo and in vitro, this study was undertaken in order to 
examine the pattern o f immediate early gene expression in striatal neurons 
grown in culture, and to elucidate a possible receptor mechanism(s) involved.
The results show for the first time that serotonin can induce the 
expression of both c-fos and zif^268 mRNA in rat primary striatal culture when 
administered alone. This inductive effect of serotonin on c-fos and zi0268 gene 
expression proved to be dose-dependent. The EC50 value for both c-fos and 
zif/268 was very similar, and in the range o f lOOnM. This value is similar to an 
EC50 value of 125 nM, recently reported for the 5-HT stimulation of cyclic 
AMP production, in striatal neurons in culture (Sebben et al.. 1994). Previous 
research indicates a balance between the dopaminergic and serotoninergic 
systems, and that the central serotoninergic system exerts an inhibitory 
influence on the central dopaminergic system. In particular this has been 
evident when looking at behavioural effects in rats. Serotonin agonists have 
been shown to potentiate the cataleptic effect of haloperidol in a dose 
dependent manner in rats, and pretreatment with serotonin antagonists was 
shown to reduce this effect (Balsara et al.. 1979). It appears that the effect of 
neuroleptics apparently depends on the balance between the two systems 
(Kostowski et al.. 1972; Balsara et al.. 1979). Recent research has suggested 
that serotonin may act synergistically in the striatum with the neurotransmitter, 
dopamine, in order to activate transcription factor genes, including c-fos and
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zif'268 in vivo (Bhat and Baraban, 1993). Our results demonstrate that 
serotonin may also have a solitary role in activating these transcription factor 
genes.
A variety of pharmacological agents known to be active at various 
subtypes of 5-HT receptors were used to characterize the subtype o f receptor 
responsible for this stimulation of c-fos and zif/268 mRNA by serotonin. It was 
thought to be unlikely that this response was mediated by a 5-HT3 subtype o f  
receptor, because pretreatment with the selective 5-HT3 receptor antagonist, 
ondansetron, had no effect on the expression of zif^268 mRNA and little effect 
on c-fos mRNA levels after 5-HT stimulation. Receptors o f the 5-HTl subclass 
generally couple to inhibition of adenylyl cyclase, although there are reports of 
the 5-HT 1A receptor coupling to stimulation of this second messenger 
(Shenker et al.. 1987). The inactivity of 8 -hydroxy-DPAT, a potent 5-HT 1A 
agonist (Gozlan et al.. 1983; Dourish et al.. 1987), indicates that the 5-HT 1 A 
receptor is not responsible for the stimulation of zif/268 or c-fos mRNA. The 
involvement o f a 5-HT IB or 5-HT ID receptor was eliminated by the finding 
that the drugs spiperone, mesulergine and cyproheptadine, all having very low 
affinity for these receptor subtypes (Peroutka, 1986; Van Wijngaarden et al..
1990), were clearly effective antagonists o f the inductive response of c-fos and 
zif/268 mRNA, to serotonin stimulation. The lack of agonist activity for mCPP 
at high doses, also suggests that the response is not mediated by the 5-HT IB 
receptor subtype (Hoyer and Schoeffter, 1991). A 5-HTlE-like receptor is 
known to be highly expressed in the rat striatum, although the primary 
structure of this receptor suggests it may be coupled to an inhibition o f  
adenylate cyclase through an inhibitory Q-like protein (Lovenberg et al.. 
1992). It is unlikely that the induction of ziP268 and c-fos is due to stimulation 
o f a receptor negatively coupled to adenylate cyclase. This, together with the 
reported low affinity of mesulergine at this receptor subtype makes it an 
unlikely candidate. The 5-HT4 subtype was also eliminated as a possible
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candidate, because the drugs spiperone and mesulergine have been reported to
be inactive at this receptor (Schiavi et al.. 1993 ). The 5-HT5A and 5-HT5B
receptors can also be eliminated, because of their moderate affinity for
methiothepin and the knowledge that these receptors are unlikely to be coupled
to either adenylate cyclase or phospholipase C (Matthes et al.. 1992). Similarly
stimulation of the newly cloned 5-HT6  receptor is unlikely to be reponsible for
the inductive effect on c-fos and zif/268 gene expression, because spiperone is
known to have a very low affinity at this receptor site (Roth et aï.. 1993),
which does not correspond to its action as a highly potent antagonist seen in
our experiments. However, the affinity o f spiperone at the 5-HT7 receptor is
much higher than at the 5-HT6 receptor subtype. The 5-HT7 or 5-HTx
receptor as it is also known, is expressed in the forebrain region in rat brain
.(Plassat et al.. 1993) and has a high affinity for atypical antipsychotic drugs 
such as clozapine (Roth et al.. 1993). This receptor subtype can not be ruled 
out totally, in view o f the current evidence.
The presence of a 5-HT-stimulated increase in zif'268 and c-fos mRNA 
initially suggested the involvement of a 5-HT2-like receptor. It is known that 
this receptor subtype is coupled to phospholipase C and the consequent 
cascade leading to diacylglycerol and inositol triphosphate production (Conn 
and Sanders-Bush, 1986; Conn et al.. 1986). In previous results we have 
suggested that both c-fos and zif'268 stimulation may be linked to protein 
kinase C, an enzyme responsible for the phosphorylation of cellular proteins. 
This further suggests that the response to 5-HT may involve a 5-HT2-like 
receptor subtype. However, the 5-HT2C (formerly known as 5-HTlC) subtype 
is unlikely to be responsible for mediating the induction of c-fos and zif/268 
mRNA in vitro, due to the low affinity of spiperone at this subtype of 5-HT2 
receptor (Hoyer et al.. 1985).The lack o f an agonist effect o f mCPP and ±-DOI 
also suggests that the 5-HT2C receptor is not involved in mediating this effect. 
Similarly the 5-HT2B receptor (formerly known as 5-HT2F) is most unlikely to
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be mediating the induction of c-fos and ziff268 mRNA in culture. This is due to 
the low affinity of spiperone for this receptor subtype (Wainscott et al.. 1992), 
together with the low abundance of this receptor subtype in the brain 
(Pompeiano et al.. 1993). The 5-HT2A subtype is possibly the most feasible 
candidate, however there are some discrepancies which do not coincide with 
the pharmacologically described 5-HT2A receptor. The 5-HT2A has high 
affinity for spiperone, mesulergine and cyproheptadine (Zifa and Pillion, 1992), 
which is in agreement with our results describing potent antagonism of the 5-
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HT-stimulated increase in c-fos and ziff268 mRNA with these three drugs. The 
5-HT2A subtype has also been shown to be expressed at moderate levels in the
caudate-putamen in the adult rat (Pompeiano et al.. 1993). In humans, 5-HT2 
binding sites have been predominantly located in striosomes in the basal ganglia 
(Waeber and Palacios, 1994). However, we found that the selective agonist at
5-HT2A and 5-HT2C receptor subtypes, ±-DOI, was unable to stimulate the 
induction of ziff268 or c-fos mRNA in striatal culture. In previous reports ±- 
DOI has been suggested to be a mixed agonist-antagonist (Dabire et al.. 1989) 
and also be able to inhibit 5-HT-induced neuronal activity in the dorsal raphe, 
an effect not blocked by classical 5-HT2 receptor antagonists (Garratt et al..
■; 3
1991). This suggests that there are properties of ±-DOI aside &om the known 
agonist activity at 5-HT2 receptors, that as yet, have not been fully 
investigated.
These results indicate that the serotonin receptor responsible for the 
stimulation of both c-fos and ziff268 mRNA in rat striatal culture may be a 5- 
HT2A-like receptor. However, there are still open avenues of investigation 
concerning the 5-HT7 receptor, which has recently been reported to have a 
high affinity for antipsychotic drugs such as clozapine. As yet, we have been 
unable to obtain a result with clozapine in this experimental model.
Ultimately the physiological significance of our results is suggestive that 
serotonin can modulate cellular gene expression which in turn may effect
behavioural responses. Accumulated experimental evidence implies that the 
immediate early genes are ‘third messengers* in signal transduction pathways 
(Goelet et al.. 1986; Curran and Morgan, 1987). In the central nervous system, 
certain late response genes have been identified as targets for transactivation 
based on the presence of the appropriate regulatory sequences in their 
promoters (Comb et al.. 1988; Sonnenberg et al.. 1989: Naranjo et al.. 1991).
It is well characterised that neuroleptics, the major treatment for 
diseases such as schizophrenia, can cause the induction of a number o f  
immediate early genes in the brain, in addition to affecting the levels of many 
late response genes. Therefore a functional link has been implied between the 
induction of immediate early genes and the consequent increase or decrease in 
late response genes such as enkephalin (Sonnenberg et al.. 1989). In view of 
the affinity of many neuroleptic drugs for 5-HT receptors, the current 
awareness is suggesting that neuroleptics may be affecting the serotoninergic 
sytem as easily as the dopaminergic system, and in fact the atypical drug 
clozapine has a particularly high affinity for some serotonin receptor subtypes. 
The properties of clozapine and similar atypical compounds result in fewer 
extrapyramidal side effects when given clinically, and it has been postulated 
that clozapine’s actions on the serotoninergic system may be an important 
contributing factor to its atypical drug profile.
" A
.General Discussion
As a whole, this work has not only uncovered some novel findings, but 
demonstrated the complexity of the functioning of the basal ganglia. In addition 
to demonstrating an induction of c-fos and ziff268 gene expression in the rat 
striatal model in vitro following a dopaminergic D1/D5 receptor stimulation, 
the expression of these immediate early genes and others, was also increased by 
dopaminergic D2-like antagonists in vivo. Dopamine DI-like-induced
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expression of c-fos in the caudate in vivo has been shown to occur only after a
6 -hydroxy-dopamine-induced lesion (Robertson et al.. 1989; 1990), although 
the D1/D5 receptor antagonist SCH23390 has been demonstrated to reduce the 
mRNA levels of the transcription factor zift268 in the adult rat intact striatum 
(Mailleux et al.. 1992). A possible explanation for the D2-like mediated 
mRNA induction o f these immediate early genes, may be that blockade of D2- 
like receptors results in an unopposed D 1 stimulation.
We have also demonstrated that a further complexity may exist concerning 
the second messenger pathway prior to immediate early gene induction after a 
Dl-like receptor stimulation. The results shown provide the first evidence that 
both PKA and PKC participate in the regulation of c-fos and zift268 gene 
expression by dopamine in striatal neurones. Further work is clearly required to 
discover the ftinctional significance of these control mechanisms.
The serotoninergic regulation of c-fos and zif/268 gene expression in the 
striatal model in vitro is the first evidence to suggest that serotonin alone can 
induce these immediate early genes. In addition, we have attempted to reveal a 
possible receptor mechanism for this induction. Our results are suggestive that 
the induction may be mediated by a 5-HT2A-Iike receptor, although conclusive 
evidence is hampered by the few selective drugs available for serotonin 
receptor subtypes. Perhaps an improved receptor antisense technology may 
provide the answer in the future.
We have also shown that the recently cloned transcription factor gene BF-1, 
present in the striatum, can be regulated by the atypical neuroleptic, clozapine, 
in vivo. This is a novel finding, which may be functionally important 
considering clozapine has a unique drug profile that provides clinical 
advantages in schizophrenia.
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An important consideration when attempting to explain many of the findings 
in this research work, is the possiblity of interaction occurring between different 
neuronal systems. The therapeutic efficacy of atypical antipsychotic agents such as 
clozapine may be attributed to the ability of the dmg to act on different 
transmitter/receptor systems in vivo. From this, it may be suggested that drug 
efficacy may rely on a complex compensatory mechanism between neuronal systems. 
Indeed, one explanation for the selective behavioural and physiological effects of 
atypical agents on the function o f the AlO dopamine system is an interaction with 
other neuronal systems which may compensate for dopamine receptor antagonism in 
the nigrostriatal system. Since clozapine is known to have a high affinity for a 
number of 5-HT receptor subtypes in vitro, of which several are known to be 
expressed in the caudate-putamen, tonic 5-HT activity may be crucial for the 
resultant physiological effects of this dmg. Wilmot and Szczepanik (1989), have 
previously demonstrated that both acute and chronic intraperitoneal administration 
of clozapine, at relatively high doses, can decrease the maximal number of cortical 5- 
HT2 receptors by greater than 50% of control, whereas typical dmgs such as 
haloperidol, had no effect. The functional significance of 5-HT2 receptor down- 
regulation following chronic treatment with an atypical antipsychotic remains to be 
determined.
The existence of a relationship between the differential effects of clozapine 
and haloperidol on subcoitical D2 dopamine receptors and cortical or sub cortical 5- 
HT2 serotonin receptors is not presently known. However, the cortical control of 
striatal function is regionally specific. The lateral striatum, which shows the greatest 
changes in D2 receptors following chronic treatment with haloperidol, receives 
afferents from the somatosensory frontoparietal cortex. It has been suggested that 
clozapine may indirectly affect the development of striatal D2 receptor up-regulation 
via its effects on cortical somatosensory neurons. Another explanation is that 
clozapine, as a 5-HT2 antagonist, directly affects raphe neurons which then influence 
dopamine neuronal fonction (Wilmot and Szczepanik, 1989). It has previously been
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shown that acute treatment with 5-HT2 antagonists can antagonize the haloperidol- 
induced increase in levels of striatal dihydroxyphenylacetic acid (DOPAC) and 
haloperidol-induced catalepsy (Balsara et al.. 1979). Lesions of the dorsal raphe are 
also known to prevent haloperidol-induced catalepsy (Kostowski et al.. 1972). 
Therefore it would seem that there is a definite interaction between the dopamine 
and serotonin transmitter systems in the central nervous system.
Regulation of tachykinin biosynthesis by serotonin has recently been shown
in the neostriatum (Walker et al, 1991). Depletion o f 5-HT with p-
chlorophenylalanine treatment decreased preprotachykinin (the prohormone 
precursor to substance P) mRNA levels in the neostriatum. By contrast, raising 
extracellular levels of 5-HT with zimelidine, a 5-HT uptake inhibitor, or clorgyline, a 
monoamine oxidase inhibitor resulted in increased levels pf preprotachykinin mRNA. 
Therefore it may be suggested that certain peptides in the striatum may be regulated 
by serotonin neurotransmission. Typical neuroleptics such as haloperidol given 
acutely or chronically, have been shown to decrease the levels o f preprotachykinin 
(PPT) mRNA in the striatum (Bannon et al.. 1986). The proposed mechanism for 
this biochemical change is a decrease in dopamine neurotransmission. In addition to 
the effect on the dopamine system, haloperidol may also be affecting the serotonin 
system. Haloperidol has been shown to have an affinity at a number of serotonin 
receptor subtypes, including the 5-HT2 receptor (Canton et al., 1993), therefore the 
decrease in PPT mRNA seen after haloperidol may be due to a decrease in serotonin 
neurotransmission in addition to a decrease in dopamine neurotransmission. Tonic 
serotonin levels may therefore have a regulatoiy role in controlling the expression of 
neuropeptides in the basal ganglia. The increase in the immediate early genes c-fos 
and zif/268 which we observed after treatment with 5-HT could also be blocked by 
5-HT2-like receptor antagonist compounds. As yet there is no clear evidence for a 
ftinctional role of immediate early genes in the brain, although it has been suggested 
that they may play a part in the regulation of gene expression. Similarly 
glutamate must also be considered to be a possible interacting component in the
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basal ganglia. A glutamatergic projection from the cortex to the striatum suggests 
that tonic glutamate may also have a homeostatic function in controlling the level of 
neurotransmitters /peptides in the striatum.
This research has also demonstrated an induction o f pro enkephalin mRNA 
after acute typical neuroleptic dmg treatment. This is in agreement with previous 
studies that have shown an induction of pro enkephalin mRNA and enkephalin 
protein in the rat striatum (Hong et al.. 1978; Sabol et al.. 1983; Tang et al.. 1983; 
Angulo et al.. 1986; Sivam et al.. 1986; Romano et al.. 1987; Morris et al.. 1988). 
We suggest that the increase of proenkephalin mRNA after 24 hours may infact be 
related to the induction of a number of immediate early genes prior to this time 
point. This would be in agreement with the idea that immediate early genes act as 
"third messengers" in the sequence of events leading to changes in gene expression. 
However, this is only indirect evidence, and therefore a relationship between 
immediate early genes and "late response genes", such as enkephalin, is only 
circumstantial.
Tonic dopamine is thought to have an inhibitory control on enkephalin gene 
expression. Enkephalin peptide is thought to be located predominantly in 
striatopallidal neurons (Gerfen and Young, 1988), and striatopallidal neurons have 
been shown to be a distinct population of neurons expressing a relatively high 
proportion of D2-like receptors (La Moine et al., 1990). Blockade of D2-like 
dopamine receptors with typical neuroleptic dmgs such as haloperidol cause an 
increase in proenkephalin mRNA, as the tonic inhibiton is removed. Lesioning the 
nigrostriatal system, which effectively removes the tonic dopamine acting 
predominantly through D2-like receptors to maintain an inhibitory control on 
enkephalin gene expression, also causes an induction of enkephalin mRNA. 
Therefore it would seem that the D2 -mediated inhibitoiy effect of tonic dopamine on 
the level o f enkephalin gene expression predominates in the 'normal' brain.
Despite the evidence previously described suggesting that Dl-like and D2- 
like dopamine receptors are expressed on different populations of cells in vivo
(Gerfen et al., 1990; Le Moine et al., 1990), our results indicate that both Dl-like 
and D2-like receptors are expressed on the same cell in vitro. Administration of the 
D2 agonist quinpirole has been shown to antagonize the SKF3 8393 -induced 
expression of both c-fos and zif/268 mRNA. If it is assumed that our model of 
striatal neurons in culture closely resembles the phenotype of striatal neurons in vivo, 
then this suggests that a population of neurons in vivo may express both Dl-like 
and D2-like dopamine receptors. There is already a large body of evidence in 
agreement with this idea (Seeman et al., 1989; Bertorello et al., 1990; PiomelÜ et al,, 
1991; Surmeier et al, 1993). Dopaminergic Dl-like receptors, when stimulated, 
appear to be in opposition to dopaminergic D2-like receptors in the striatum. 
However, it must be remembered that the population size which possess both D l-  
like and D2-like dopamine receptor subtypes is unknown. It is possible that a 
relatively small population of neurons possess both phenotypes. Perhaps the 
proportion o f D1:D2 phenotype on neuronal populations within the basal ganglia 
differ such that one phenotype predominates over the other in vivo. The tonic 
activity o f dopamine on different neuronal populations within the caudate may 
therefore have localized effects in terms of gene regulation, dependent on the 
predominant phenotype o f dopamine receptor. Several serotonin receptor subtypes 
are known to be present in the striatum. The physiological significance of these 
receptors has yet to be determined. Similar to the dopaminergic system, it is not 
unlikely that these receptor subtypes may be localised to particular neuronal cell 
populations and in turn regulate gene expression.
The relatively new concept of 'antisense strategy' to block the synthesis of 
specific proteins, has been employed in this research. The phosphorothioate 
antisense oligonucleotide directed towards the D1 dopamine receptor clearly 
reduced c-fos mRNA expression in striatal neurons after treatment with a range of 
doses of the Dl-like receptor agonist SKF38393. The effect on c-fos mRNA 
expression after treatment with the D5 antisense oligonucleotide was less robust 
than that observed after treatment with the D1 antisense, although a significant
decline in mRNA levels were still obseiwed. We have suggested that the 
physiological effect of c-fos induction following SKF38393, is predominantly 
mediated through stimulation of the D1 dopamine receptor subtype. However, as the 
D5 antisense was also effective, it may not be dismissed that the induction of c-fos 
mRNA in striatal neurons may also by mediated, but to a lesser extent, by the D5 
dopamine receptor subtype. We have proposed that the D5 subtype may represent 
the 'fine control' over the dopaminergic system, due to only a small percentage of D5 
receptors being expressed in the striatum, and dopamine, the endogenous ligand in 
vivo, having a higher affinity for the D5 dopamine receptor subtype than for D1 
subtype.
At present there are a number of disadvantages with this method o f protein 
'knockdown'. Clearly, from the data on zifi268 mRNA expression after antisense 
use, non-specific effects can be a major problem. A number of separate controls, 
including the use o f random sequence oligonucleotides, 'mismatch' oligonucleotides, 
radioligand binding studies and toxicity testing, should be performed in addition to 
the 'sense' control oligonucleotide that was used in our study in an attempt to clarify 
these results.
This research as a whole, has provided an important insight into the changes 
in gene expression in the basal ganglia. We have investigated the transient changes in 
immediate early gene expression, together with the more sustained changes in 
peptide gene expression in the striatum, in response to neuroleptic drug treatments, 
the clinical therapy for many neurodegenerative diseases. We have uncovered a 
complex cascade o f events prior to the change in expression o f the immediate early 
genes c-fos and zif/268 in the striatum after a dopaminergic stimulus. In addition we 
have also investigated another major transmitter system in the striatum, namely the 
serotoninergic system, and attempted to reveal the receptor(s) involved in the 
induction of the immediate early genes c-fos and zif/268 after serotonin treatment.
The complexity of the basal ganglia has undoubtedly left several questions 
unanswered until a future date.
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